match_id	MYCN_TPM	MYCN_CN	MYCN_CN_status	molecular_subtype	Kids_First_Participant_ID	Kids_First_Biospecimen_ID	sample_id
Maris_P0001_SH-SY5Y_Derived Cell Line_Progressive_NA_NA	2.11	NA	NA	NBL, MYCN non-amplified	Maris_P0001	MARIS_HEMEDKRG	SH-SY5Y
Maris_P0001_SK-N-SH_Derived Cell Line_Progressive_NA_NA	6.99	NA	NA	NBL, MYCN non-amplified	Maris_P0001	MARIS_M10LINIO	SK-N-SH
Maris_P0002_SK-N-BE2-C_Derived Cell Line_Progressive_NA_NA	544.81	NA	NA	NBL, MYCN amplified	Maris_P0002	MARIS_WQRZBZ4G	SK-N-BE2-C
Maris_P0002_SK-N-BE2_Derived Cell Line_Progressive_NA_NA	873	NA	NA	NBL, MYCN amplified	Maris_P0002	MARIS_JE9T5LOF	SK-N-BE2
Maris_P0003_CHP-134_Derived Cell Line_Progressive_NA_NA	674.77	NA	NA	NBL, MYCN amplified	Maris_P0003	MARIS_7NZCWMJE	CHP-134
Maris_P0004_CHP-212_Derived Cell Line_Unknown_NA_NA	512.12	NA	NA	NBL, MYCN amplified	Maris_P0004	MARIS_SXL48UGF	CHP-212
Maris_P0005_IMR-05_Derived Cell Line_Progressive_NA_NA	369.16	NA	NA	NBL, MYCN amplified	Maris_P0005	MARIS_VX4JCU78	IMR-05
Maris_P0005_IMR-32_Derived Cell Line_Progressive_NA_NA	465.46	NA	NA	NBL, MYCN amplified	Maris_P0005	MARIS_NMSC6BVZ	IMR-32
Maris_P0006_KELLY_Derived Cell Line_Unknown_NA_NA	742.24	NA	NA	NBL, MYCN amplified	Maris_P0006	MARIS_X2ET87GI	KELLY
Maris_P0007_COG-N-534_Derived Cell Line_Unknown_NA_NA	13.16	NA	NA	NBL, MYCN non-amplified	Maris_P0007	MARIS_54FAKEIN	COG-N-534
Maris_P0008_COG-N-573_Derived Cell Line_Unknown_NA_NA	1134.68	NA	NA	NBL, MYCN amplified	Maris_P0008	MARIS_6UV3BJAL	COG-N-573
Maris_P0009_LA-N-5_Derived Cell Line_Progressive_NA_NA	1399.29	NA	NA	NBL, MYCN amplified	Maris_P0009	MARIS_HK31CBVO	LA-N-5
Maris_P0010_LA-N-6_Derived Cell Line_Progressive_NA_NA	3.95	NA	NA	NBL, MYCN non-amplified	Maris_P0010	MARIS_LJRX2KUQ	LA-N-6
Maris_P0011_NB-1_Derived Cell Line_Progressive_NA_NA	328.66	NA	NA	NBL, MYCN amplified	Maris_P0011	MARIS_6ZJTUIGZ	NB-1
Maris_P0012_NB-69_Derived Cell Line_Unknown_NA_NA	0.81	NA	NA	NBL, MYCN non-amplified	Maris_P0012	MARIS_5YY8GILQ	NB-69
Maris_P0013_NBL-S_Derived Cell Line_Unknown_NA_NA	44.34	NA	NA	NBL, MYCN non-amplified	Maris_P0013	MARIS_MWYH16EQ	NBL-S
Maris_P0014_NGP_Derived Cell Line_Progressive_NA_NA	823.02	NA	NA	NBL, MYCN amplified	Maris_P0014	MARIS_TDY23ZA5	NGP
Maris_P0015_NLF_Derived Cell Line_Unknown_NA_NA	74.04	NA	NA	NBL, MYCN amplified	Maris_P0015	MARIS_IICVUNN8	NLF
Maris_P0016_NMB_Derived Cell Line_Unknown_NA_NA	534.85	NA	NA	NBL, MYCN amplified	Maris_P0016	MARIS_IJBHSKKC	NMB
Maris_P0017_SK-N-AS_Derived Cell Line_Progressive_NA_NA	0.08	NA	NA	NBL, MYCN non-amplified	Maris_P0017	MARIS_RMULBCDT	SK-N-AS
Maris_P0018_SK-N-DZ_Derived Cell Line_Progressive_NA_NA	359.6	NA	NA	NBL, MYCN amplified	Maris_P0018	MARIS_ICP9L0D7	SK-N-DZ
Maris_P0019_SK-N-FI_Derived Cell Line_Progressive_NA_NA	28.28	NA	NA	NBL, MYCN non-amplified	Maris_P0019	MARIS_H8FYX6YM	SK-N-FI
Maris_P0020_SMS-KAN_Derived Cell Line_Unknown_NA_NA	553.22	NA	NA	NBL, MYCN amplified	Maris_P0020	MARIS_GKS38MPB	SMS-KAN
Maris_P0021_SMS-SAN_Derived Cell Line_Progressive_NA_NA	1116.65	NA	NA	NBL, MYCN amplified	Maris_P0021	MARIS_XVVK4ZCI	SMS-SAN
PAHYWC_01_Solid Tissue_Primary Tumor	NA	35	amplification	NBL, MYCN amplified	PAHYWC	TARGET-30-PAHYWC-01A-01W	01
PAICGF_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PAICGF	TARGET-30-PAICGF-01A-01W	01
PAIFCS_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PAIFCS	TARGET-30-PAIFCS-01A-01W	01
PAIFXV_01_Solid Tissue_Primary Tumor	3.17	3	gain	NBL, MYCN non-amplified	PAIFXV	TARGET-30-PAIFXV-01A-01D	01
PAIFXV_01_Solid Tissue_Primary Tumor	3.17	3	gain	NBL, MYCN non-amplified	PAIFXV	TARGET-30-PAIFXV-01A-01D.M	01
PAIFXV_01_Solid Tissue_Primary Tumor	3.17	3	gain	NBL, MYCN non-amplified	PAIFXV	TARGET-30-PAIFXV-01A-01R	01
PAILNU_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAILNU	TARGET-30-PAILNU-01A-01W	01
PAIMDT_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PAIMDT	TARGET-30-PAIMDT-01A-01W	01
PAINLN_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAINLN	TARGET-30-PAINLN-01A-01W	01
PAIPGU_01_Solid Tissue_Primary Tumor	17.57	3	gain	NBL, MYCN non-amplified	PAIPGU	TARGET-30-PAIPGU-01A-01D.M	01
PAIPGU_01_Solid Tissue_Primary Tumor	17.57	3	gain	NBL, MYCN non-amplified	PAIPGU	TARGET-30-PAIPGU-01A-01R	01
PAIPGU_01_Solid Tissue_Primary Tumor	17.57	3	gain	NBL, MYCN non-amplified	PAIPGU	TARGET-30-PAIPGU-01A-01W	01
PAISNS_01_Solid Tissue_Primary Tumor	35.59	NA	NA	NBL, MYCN amplified	PAISNS	TARGET-30-PAISNS-01A-01D.M	01
PAISNS_01_Solid Tissue_Primary Tumor	35.59	NA	NA	NBL, MYCN amplified	PAISNS	TARGET-30-PAISNS-01A-01R	01
PAISSH_01_Solid Tissue_Primary Tumor	NA	30	amplification	NBL, MYCN amplified	PAISSH	TARGET-30-PAISSH-01A-01W	01
PAITCI_01_Solid Tissue_Primary Tumor	17.43	2	loss	NBL, MYCN non-amplified	PAITCI	TARGET-30-PAITCI-01A-01D.M	01
PAITCI_01_Solid Tissue_Primary Tumor	17.43	2	loss	NBL, MYCN non-amplified	PAITCI	TARGET-30-PAITCI-01A-01R	01
PAITCI_01_Solid Tissue_Primary Tumor	17.43	2	loss	NBL, MYCN non-amplified	PAITCI	TARGET-30-PAITCI-01A-01W	01
PAITEG_01_Solid Tissue_Primary Tumor	1.24	2	neutral	NBL, MYCN non-amplified	PAITEG	TARGET-30-PAITEG-01A-01R	01
PAITEG_01_Solid Tissue_Primary Tumor	1.24	2	neutral	NBL, MYCN non-amplified	PAITEG	TARGET-30-PAITEG-01A-01W	01
PAIVHE_01_Solid Tissue_Primary Tumor	39.72	2	loss	NBL, MYCN non-amplified	PAIVHE	TARGET-30-PAIVHE-01A-01D.M	01
PAIVHE_01_Solid Tissue_Primary Tumor	39.72	2	loss	NBL, MYCN non-amplified	PAIVHE	TARGET-30-PAIVHE-01A-01R	01
PAIVHE_01_Solid Tissue_Primary Tumor	39.72	2	loss	NBL, MYCN non-amplified	PAIVHE	TARGET-30-PAIVHE-01A-01W	01
PAIVMJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAIVMJ	TARGET-30-PAIVMJ-01A-01D.M	01
PAIVZR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAIVZR	TARGET-30-PAIVZR-01A-01D.M	01
PAIWRB_01_Solid Tissue_Primary Tumor	NA	225	amplification	NBL, MYCN amplified	PAIWRB	TARGET-30-PAIWRB-01A-01D	01
PAIXFZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAIXFZ	TARGET-30-PAIXFZ-01A-01D.M	01
PAIXIF_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAIXIF	TARGET-30-PAIXIF-01A-01W	01
PAIXNC_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAIXNC	TARGET-30-PAIXNC-01A-01W	01
PAIXNV_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PAIXNV	TARGET-30-PAIXNV-01A-01W	01
PAIXRK_01_Solid Tissue_Primary Tumor	NA	66	amplification	NBL, MYCN amplified	PAIXRK	TARGET-30-PAIXRK-01A-01W	01
PAKFUY_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAKFUY	TARGET-30-PAKFUY-01A-01W	01
PAKGCI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAKGCI	TARGET-30-PAKGCI-01A-01D.M	01
PAKGKH_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PAKGKH	TARGET-30-PAKGKH-01A-01W	01
PAKHAV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAKHAV	TARGET-30-PAKHAV-01A-01D.M	01
PAKHCF_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAKHCF	TARGET-30-PAKHCF-01A-01W	01
PAKHHB_01_Solid Tissue_Primary Tumor	NA	84	amplification	NBL, MYCN amplified	PAKHHB	TARGET-30-PAKHHB-01A-01W	01
PAKINP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAKINP	TARGET-30-PAKINP-01A-01D.M	01
PAKIPY_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PAKIPY	TARGET-30-PAKIPY-01A-01W	01
PAKJRE_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PAKJRE	TARGET-30-PAKJRE-01A-01W	01
PAKVUY_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, To be classified	PAKVUY	TARGET-30-PAKVUY-01A-01D	01
PAKXDZ_01_Solid Tissue_Primary Tumor	NA	37	amplification	NBL, MYCN amplified	PAKXDZ	TARGET-30-PAKXDZ-01A-01W	01
PAKYZS_01_Solid Tissue_Primary Tumor	9.23	2	neutral	NBL, MYCN non-amplified	PAKYZS	TARGET-30-PAKYZS-01A-01D.M	01
PAKYZS_01_Solid Tissue_Primary Tumor	9.23	2	neutral	NBL, MYCN non-amplified	PAKYZS	TARGET-30-PAKYZS-01A-01R	01
PAKYZS_01_Solid Tissue_Primary Tumor	9.23	2	neutral	NBL, MYCN non-amplified	PAKYZS	TARGET-30-PAKYZS-01A-01W	01
PAKZRE_01_Solid Tissue_Primary Tumor	NA	43	amplification	NBL, MYCN amplified	PAKZRE	TARGET-30-PAKZRE-01A-01W	01
PAKZRF_01_Solid Tissue_Primary Tumor	NA	3	loss	NBL, To be classified	PAKZRF	TARGET-30-PAKZRF-01A-01W	01
PAKZRH_01_Solid Tissue_Primary Tumor	19.5	NA	NA	NBL, MYCN amplified	PAKZRH	TARGET-30-PAKZRH-01A-01D.M	01
PAKZRH_01_Solid Tissue_Primary Tumor	19.5	NA	NA	NBL, MYCN amplified	PAKZRH	TARGET-30-PAKZRH-01A-01R	01
PALAKE_01_Solid Tissue_Primary Tumor	NA	115	amplification	NBL, MYCN amplified	PALAKE	TARGET-30-PALAKE-01A-01W	01
PALAKM_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PALAKM	TARGET-30-PALAKM-01A-01W	01
PALBFW_01_Solid Tissue_Primary Tumor	22.9	2	neutral	NBL, MYCN non-amplified	PALBFW	TARGET-30-PALBFW-01A-01D.M	01
PALBFW_01_Solid Tissue_Primary Tumor	22.9	2	neutral	NBL, MYCN non-amplified	PALBFW	TARGET-30-PALBFW-01A-01R	01
PALBFW_01_Solid Tissue_Primary Tumor	22.9	2	neutral	NBL, MYCN non-amplified	PALBFW	TARGET-30-PALBFW-01A-01W	01
PALCBW_01_Solid Tissue_Primary Tumor	3.51	2	loss	NBL, MYCN non-amplified	PALCBW	TARGET-30-PALCBW-01A-01D.M	01
PALCBW_01_Solid Tissue_Primary Tumor	3.51	2	loss	NBL, MYCN non-amplified	PALCBW	TARGET-30-PALCBW-01A-01R	01
PALCBW_01_Solid Tissue_Primary Tumor	3.51	2	loss	NBL, MYCN non-amplified	PALCBW	TARGET-30-PALCBW-01A-01W	01
PALEAC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PALEAC	TARGET-30-PALEAC-01A-01D.M	01
PALETP_01_Solid Tissue_Primary Tumor	35.31	2	neutral	NBL, MYCN non-amplified	PALETP	TARGET-30-PALETP-01A-01D.M	01
PALETP_01_Solid Tissue_Primary Tumor	35.31	2	neutral	NBL, MYCN non-amplified	PALETP	TARGET-30-PALETP-01A-01R	01
PALETP_01_Solid Tissue_Primary Tumor	35.31	2	neutral	NBL, MYCN non-amplified	PALETP	TARGET-30-PALETP-01A-01W	01
PALEVG_01_Solid Tissue_Primary Tumor	732.82	44	amplification	NBL, MYCN amplified	PALEVG	TARGET-30-PALEVG-01A-01D.M	01
PALEVG_01_Solid Tissue_Primary Tumor	732.82	44	amplification	NBL, MYCN amplified	PALEVG	TARGET-30-PALEVG-01A-01R	01
PALEVG_01_Solid Tissue_Primary Tumor	732.82	44	amplification	NBL, MYCN amplified	PALEVG	TARGET-30-PALEVG-01A-01W	01
PALFPI_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PALFPI	TARGET-30-PALFPI-01A-01W	01
PALFSE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PALFSE	TARGET-30-PALFSE-01A-01D.M	01
PALHVD_01_Solid Tissue_Primary Tumor	NA	4	gain	NBL, MYCN non-amplified	PALHVD	TARGET-30-PALHVD-01A-01D.M	01
PALHVD_01_Solid Tissue_Primary Tumor	NA	4	gain	NBL, MYCN non-amplified	PALHVD	TARGET-30-PALHVD-01A-01W	01
PALIIN_01_Solid Tissue_Primary Tumor	55.37	2	loss	NBL, MYCN non-amplified	PALIIN	TARGET-30-PALIIN-01A-01D.M	01
PALIIN_01_Solid Tissue_Primary Tumor	55.37	2	loss	NBL, MYCN non-amplified	PALIIN	TARGET-30-PALIIN-01A-01R	01
PALIIN_01_Solid Tissue_Primary Tumor	55.37	2	loss	NBL, MYCN non-amplified	PALIIN	TARGET-30-PALIIN-01A-01W	01
PALJPX_01_Solid Tissue_Primary Tumor	NA	27	amplification	NBL, MYCN amplified	PALJPX	TARGET-30-PALJPX-01A-01W	01
PALJUV_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PALJUV	TARGET-30-PALJUV-01A-01W	01
PALKKV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PALKKV	TARGET-30-PALKKV-01A-01D.M	01
PALKUC_01_Solid Tissue_Primary Tumor	147.41	NA	NA	NBL, MYCN amplified	PALKUC	TARGET-30-PALKUC-01A-01R	01
PALKXJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PALKXJ	TARGET-30-PALKXJ-01A-01D.M	01
PALLJJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PALLJJ	TARGET-30-PALLJJ-01A-01D.M	01
PALNLU_01_Solid Tissue_Primary Tumor	NA	3	loss	NBL, MYCN non-amplified	PALNLU	TARGET-30-PALNLU-01A-01W	01
PALNVP_01_Solid Tissue_Primary Tumor	22.36	NA	NA	NBL, MYCN amplified	PALNVP	TARGET-30-PALNVP-01A-01D.M	01
PALNVP_01_Solid Tissue_Primary Tumor	22.36	NA	NA	NBL, MYCN amplified	PALNVP	TARGET-30-PALNVP-01A-01R	01
PALPGG_01_Solid Tissue_Primary Tumor	NA	171	amplification	NBL, MYCN amplified	PALPGG	TARGET-30-PALPGG-01A-01W	01
PALRIA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PALRIA	TARGET-30-PALRIA-01A-01D.M	01
PALRSD_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PALRSD	TARGET-30-PALRSD-01A-01D	01
PALSAE_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PALSAE	TARGET-30-PALSAE-01A-01D.M	01
PALSAE_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PALSAE	TARGET-30-PALSAE-01A-01W	01
PALTEG_01_Solid Tissue_Primary Tumor	17.22	2	neutral	NBL, MYCN non-amplified	PALTEG	TARGET-30-PALTEG-01A-01R	01
PALTEG_01_Solid Tissue_Primary Tumor	17.22	2	neutral	NBL, MYCN non-amplified	PALTEG	TARGET-30-PALTEG-01A-01W	01
PALTYB_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PALTYB	TARGET-30-PALTYB-01A-01W	01
PALUDH_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PALUDH	TARGET-30-PALUDH-01A-01D.M	01
PALUDH_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PALUDH	TARGET-30-PALUDH-01A-01W	01
PALUYS_01_Solid Tissue_Primary Tumor	64.75	NA	NA	NBL, MYCN amplified	PALUYS	TARGET-30-PALUYS-01A-01R	01
PALVKK_01_Solid Tissue_Primary Tumor	11.63	NA	NA	NBL, MYCN non-amplified	PALVKK	TARGET-30-PALVKK-01A-01R	01
PALVUC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PALVUC	TARGET-30-PALVUC-01A-01D.M	01
PALVVH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PALVVH	TARGET-30-PALVVH-01A-01D.M	01
PALWIP_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PALWIP	TARGET-30-PALWIP-01A-01W	01
PALWVJ_01_Solid Tissue_Primary Tumor	8.86	2	neutral	NBL, MYCN non-amplified	PALWVJ	TARGET-30-PALWVJ-01A-01R	01
PALWVJ_01_Solid Tissue_Primary Tumor	8.86	2	neutral	NBL, MYCN non-amplified	PALWVJ	TARGET-30-PALWVJ-01A-01W	01
PALXHW_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PALXHW	TARGET-30-PALXHW-01A-01W	01
PALXMM_01_Solid Tissue_Primary Tumor	NA	1	loss	NBL, MYCN non-amplified	PALXMM	TARGET-30-PALXMM-01A-01W	01
PALXTB_01_Solid Tissue_Primary Tumor	35.21	NA	NA	NBL, MYCN amplified	PALXTB	TARGET-30-PALXTB-01A-01D.M	01
PALXTB_01_Solid Tissue_Primary Tumor	35.21	NA	NA	NBL, MYCN amplified	PALXTB	TARGET-30-PALXTB-01A-01R	01
PALZRG_01_Solid Tissue_Primary Tumor	NA	57	amplification	NBL, MYCN amplified	PALZRG	TARGET-30-PALZRG-01A-01D.M	01
PALZRG_01_Solid Tissue_Primary Tumor	NA	57	amplification	NBL, MYCN amplified	PALZRG	TARGET-30-PALZRG-01A-01W	01
PALZSL_01_Solid Tissue_Primary Tumor	NA	69	amplification	NBL, MYCN amplified	PALZSL	TARGET-30-PALZSL-01A-01W	01
PALZZV_01_Solid Tissue_Primary Tumor	818.77	86	amplification	NBL, MYCN amplified	PALZZV	TARGET-30-PALZZV-01A-01D.M	01
PALZZV_01_Solid Tissue_Primary Tumor	818.77	86	amplification	NBL, MYCN amplified	PALZZV	TARGET-30-PALZZV-01A-01R	01
PALZZV_01_Solid Tissue_Primary Tumor	818.77	86	amplification	NBL, MYCN amplified	PALZZV	TARGET-30-PALZZV-01A-01W	01
PAMAFV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAMAFV	TARGET-30-PAMAFV-01A-01D.M	01
PAMBAC_01_Solid Tissue_Primary Tumor	NA	101	amplification	NBL, MYCN amplified	PAMBAC	TARGET-30-PAMBAC-01A-01W	01
PAMBMJ_01_Solid Tissue_Primary Tumor	71.2	NA	NA	NBL, MYCN amplified	PAMBMJ	TARGET-30-PAMBMJ-01A-01R	01
PAMCXF_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, To be classified	PAMCXF	TARGET-30-PAMCXF-01A-01D.M	01
PAMCXF_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, To be classified	PAMCXF	TARGET-30-PAMCXF-01A-01W	01
PAMDAL_01_Solid Tissue_Primary Tumor	NA	50	amplification	NBL, MYCN amplified	PAMDAL	TARGET-30-PAMDAL-01A-01W	01
PAMEZH_01_Solid Tissue_Primary Tumor	121.89	NA	NA	NBL, MYCN non-amplified	PAMEZH	TARGET-30-PAMEZH-01A-01R	01
PAMLNB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAMLNB	TARGET-30-PAMLNB-01A-01D.M	01
PAMMWD_01_Solid Tissue_Primary Tumor	NA	260	amplification	NBL, MYCN amplified	PAMMWD	TARGET-30-PAMMWD-01A-01W	01
PAMMXF_01_Solid Tissue_Primary Tumor	482.57	2	neutral	NBL, MYCN amplified	PAMMXF	TARGET-30-PAMMXF-01A-01D.M	01
PAMMXF_01_Solid Tissue_Primary Tumor	482.57	2	neutral	NBL, MYCN amplified	PAMMXF	TARGET-30-PAMMXF-01A-01R	01
PAMMXF_01_Solid Tissue_Primary Tumor	482.57	2	neutral	NBL, MYCN amplified	PAMMXF	TARGET-30-PAMMXF-01A-01W	01
PAMNLH_01_Solid Tissue_Primary Tumor	29.77	NA	NA	NBL, MYCN amplified	PAMNLH	TARGET-30-PAMNLH-01A-01D.M	01
PAMNLH_01_Solid Tissue_Primary Tumor	29.77	NA	NA	NBL, MYCN amplified	PAMNLH	TARGET-30-PAMNLH-01A-01R	01
PAMNYX_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PAMNYX	TARGET-30-PAMNYX-01A-01D	01
PAMUTD_01_Solid Tissue_Primary Tumor	NA	55	amplification	NBL, MYCN amplified	PAMUTD	TARGET-30-PAMUTD-01A-01W	01
PAMVLG_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PAMVLG	TARGET-30-PAMVLG-01A-01D	01
PAMVRA_01_Solid Tissue_Primary Tumor	57.44	2	loss	NBL, MYCN non-amplified	PAMVRA	TARGET-30-PAMVRA-01A-01R	01
PAMVRA_01_Solid Tissue_Primary Tumor	57.44	2	loss	NBL, MYCN non-amplified	PAMVRA	TARGET-30-PAMVRA-01A-01W	01
PAMYCE_01_Solid Tissue_Primary Tumor	24.37	2	loss	NBL, MYCN non-amplified	PAMYCE	TARGET-30-PAMYCE-01A-01D.M	01
PAMYCE_01_Solid Tissue_Primary Tumor	24.37	2	loss	NBL, MYCN non-amplified	PAMYCE	TARGET-30-PAMYCE-01A-01R	01
PAMYCE_01_Solid Tissue_Primary Tumor	24.37	2	loss	NBL, MYCN non-amplified	PAMYCE	TARGET-30-PAMYCE-01A-01W	01
PAMZGT_01_Solid Tissue_Primary Tumor	214.79	23	amplification	NBL, MYCN amplified	PAMZGT	TARGET-30-PAMZGT-01A-01D.M	01
PAMZGT_01_Solid Tissue_Primary Tumor	214.79	23	amplification	NBL, MYCN amplified	PAMZGT	TARGET-30-PAMZGT-01A-01R	01
PAMZGT_01_Solid Tissue_Primary Tumor	214.79	23	amplification	NBL, MYCN amplified	PAMZGT	TARGET-30-PAMZGT-01A-01W	01
PAMZMG_01_Solid Tissue_Primary Tumor	594.01	44	amplification	NBL, MYCN amplified	PAMZMG	TARGET-30-PAMZMG-01A-01D.M	01
PAMZMG_01_Solid Tissue_Primary Tumor	594.01	44	amplification	NBL, MYCN amplified	PAMZMG	TARGET-30-PAMZMG-01A-01R	01
PAMZMG_01_Solid Tissue_Primary Tumor	594.01	44	amplification	NBL, MYCN amplified	PAMZMG	TARGET-30-PAMZMG-01A-01W	01
PAMZMJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAMZMJ	TARGET-30-PAMZMJ-01A-01D.M	01
PAMZSH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAMZSH	TARGET-30-PAMZSH-01A-01D.M	01
PANBCI_01_Solid Tissue_Primary Tumor	NA	28	amplification	NBL, MYCN amplified	PANBCI	TARGET-30-PANBCI-01A-01W	01
PANBJH_01_Solid Tissue_Primary Tumor	81.56	NA	NA	NBL, MYCN amplified	PANBJH	TARGET-30-PANBJH-01A-01R	01
PANBMJ_01_Solid Tissue_Primary Tumor	3.53	2	neutral	NBL, MYCN non-amplified	PANBMJ	TARGET-30-PANBMJ-01A-01D.M	01
PANBMJ_01_Solid Tissue_Primary Tumor	3.53	2	neutral	NBL, MYCN non-amplified	PANBMJ	TARGET-30-PANBMJ-01A-01R	01
PANBMJ_01_Solid Tissue_Primary Tumor	3.53	2	neutral	NBL, MYCN non-amplified	PANBMJ	TARGET-30-PANBMJ-01A-01W	01
PANBSP_01_Solid Tissue_Primary Tumor	45.6	3	neutral	NBL, MYCN non-amplified	PANBSP	TARGET-30-PANBSP-01A-01D.M	01
PANBSP_01_Solid Tissue_Primary Tumor	45.6	3	neutral	NBL, MYCN non-amplified	PANBSP	TARGET-30-PANBSP-01A-01R	01
PANBSP_01_Solid Tissue_Primary Tumor	45.6	3	neutral	NBL, MYCN non-amplified	PANBSP	TARGET-30-PANBSP-01A-01W	01
PANGXK_01_Solid Tissue_Primary Tumor	3.28	NA	NA	NBL, MYCN amplified	PANGXK	TARGET-30-PANGXK-01A-01R	01
PANIPC_06_Solid Tissue_Metastatic	NA	35	amplification	NBL, MYCN amplified	PANIPC	TARGET-30-PANIPC-06A-01W	06
PANJLH_01_Solid Tissue_Primary Tumor	403.51	NA	NA	NBL, MYCN amplified	PANJLH	TARGET-30-PANJLH-01A-01R	01
PANKFE_01_Solid Tissue_Primary Tumor	4.39	2	neutral	NBL, MYCN non-amplified	PANKFE	TARGET-30-PANKFE-01A-01D.M	01
PANKFE_01_Solid Tissue_Primary Tumor	4.39	2	neutral	NBL, MYCN non-amplified	PANKFE	TARGET-30-PANKFE-01A-01R	01
PANKFE_01_Solid Tissue_Primary Tumor	4.39	2	neutral	NBL, MYCN non-amplified	PANKFE	TARGET-30-PANKFE-01A-01W	01
PANLET_01_Solid Tissue_Primary Tumor	31.45	2	loss	NBL, MYCN non-amplified	PANLET	TARGET-30-PANLET-01A-01D	01
PANLET_01_Solid Tissue_Primary Tumor	31.45	2	loss	NBL, MYCN non-amplified	PANLET	TARGET-30-PANLET-01A-01D.M	01
PANLET_01_Solid Tissue_Primary Tumor	31.45	2	loss	NBL, MYCN non-amplified	PANLET	TARGET-30-PANLET-01A-01R	01
PANNMS_01_Solid Tissue_Primary Tumor	73.96	NA	NA	NBL, MYCN amplified	PANNMS	TARGET-30-PANNMS-01A-01D.M	01
PANNMS_01_Solid Tissue_Primary Tumor	73.96	NA	NA	NBL, MYCN amplified	PANNMS	TARGET-30-PANNMS-01A-01R	01
PANPVI_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PANPVI	TARGET-30-PANPVI-01A-01W	01
PANRHJ_01_Solid Tissue_Primary Tumor	22.58	2	neutral	NBL, MYCN non-amplified	PANRHJ	TARGET-30-PANRHJ-01A-01D.M	01
PANRHJ_01_Solid Tissue_Primary Tumor	22.58	2	neutral	NBL, MYCN non-amplified	PANRHJ	TARGET-30-PANRHJ-01A-01R	01
PANRHJ_01_Solid Tissue_Primary Tumor	22.58	2	neutral	NBL, MYCN non-amplified	PANRHJ	TARGET-30-PANRHJ-01A-01W	01
PANRRW_01_Solid Tissue_Primary Tumor	42.67	NA	NA	NBL, MYCN amplified	PANRRW	TARGET-30-PANRRW-01A-01D.M	01
PANRRW_01_Solid Tissue_Primary Tumor	42.67	NA	NA	NBL, MYCN amplified	PANRRW	TARGET-30-PANRRW-01A-01R	01
PANRVJ_01_Solid Tissue_Primary Tumor	26.77	2	loss	NBL, MYCN non-amplified	PANRVJ	TARGET-30-PANRVJ-01A-01D	01
PANRVJ_01_Solid Tissue_Primary Tumor	26.77	2	loss	NBL, MYCN non-amplified	PANRVJ	TARGET-30-PANRVJ-01A-01D.M	01
PANRVJ_01_Solid Tissue_Primary Tumor	26.77	2	loss	NBL, MYCN non-amplified	PANRVJ	TARGET-30-PANRVJ-01A-01R	01
PANSBN_01_Solid Tissue_Primary Tumor	0.64	2	neutral	NBL, MYCN non-amplified	PANSBN	TARGET-30-PANSBN-01A-01D	01
PANSBN_01_Solid Tissue_Primary Tumor	0.64	2	neutral	NBL, MYCN non-amplified	PANSBN	TARGET-30-PANSBN-01A-01R	01
PANUIF_01_Solid Tissue_Primary Tumor	11.99	3	gain	NBL, MYCN non-amplified	PANUIF	TARGET-30-PANUIF-01A-01D	01
PANUIF_01_Solid Tissue_Primary Tumor	11.99	3	gain	NBL, MYCN non-amplified	PANUIF	TARGET-30-PANUIF-01A-01D.M	01
PANUIF_01_Solid Tissue_Primary Tumor	11.99	3	gain	NBL, MYCN non-amplified	PANUIF	TARGET-30-PANUIF-01A-01R	01
PANUKV_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, To be classified	PANUKV	TARGET-30-PANUKV-01A-01D.M	01
PANUKV_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, To be classified	PANUKV	TARGET-30-PANUKV-01A-01W	01
PANWRR_01_Solid Tissue_Primary Tumor	40.86	2	neutral	NBL, MYCN non-amplified	PANWRR	TARGET-30-PANWRR-01A-01D	01
PANWRR_01_Solid Tissue_Primary Tumor	40.86	2	neutral	NBL, MYCN non-amplified	PANWRR	TARGET-30-PANWRR-01A-01D.M	01
PANWRR_01_Solid Tissue_Primary Tumor	40.86	2	neutral	NBL, MYCN non-amplified	PANWRR	TARGET-30-PANWRR-01A-01R	01
PANXJL_01_Solid Tissue_Primary Tumor	1.55	2	loss	NBL, MYCN non-amplified	PANXJL	TARGET-30-PANXJL-01A-01D	01
PANXJL_01_Solid Tissue_Primary Tumor	1.55	2	loss	NBL, MYCN non-amplified	PANXJL	TARGET-30-PANXJL-01A-01D.M	01
PANXJL_01_Solid Tissue_Primary Tumor	1.55	2	loss	NBL, MYCN non-amplified	PANXJL	TARGET-30-PANXJL-01A-01R	01
PANYBL_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PANYBL	TARGET-30-PANYBL-01A-01W	01
PANYGR_01_Solid Tissue_Primary Tumor	30.92	2	loss	NBL, MYCN non-amplified	PANYGR	TARGET-30-PANYGR-01A-01D.M	01
PANYGR_01_Solid Tissue_Primary Tumor	30.92	2	loss	NBL, MYCN non-amplified	PANYGR	TARGET-30-PANYGR-01A-01R	01
PANYGR_01_Solid Tissue_Primary Tumor	30.92	2	loss	NBL, MYCN non-amplified	PANYGR	TARGET-30-PANYGR-01A-01W	01
PANZPV_01_Solid Tissue_Primary Tumor	12.01	2	loss	NBL, MYCN non-amplified	PANZPV	TARGET-30-PANZPV-01A-01D.M	01
PANZPV_01_Solid Tissue_Primary Tumor	12.01	2	loss	NBL, MYCN non-amplified	PANZPV	TARGET-30-PANZPV-01A-01R	01
PANZPV_01_Solid Tissue_Primary Tumor	12.01	2	loss	NBL, MYCN non-amplified	PANZPV	TARGET-30-PANZPV-01A-01W	01
PANZRV_01_Solid Tissue_Primary Tumor	73.06	NA	NA	NBL, MYCN amplified	PANZRV	TARGET-30-PANZRV-01A-01R	01
PANZVU_01_Solid Tissue_Primary Tumor	37.11	2	loss	NBL, MYCN non-amplified	PANZVU	TARGET-30-PANZVU-01A-01D.M	01
PANZVU_01_Solid Tissue_Primary Tumor	37.11	2	loss	NBL, MYCN non-amplified	PANZVU	TARGET-30-PANZVU-01A-01R	01
PANZVU_01_Solid Tissue_Primary Tumor	37.11	2	loss	NBL, MYCN non-amplified	PANZVU	TARGET-30-PANZVU-01A-01W	01
PAPBGH_01_Solid Tissue_Primary Tumor	0.47	2	loss	NBL, MYCN non-amplified	PAPBGH	TARGET-30-PAPBGH-01A-01D.M	01
PAPBGH_01_Solid Tissue_Primary Tumor	0.47	2	loss	NBL, MYCN non-amplified	PAPBGH	TARGET-30-PAPBGH-01A-01R	01
PAPBGH_01_Solid Tissue_Primary Tumor	0.47	2	loss	NBL, MYCN non-amplified	PAPBGH	TARGET-30-PAPBGH-01A-01W	01
PAPBJE_01_Solid Tissue_Primary Tumor	703.67	216	amplification	NBL, MYCN amplified	PAPBJE	TARGET-30-PAPBJE-01A-01D	01
PAPBJE_01_Solid Tissue_Primary Tumor	703.67	216	amplification	NBL, MYCN amplified	PAPBJE	TARGET-30-PAPBJE-01A-01D.M	01
PAPBJE_01_Solid Tissue_Primary Tumor	703.67	216	amplification	NBL, MYCN amplified	PAPBJE	TARGET-30-PAPBJE-01A-01R	01
PAPBJT_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PAPBJT	TARGET-30-PAPBJT-01A-01W	01
PAPBZI_01_Solid Tissue_Primary Tumor	22.34	4	gain	NBL, MYCN non-amplified	PAPBZI	TARGET-30-PAPBZI-01A-01D.M	01
PAPBZI_01_Solid Tissue_Primary Tumor	22.34	4	gain	NBL, MYCN non-amplified	PAPBZI	TARGET-30-PAPBZI-01A-01R	01
PAPBZI_01_Solid Tissue_Primary Tumor	22.34	4	gain	NBL, MYCN non-amplified	PAPBZI	TARGET-30-PAPBZI-01A-01W	01
PAPCTS_01_Solid Tissue_Primary Tumor	1530.68	129	amplification	NBL, MYCN amplified	PAPCTS	TARGET-30-PAPCTS-01A-01D	01
PAPCTS_01_Solid Tissue_Primary Tumor	1530.68	129	amplification	NBL, MYCN amplified	PAPCTS	TARGET-30-PAPCTS-01A-01D.M	01
PAPCTS_01_Solid Tissue_Primary Tumor	1530.68	129	amplification	NBL, MYCN amplified	PAPCTS	TARGET-30-PAPCTS-01A-01R	01
PAPEAV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPEAV	TARGET-30-PAPEAV-01A-01D.M	01
PAPEFE_01_Solid Tissue_Primary Tumor	235.04	7	amplification	NBL, MYCN amplified	PAPEFE	TARGET-30-PAPEFE-01A-01D.M	01
PAPEFE_01_Solid Tissue_Primary Tumor	235.04	7	amplification	NBL, MYCN amplified	PAPEFE	TARGET-30-PAPEFE-01A-01R	01
PAPEFE_01_Solid Tissue_Primary Tumor	235.04	7	amplification	NBL, MYCN amplified	PAPEFE	TARGET-30-PAPEFE-01A-01W	01
PAPHPE_01_Solid Tissue_Primary Tumor	6.12	3	neutral	NBL, MYCN non-amplified	PAPHPE	TARGET-30-PAPHPE-01A-01D.M	01
PAPHPE_01_Solid Tissue_Primary Tumor	6.12	3	neutral	NBL, MYCN non-amplified	PAPHPE	TARGET-30-PAPHPE-01A-01R	01
PAPHPE_01_Solid Tissue_Primary Tumor	6.12	3	neutral	NBL, MYCN non-amplified	PAPHPE	TARGET-30-PAPHPE-01A-01W	01
PAPICY_01_Solid Tissue_Primary Tumor	52.53	NA	NA	NBL, MYCN amplified	PAPICY	TARGET-30-PAPICY-01A-01D.M	01
PAPICY_01_Solid Tissue_Primary Tumor	52.53	NA	NA	NBL, MYCN amplified	PAPICY	TARGET-30-PAPICY-01A-01R	01
PAPKWN_01_Solid Tissue_Primary Tumor	51.31	13	amplification	NBL, MYCN amplified	PAPKWN	TARGET-30-PAPKWN-01A-01D.M	01
PAPKWN_01_Solid Tissue_Primary Tumor	51.31	13	amplification	NBL, MYCN amplified	PAPKWN	TARGET-30-PAPKWN-01A-01R	01
PAPKWN_01_Solid Tissue_Primary Tumor	51.31	13	amplification	NBL, MYCN amplified	PAPKWN	TARGET-30-PAPKWN-01A-01W	01
PAPKXS_01_Solid Tissue_Primary Tumor	138.23	3	gain	NBL, MYCN non-amplified	PAPKXS	TARGET-30-PAPKXS-01A-01D	01
PAPKXS_01_Solid Tissue_Primary Tumor	138.23	3	gain	NBL, MYCN non-amplified	PAPKXS	TARGET-30-PAPKXS-01A-01D.M	01
PAPKXS_01_Solid Tissue_Primary Tumor	138.23	3	gain	NBL, MYCN non-amplified	PAPKXS	TARGET-30-PAPKXS-01A-01R	01
PAPLSD_01_Solid Tissue_Primary Tumor	22.99	3	gain	NBL, MYCN non-amplified	PAPLSD	TARGET-30-PAPLSD-01A-01D	01
PAPLSD_01_Solid Tissue_Primary Tumor	22.99	3	gain	NBL, MYCN non-amplified	PAPLSD	TARGET-30-PAPLSD-01A-01R	01
PAPNEP_01_Solid Tissue_Primary Tumor	NA	42	amplification	NBL, MYCN amplified	PAPNEP	TARGET-30-PAPNEP-01A-01W	01
PAPPKJ_01_Solid Tissue_Primary Tumor	NA	4	gain	NBL, MYCN non-amplified	PAPPKJ	TARGET-30-PAPPKJ-01A-01W	01
PAPREJ_01_Solid Tissue_Primary Tumor	NA	181	amplification	NBL, MYCN amplified	PAPREJ	TARGET-30-PAPREJ-01A-01D	01
PAPRMJ_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PAPRMJ	TARGET-30-PAPRMJ-01A-01D	01
PAPRPR_01_Solid Tissue_Primary Tumor	NA	69	amplification	NBL, MYCN amplified	PAPRPR	TARGET-30-PAPRPR-01A-01D	01
PAPRXW_01_Solid Tissue_Primary Tumor	NA	29	amplification	NBL, MYCN amplified	PAPRXW	TARGET-30-PAPRXW-01A-01D	01
PAPRXW_01_Solid Tissue_Primary Tumor	NA	29	amplification	NBL, MYCN amplified	PAPRXW	TARGET-30-PAPRXW-01A-01D.M	01
PAPSEI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPSEI	TARGET-30-PAPSEI-01A-01D.M	01
PAPSKM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPSKM	TARGET-30-PAPSKM-01A-01D.M	01
PAPSMC_01_Solid Tissue_Primary Tumor	NA	34	amplification	NBL, MYCN amplified	PAPSMC	TARGET-30-PAPSMC-01A-01W	01
PAPTAN_01_Solid Tissue_Primary Tumor	16.17	2	neutral	NBL, MYCN non-amplified	PAPTAN	TARGET-30-PAPTAN-01A-01D	01
PAPTAN_01_Solid Tissue_Primary Tumor	16.17	2	neutral	NBL, MYCN non-amplified	PAPTAN	TARGET-30-PAPTAN-01A-01D.M	01
PAPTAN_01_Solid Tissue_Primary Tumor	16.17	2	neutral	NBL, MYCN non-amplified	PAPTAN	TARGET-30-PAPTAN-01A-01R	01
PAPTCR_01_Solid Tissue_Primary Tumor	5.71	2	neutral	NBL, MYCN amplified	PAPTCR	TARGET-30-PAPTCR-01A-01D	01
PAPTCR_01_Solid Tissue_Primary Tumor	5.71	2	neutral	NBL, MYCN amplified	PAPTCR	TARGET-30-PAPTCR-01A-01D.M	01
PAPTCR_01_Solid Tissue_Primary Tumor	5.71	2	neutral	NBL, MYCN amplified	PAPTCR	TARGET-30-PAPTCR-01A-01R	01
PAPTDH_01_Solid Tissue_Primary Tumor	38.65	NA	NA	NBL, MYCN amplified	PAPTDH	TARGET-30-PAPTDH-01A-01D.M	01
PAPTDH_01_Solid Tissue_Primary Tumor	38.65	NA	NA	NBL, MYCN amplified	PAPTDH	TARGET-30-PAPTDH-01A-01R	01
PAPTFZ_01_Solid Tissue_Primary Tumor	841.05	125	amplification	NBL, MYCN amplified	PAPTFZ	TARGET-30-PAPTFZ-01A-01D	01
PAPTFZ_01_Solid Tissue_Primary Tumor	841.05	125	amplification	NBL, MYCN amplified	PAPTFZ	TARGET-30-PAPTFZ-01A-01D.M	01
PAPTFZ_01_Solid Tissue_Primary Tumor	841.05	125	amplification	NBL, MYCN amplified	PAPTFZ	TARGET-30-PAPTFZ-01A-01R	01
PAPTIP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPTIP	TARGET-30-PAPTIP-01A-01D.M	01
PAPTJB_01_Solid Tissue_Primary Tumor	NA	4	gain	NBL, MYCN non-amplified	PAPTJB	TARGET-30-PAPTJB-01A-01D	01
PAPTLA_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAPTLA	TARGET-30-PAPTLA-01A-01D	01
PAPTLA_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAPTLA	TARGET-30-PAPTLA-01A-01D.M	01
PAPTLD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPTLD	TARGET-30-PAPTLD-01A-01D.M	01
PAPTLV_01_Solid Tissue_Primary Tumor	255.44	24	amplification	NBL, MYCN amplified	PAPTLV	TARGET-30-PAPTLV-01A-01D	01
PAPTLV_01_Solid Tissue_Primary Tumor	255.44	24	amplification	NBL, MYCN amplified	PAPTLV	TARGET-30-PAPTLV-01A-01D.M	01
PAPTLV_01_Solid Tissue_Primary Tumor	255.44	24	amplification	NBL, MYCN amplified	PAPTLV	TARGET-30-PAPTLV-01A-01R	01
PAPTLY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPTLY	TARGET-30-PAPTLY-01A-01D.M	01
PAPTMM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPTMM	TARGET-30-PAPTMM-01A-01D.M	01
PAPUAR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPUAR	TARGET-30-PAPUAR-01A-01D.M	01
PAPUEB_01_Solid Tissue_Primary Tumor	20.09	NA	NA	NBL, MYCN amplified	PAPUEB	TARGET-30-PAPUEB-01A-01R	01
PAPUJU_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PAPUJU	TARGET-30-PAPUJU-01A-01D	01
PAPUJU_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PAPUJU	TARGET-30-PAPUJU-01A-01D.M	01
PAPUNH_01_Solid Tissue_Primary Tumor	2481.33	NA	NA	NBL, MYCN amplified	PAPUNH	TARGET-30-PAPUNH-01A-01D.M	01
PAPUNH_01_Solid Tissue_Primary Tumor	2481.33	NA	NA	NBL, MYCN amplified	PAPUNH	TARGET-30-PAPUNH-01A-01R	01
PAPUTN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPUTN	TARGET-30-PAPUTN-01A-01D.M	01
PAPUWY_01_Solid Tissue_Primary Tumor	48.51	2	loss	NBL, MYCN non-amplified	PAPUWY	TARGET-30-PAPUWY-01A-01D	01
PAPUWY_01_Solid Tissue_Primary Tumor	48.51	2	loss	NBL, MYCN non-amplified	PAPUWY	TARGET-30-PAPUWY-01A-01D.M	01
PAPUWY_01_Solid Tissue_Primary Tumor	48.51	2	loss	NBL, MYCN non-amplified	PAPUWY	TARGET-30-PAPUWY-01A-01R	01
PAPVEB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPVEB	TARGET-30-PAPVEB-01A-01D.M	01
PAPVEB_04_Bone Marrow_Recurrence	11.44	NA	NA	NBL, MYCN non-amplified	PAPVEB	TARGET-30-PAPVEB-04A-01D.M	04
PAPVEB_04_Bone Marrow_Recurrence	11.44	NA	NA	NBL, MYCN non-amplified	PAPVEB	TARGET-30-PAPVEB-04A-01R	04
PAPVFD_01_Solid Tissue_Primary Tumor	76.15	2	loss	NBL, MYCN non-amplified	PAPVFD	TARGET-30-PAPVFD-01A-01D	01
PAPVFD_01_Solid Tissue_Primary Tumor	76.15	2	loss	NBL, MYCN non-amplified	PAPVFD	TARGET-30-PAPVFD-01A-01D.M	01
PAPVFD_01_Solid Tissue_Primary Tumor	76.15	2	loss	NBL, MYCN non-amplified	PAPVFD	TARGET-30-PAPVFD-01A-01R	01
PAPVRN_01_Solid Tissue_Primary Tumor	6.59	2	loss	NBL, MYCN non-amplified	PAPVRN	TARGET-30-PAPVRN-01A-01D	01
PAPVRN_01_Solid Tissue_Primary Tumor	6.59	2	loss	NBL, MYCN non-amplified	PAPVRN	TARGET-30-PAPVRN-01A-01D.M	01
PAPVRN_01_Solid Tissue_Primary Tumor	6.59	2	loss	NBL, MYCN non-amplified	PAPVRN	TARGET-30-PAPVRN-01A-01R	01
PAPVXS_01_Solid Tissue_Primary Tumor	36.95	3	neutral	NBL, MYCN non-amplified	PAPVXS	TARGET-30-PAPVXS-01A-01D	01
PAPVXS_01_Solid Tissue_Primary Tumor	36.95	3	neutral	NBL, MYCN non-amplified	PAPVXS	TARGET-30-PAPVXS-01A-01D.M	01
PAPVXS_01_Solid Tissue_Primary Tumor	36.95	3	neutral	NBL, MYCN non-amplified	PAPVXS	TARGET-30-PAPVXS-01A-01R	01
PAPWFY_01_Solid Tissue_Primary Tumor	NA	34	amplification	NBL, MYCN amplified	PAPWFY	TARGET-30-PAPWFY-01A-01D	01
PAPWUC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAPWUC	TARGET-30-PAPWUC-01A-01D.M	01
PAPYNZ_01_Solid Tissue_Primary Tumor	NA	69	amplification	NBL, MYCN amplified	PAPYNZ	TARGET-30-PAPYNZ-01A-01D	01
PAPZFW_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PAPZFW	TARGET-30-PAPZFW-01A-01D	01
PAPZFW_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PAPZFW	TARGET-30-PAPZFW-01A-01D.M	01
PAPZYP_01_Solid Tissue_Primary Tumor	404.52	NA	NA	NBL, MYCN amplified	PAPZYP	TARGET-30-PAPZYP-01A-01D.M	01
PAPZYP_01_Solid Tissue_Primary Tumor	404.52	NA	NA	NBL, MYCN amplified	PAPZYP	TARGET-30-PAPZYP-01A-01R	01
PAPZYZ_01_Solid Tissue_Primary Tumor	273.22	131	amplification	NBL, MYCN amplified	PAPZYZ	TARGET-30-PAPZYZ-01A-01D	01
PAPZYZ_01_Solid Tissue_Primary Tumor	273.22	131	amplification	NBL, MYCN amplified	PAPZYZ	TARGET-30-PAPZYZ-01A-01D.M	01
PAPZYZ_01_Solid Tissue_Primary Tumor	273.22	131	amplification	NBL, MYCN amplified	PAPZYZ	TARGET-30-PAPZYZ-01A-01R	01
PARABJ_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PARABJ	TARGET-30-PARABJ-01A-01D	01
PARABN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARABN	TARGET-30-PARABN-01A-01D.M	01
PARACM_01_Solid Tissue_Primary Tumor	35.88	NA	NA	NBL, MYCN amplified	PARACM	TARGET-30-PARACM-01A-01D.M	01
PARACM_01_Solid Tissue_Primary Tumor	35.88	NA	NA	NBL, MYCN amplified	PARACM	TARGET-30-PARACM-01A-01R	01
PARACR_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, To be classified	PARACR	TARGET-30-PARACR-01A-01D	01
PARACS_01_Solid Tissue_Primary Tumor	36.69	3	neutral	NBL, MYCN non-amplified	PARACS	TARGET-30-PARACS-01A-01D	01
PARACS_01_Solid Tissue_Primary Tumor	36.69	3	neutral	NBL, MYCN non-amplified	PARACS	TARGET-30-PARACS-01A-01D.M	01
PARACS_01_Solid Tissue_Primary Tumor	36.69	3	neutral	NBL, MYCN non-amplified	PARACS	TARGET-30-PARACS-01A-01R	01
PARAHE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARAHE	TARGET-30-PARAHE-01A-01D.M	01
PARAMT_01_Solid Tissue_Primary Tumor	73.4	3	neutral	NBL, MYCN non-amplified	PARAMT	TARGET-30-PARAMT-01A-01D	01
PARAMT_01_Solid Tissue_Primary Tumor	73.4	3	neutral	NBL, MYCN non-amplified	PARAMT	TARGET-30-PARAMT-01A-01D.M	01
PARAMT_01_Solid Tissue_Primary Tumor	73.4	3	neutral	NBL, MYCN non-amplified	PARAMT	TARGET-30-PARAMT-01A-01R	01
PARASL_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PARASL	TARGET-30-PARASL-01A-01D	01
PARASL_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PARASL	TARGET-30-PARASL-01A-01D.M	01
PARBAJ_01_Solid Tissue_Primary Tumor	20.35	NA	NA	NBL, MYCN amplified	PARBAJ	TARGET-30-PARBAJ-01A-01D.M	01
PARBAJ_01_Solid Tissue_Primary Tumor	20.35	NA	NA	NBL, MYCN amplified	PARBAJ	TARGET-30-PARBAJ-01A-01R	01
PARBAJ_02_Solid Tissue_Recurrence	11.17	NA	NA	NBL, MYCN non-amplified	PARBAJ	TARGET-30-PARBAJ-02A-01D.M	02
PARBAJ_02_Solid Tissue_Recurrence	11.17	NA	NA	NBL, MYCN non-amplified	PARBAJ	TARGET-30-PARBAJ-02A-01R	02
PARBGP_01_Solid Tissue_Primary Tumor	59.05	2	loss	NBL, MYCN non-amplified	PARBGP	TARGET-30-PARBGP-01A-01D	01
PARBGP_01_Solid Tissue_Primary Tumor	59.05	2	loss	NBL, MYCN non-amplified	PARBGP	TARGET-30-PARBGP-01A-01D.M	01
PARBGP_01_Solid Tissue_Primary Tumor	59.05	2	loss	NBL, MYCN non-amplified	PARBGP	TARGET-30-PARBGP-01A-01R	01
PARBLH_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PARBLH	TARGET-30-PARBLH-01A-01D	01
PARBLH_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PARBLH	TARGET-30-PARBLH-01A-01D.M	01
PARCET_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARCET	TARGET-30-PARCET-01A-01D.M	01
PARCRR_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PARCRR	TARGET-30-PARCRR-01A-01D	01
PARDCK_01_Solid Tissue_Primary Tumor	8.07	2	loss	NBL, MYCN non-amplified	PARDCK	TARGET-30-PARDCK-01A-01D	01
PARDCK_01_Solid Tissue_Primary Tumor	8.07	2	loss	NBL, MYCN non-amplified	PARDCK	TARGET-30-PARDCK-01A-01D.M	01
PARDCK_01_Solid Tissue_Primary Tumor	8.07	2	loss	NBL, MYCN non-amplified	PARDCK	TARGET-30-PARDCK-01A-01R	01
PARDIW_01_Solid Tissue_Primary Tumor	22.26	2	loss	NBL, MYCN non-amplified	PARDIW	TARGET-30-PARDIW-01A-01D	01
PARDIW_01_Solid Tissue_Primary Tumor	22.26	2	loss	NBL, MYCN non-amplified	PARDIW	TARGET-30-PARDIW-01A-01D.M	01
PARDIW_01_Solid Tissue_Primary Tumor	22.26	2	loss	NBL, MYCN non-amplified	PARDIW	TARGET-30-PARDIW-01A-01R	01
PARDUJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARDUJ	TARGET-30-PARDUJ-01A-01D.M	01
PARDVT_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PARDVT	TARGET-30-PARDVT-01A-01D	01
PARDVT_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PARDVT	TARGET-30-PARDVT-01A-01D.M	01
PARDYU_01_Solid Tissue_Primary Tumor	NA	213	amplification	NBL, MYCN amplified	PARDYU	TARGET-30-PARDYU-01A-01D	01
PARDYU_01_Solid Tissue_Primary Tumor	NA	213	amplification	NBL, MYCN amplified	PARDYU	TARGET-30-PARDYU-01A-01D.M	01
PAREAG_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PAREAG	TARGET-30-PAREAG-01A-01D	01
PAREGK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAREGK	TARGET-30-PAREGK-01A-01D.M	01
PARETE_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, To be classified	PARETE	TARGET-30-PARETE-01A-01D	01
PARETE_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, To be classified	PARETE	TARGET-30-PARETE-01A-01D.M	01
PARFRE_01_Solid Tissue_Primary Tumor	37.8	NA	NA	NBL, MYCN amplified	PARFRE	TARGET-30-PARFRE-01A-01D.M	01
PARFRE_01_Solid Tissue_Primary Tumor	37.8	NA	NA	NBL, MYCN amplified	PARFRE	TARGET-30-PARFRE-01A-01R	01
PARFWB_01_Solid Tissue_Primary Tumor	34.21	2	neutral	NBL, MYCN non-amplified	PARFWB	TARGET-30-PARFWB-01A-01D	01
PARFWB_01_Solid Tissue_Primary Tumor	34.21	2	neutral	NBL, MYCN non-amplified	PARFWB	TARGET-30-PARFWB-01A-01D.M	01
PARFWB_01_Solid Tissue_Primary Tumor	34.21	2	neutral	NBL, MYCN non-amplified	PARFWB	TARGET-30-PARFWB-01A-01R	01
PARGDJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARGDJ	TARGET-30-PARGDJ-01A-01D.M	01
PARGHY_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PARGHY	TARGET-30-PARGHY-01A-01D	01
PARGKK_01_Solid Tissue_Primary Tumor	32.9	2	neutral	NBL, MYCN non-amplified	PARGKK	TARGET-30-PARGKK-01A-01D	01
PARGKK_01_Solid Tissue_Primary Tumor	32.9	2	neutral	NBL, MYCN non-amplified	PARGKK	TARGET-30-PARGKK-01A-01D.M	01
PARGKK_01_Solid Tissue_Primary Tumor	32.9	2	neutral	NBL, MYCN non-amplified	PARGKK	TARGET-30-PARGKK-01A-01R	01
PARGUX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARGUX	TARGET-30-PARGUX-01A-01D.M	01
PARGZK_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, To be classified	PARGZK	TARGET-30-PARGZK-01A-01D	01
PARHAM_01_Solid Tissue_Primary Tumor	29.37	NA	NA	NBL, MYCN amplified	PARHAM	TARGET-30-PARHAM-01A-01D.M	01
PARHAM_01_Solid Tissue_Primary Tumor	29.37	NA	NA	NBL, MYCN amplified	PARHAM	TARGET-30-PARHAM-01A-01R	01
PARHAM_02_Solid Tissue_Recurrence	11.26	NA	NA	NBL, MYCN non-amplified	PARHAM	TARGET-30-PARHAM-02A-01D.M	02
PARHAM_02_Solid Tissue_Recurrence	11.26	NA	NA	NBL, MYCN non-amplified	PARHAM	TARGET-30-PARHAM-02A-01R	02
PARHDE_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, To be classified	PARHDE	TARGET-30-PARHDE-01A-01D	01
PARHUX_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, To be classified	PARHUX	TARGET-30-PARHUX-01A-01D	01
PARHYL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARHYL	TARGET-30-PARHYL-01A-01D.M	01
PARIKF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARIKF	TARGET-30-PARIKF-01A-01D.M	01
PARIRD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARIRD	TARGET-30-PARIRD-01A-01D.M	01
PARJEN_01_Solid Tissue_Primary Tumor	NA	35	amplification	NBL, MYCN amplified	PARJEN	TARGET-30-PARJEN-01A-01D	01
PARJMX_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PARJMX	TARGET-30-PARJMX-01A-01D	01
PARJVP_01_Solid Tissue_Primary Tumor	70.22	NA	NA	NBL, MYCN amplified	PARJVP	TARGET-30-PARJVP-01A-01D.M	01
PARJVP_01_Solid Tissue_Primary Tumor	70.22	NA	NA	NBL, MYCN amplified	PARJVP	TARGET-30-PARJVP-01A-01R	01
PARKAG_01_Solid Tissue_Primary Tumor	NA	99	amplification	NBL, MYCN amplified	PARKAG	TARGET-30-PARKAG-01A-01D	01
PARKGJ_01_Solid Tissue_Primary Tumor	10.02	3	gain	NBL, MYCN non-amplified	PARKGJ	TARGET-30-PARKGJ-01A-01D	01
PARKGJ_01_Solid Tissue_Primary Tumor	10.02	3	gain	NBL, MYCN non-amplified	PARKGJ	TARGET-30-PARKGJ-01A-01D.M	01
PARKGJ_01_Solid Tissue_Primary Tumor	10.02	3	gain	NBL, MYCN non-amplified	PARKGJ	TARGET-30-PARKGJ-01A-01R	01
PARKGJ_01_Solid Tissue_Primary Tumor	10.02	3	gain	NBL, MYCN non-amplified	PARKGJ	TARGET-30-PARKGJ-01A-02D.M	01
PARKNP_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PARKNP	TARGET-30-PARKNP-01A-01D	01
PARKZF_01_Solid Tissue_Primary Tumor	NA	103	amplification	NBL, MYCN amplified	PARKZF	TARGET-30-PARKZF-01A-01D	01
PARLMK_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PARLMK	TARGET-30-PARLMK-01A-01D	01
PARLTG_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PARLTG	TARGET-30-PARLTG-01A-01D	01
PARMDD_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PARMDD	TARGET-30-PARMDD-01A-01D	01
PARMFA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARMFA	TARGET-30-PARMFA-01A-01D.M	01
PARMLF_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PARMLF	TARGET-30-PARMLF-01A-01D	01
PARMPP_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PARMPP	TARGET-30-PARMPP-01A-01D	01
PARMTT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARMTT	TARGET-30-PARMTT-01A-01D.M	01
PARNCW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARNCW	TARGET-30-PARNCW-01A-01D.M	01
PARNEE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARNEE	TARGET-30-PARNEE-01A-01D.M	01
PARNLJ_01_Solid Tissue_Primary Tumor	NA	101	amplification	NBL, MYCN amplified	PARNLJ	TARGET-30-PARNLJ-01A-01D	01
PARNNC_01_Solid Tissue_Primary Tumor	42.52	NA	NA	NBL, MYCN amplified	PARNNC	TARGET-30-PARNNC-01A-01D.M	01
PARNNC_01_Solid Tissue_Primary Tumor	42.52	NA	NA	NBL, MYCN amplified	PARNNC	TARGET-30-PARNNC-01A-01R	01
PARNNG_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PARNNG	TARGET-30-PARNNG-01A-01D	01
PARNTS_01_Solid Tissue_Primary Tumor	NA	32	amplification	NBL, MYCN amplified	PARNTS	TARGET-30-PARNTS-01A-01D	01
PARNTS_01_Solid Tissue_Primary Tumor	NA	32	amplification	NBL, MYCN amplified	PARNTS	TARGET-30-PARNTS-01A-01D.M	01
PARPGU_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, To be classified	PARPGU	TARGET-30-PARPGU-01A-01D	01
PARPUF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARPUF	TARGET-30-PARPUF-01A-01D	01
PARRBU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARRBU	TARGET-30-PARRBU-01A-01D.M	01
PARRLH_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PARRLH	TARGET-30-PARRLH-01A-01D	01
PARSBI_01_Solid Tissue_Primary Tumor	13.29	2	loss	NBL, MYCN non-amplified	PARSBI	TARGET-30-PARSBI-01A-01D	01
PARSBI_01_Solid Tissue_Primary Tumor	13.29	2	loss	NBL, MYCN non-amplified	PARSBI	TARGET-30-PARSBI-01A-01D.M	01
PARSBI_01_Solid Tissue_Primary Tumor	13.29	2	loss	NBL, MYCN non-amplified	PARSBI	TARGET-30-PARSBI-01A-01R	01
PARSEA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARSEA	TARGET-30-PARSEA-01A-01D.M	01
PARSHT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARSHT	TARGET-30-PARSHT-01A-01D.M	01
PARSRJ_01_Solid Tissue_Primary Tumor	NA	26	amplification	NBL, MYCN amplified	PARSRJ	TARGET-30-PARSRJ-01A-01D	01
PARSRJ_01_Solid Tissue_Primary Tumor	NA	26	amplification	NBL, MYCN amplified	PARSRJ	TARGET-30-PARSRJ-01A-01D.M	01
PARSVF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARSVF	TARGET-30-PARSVF-01A-01D	01
PARSXI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARSXI	TARGET-30-PARSXI-01A-01D	01
PARSZV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARSZV	TARGET-30-PARSZV-01A-01D	01
PARTCE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARTCE	TARGET-30-PARTCE-01A-01D	01
PARTPF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARTPF	TARGET-30-PARTPF-01A-01D	01
PARTRP_01_Solid Tissue_Primary Tumor	16.43	NA	NA	NBL, MYCN amplified	PARTRP	BS_4RX1AAVV	01
PARTRP_01_Solid Tissue_Primary Tumor	16.43	NA	NA	NBL, MYCN amplified	PARTRP	BS_S0B4WASX	01
PARTRP_01_Solid Tissue_Primary Tumor	16.43	NA	NA	NBL, MYCN amplified	PARTRP	TARGET-30-PARTRP-01A-01D	01
PARTYI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARTYI	TARGET-30-PARTYI-01A-01D	01
PARTZW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARTZW	TARGET-30-PARTZW-01A-01D	01
PARUCL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARUCL	TARGET-30-PARUCL-01A-01D	01
PARUCM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARUCM	TARGET-30-PARUCM-01A-01D	01
PARUFS_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PARUFS	BS_J2DA5W77	01
PARUGX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARUGX	TARGET-30-PARUGX-01A-01D	01
PARUPN_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, To be classified	PARUPN	TARGET-30-PARUPN-01A-01D	01
PARUPT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARUPT	TARGET-30-PARUPT-01A-01D	01
PARURB_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PARURB	TARGET-30-PARURB-01A-01D	01
PARURB_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PARURB	TARGET-30-PARURB-01A-01D.M	01
PARUTJ_01_Solid Tissue_Primary Tumor	0.41	NA	NA	NBL, MYCN non-amplified	PARUTJ	BS_K2K5YSDS	01
PARUTJ_01_Solid Tissue_Primary Tumor	0.41	NA	NA	NBL, MYCN non-amplified	PARUTJ	BS_S5KDWVEA	01
PARUTJ_01_Solid Tissue_Primary Tumor	0.41	NA	NA	NBL, MYCN non-amplified	PARUTJ	TARGET-30-PARUTJ-01A-01D	01
PARUTX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARUTX	TARGET-30-PARUTX-01A-01D	01
PARUXY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARUXY	TARGET-30-PARUXY-01A-01D.M	01
PARUZA_01_Solid Tissue_Primary Tumor	0.49	NA	NA	NBL, MYCN non-amplified	PARUZA	BS_808H2FQN	01
PARUZA_01_Solid Tissue_Primary Tumor	0.49	NA	NA	NBL, MYCN non-amplified	PARUZA	BS_ERHKS2Y7	01
PARVFJ_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PARVFJ	TARGET-30-PARVFJ-01A-01D	01
PARVHG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARVHG	TARGET-30-PARVHG-01A-01D	01
PARVIH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARVIH	TARGET-30-PARVIH-01A-01D	01
PARVLK_01_Solid Tissue_Primary Tumor	11.15	2	loss	NBL, MYCN non-amplified	PARVLK	TARGET-30-PARVLK-01A-01D	01
PARVLK_01_Solid Tissue_Primary Tumor	11.15	2	loss	NBL, MYCN non-amplified	PARVLK	TARGET-30-PARVLK-01A-01D.M	01
PARVLK_01_Solid Tissue_Primary Tumor	11.15	2	loss	NBL, MYCN non-amplified	PARVLK	TARGET-30-PARVLK-01A-01R	01
PARVME_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARVME	TARGET-30-PARVME-01A-01D.M	01
PARVMU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARVMU	TARGET-30-PARVMU-01A-01D	01
PARVNT_01_Solid Tissue_Primary Tumor	NA	6	amplification	NBL, MYCN amplified	PARVNT	TARGET-30-PARVNT-01A-01D	01
PARVPD_01_Solid Tissue_Primary Tumor	12.89	3	gain	NBL, MYCN non-amplified	PARVPD	BS_NPVE58AT	01
PARVPD_01_Solid Tissue_Primary Tumor	12.89	3	gain	NBL, MYCN non-amplified	PARVPD	BS_Z862V8M7	01
PARVVM_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PARVVM	TARGET-30-PARVVM-09A-01D	09
PARVWL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARVWL	TARGET-30-PARVWL-01A-01D	01
PARVZT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARVZT	BS_8FYZMP93	01
PARVZT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARVZT	TARGET-30-PARVZT-01A-01D	01
PARWAM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARWAM	TARGET-30-PARWAM-01A-01D	01
PARWBC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARWBC	TARGET-30-PARWBC-01A-01D	01
PARWEH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARWEH	TARGET-30-PARWEH-01A-01D	01
PARWEV_01_Solid Tissue_Primary Tumor	33.86	NA	NA	NBL, MYCN amplified	PARWEV	BS_C8T56CWR	01
PARWEV_01_Solid Tissue_Primary Tumor	33.86	NA	NA	NBL, MYCN amplified	PARWEV	BS_DBXCETW2	01
PARWEV_01_Solid Tissue_Primary Tumor	33.86	NA	NA	NBL, MYCN amplified	PARWEV	TARGET-30-PARWEV-01A-01D	01
PARWTY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARWTY	TARGET-30-PARWTY-01A-01D	01
PARXAX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXAX	TARGET-30-PARXAX-01A-01D	01
PARXDW_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PARXDW	BS_75HW641M	01
PARXLL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXLL	TARGET-30-PARXLL-01A-01D	01
PARXLM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXLM	TARGET-30-PARXLM-01A-01D.M	01
PARXLN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXLN	TARGET-30-PARXLN-01A-01D	01
PARXMH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXMH	TARGET-30-PARXMH-01A-01D	01
PARXMM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXMM	TARGET-30-PARXMM-01A-01D	01
PARXPD_01_Solid Tissue_Primary Tumor	24.86	NA	loss	NBL, MYCN non-amplified	PARXPD	BS_29DZNQYC	01
PARXPD_01_Solid Tissue_Primary Tumor	24.86	NA	loss	NBL, MYCN non-amplified	PARXPD	BS_3N0ZS3G3	01
PARXPD_01_Solid Tissue_Primary Tumor	24.86	NA	loss	NBL, MYCN non-amplified	PARXPD	TARGET-30-PARXPD-01A-01D	01
PARXVA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXVA	TARGET-30-PARXVA-01A-01D	01
PARXXC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXXC	TARGET-30-PARXXC-01A-01D	01
PARXZA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARXZA	TARGET-30-PARXZA-01A-01D	01
PARYAG_01_Solid Tissue_Primary Tumor	1.84	NA	NA	NBL, MYCN non-amplified	PARYAG	BS_29MQMSCM	01
PARYAG_01_Solid Tissue_Primary Tumor	1.84	NA	NA	NBL, MYCN non-amplified	PARYAG	BS_YZJ5YQ12	01
PARYEH_01_Solid Tissue_Primary Tumor	22.31	NA	loss	NBL, MYCN non-amplified	PARYEH	BS_1G5N5R8S	01
PARYEH_01_Solid Tissue_Primary Tumor	22.31	NA	loss	NBL, MYCN non-amplified	PARYEH	BS_2Y28PRQC	01
PARYEH_01_Solid Tissue_Primary Tumor	22.31	NA	loss	NBL, MYCN non-amplified	PARYEH	TARGET-30-PARYEH-01A-01D	01
PARYNK_01_Solid Tissue_Primary Tumor	5.63	2	neutral	NBL, MYCN non-amplified	PARYNK	TARGET-30-PARYNK-01A-01D	01
PARYNK_01_Solid Tissue_Primary Tumor	5.63	2	neutral	NBL, MYCN non-amplified	PARYNK	TARGET-30-PARYNK-01A-01D.M	01
PARYNK_01_Solid Tissue_Primary Tumor	5.63	2	neutral	NBL, MYCN non-amplified	PARYNK	TARGET-30-PARYNK-01A-01R	01
PARYRJ_01_Solid Tissue_Primary Tumor	26.4	NA	NA	NBL, MYCN amplified	PARYRJ	BS_92YFTG9R	01
PARYRJ_01_Solid Tissue_Primary Tumor	26.4	NA	NA	NBL, MYCN amplified	PARYRJ	BS_JY850J9G	01
PARYRJ_01_Solid Tissue_Primary Tumor	26.4	NA	NA	NBL, MYCN amplified	PARYRJ	TARGET-30-PARYRJ-01A-01D	01
PARYSR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARYSR	TARGET-30-PARYSR-01A-01D	01
PARYUK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARYUK	TARGET-30-PARYUK-01A-01D	01
PARYVD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARYVD	TARGET-30-PARYVD-01A-01D	01
PARYWX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARYWX	TARGET-30-PARYWX-01A-01D	01
PARYXW_01_Solid Tissue_Primary Tumor	NA	5	amplification	NBL, MYCN amplified	PARYXW	TARGET-30-PARYXW-01A-01D	01
PARZBH_01_Solid Tissue_Primary Tumor	22.7	NA	NA	NBL, MYCN amplified	PARZBH	BS_BG0ZDND2	01
PARZBH_01_Solid Tissue_Primary Tumor	22.7	NA	NA	NBL, MYCN amplified	PARZBH	BS_F6MNG2S0	01
PARZBH_01_Solid Tissue_Primary Tumor	22.7	NA	NA	NBL, MYCN amplified	PARZBH	TARGET-30-PARZBH-01A-01D	01
PARZCJ_01_Solid Tissue_Primary Tumor	22.125	NA	NA	NBL, MYCN amplified	PARZCJ	BS_1G3QX306	01
PARZCJ_01_Solid Tissue_Primary Tumor	22.125	NA	NA	NBL, MYCN amplified	PARZCJ	BS_FHNTKFVJ	01
PARZCJ_01_Solid Tissue_Primary Tumor	22.125	NA	NA	NBL, MYCN amplified	PARZCJ	TARGET-30-PARZCJ-01A-01D.M	01
PARZCJ_01_Solid Tissue_Primary Tumor	22.125	NA	NA	NBL, MYCN amplified	PARZCJ	TARGET-30-PARZCJ-01A-01R	01
PARZHA_01_Solid Tissue_Primary Tumor	68.06	NA	NA	NBL, MYCN amplified	PARZHA	TARGET-30-PARZHA-01A-01D.M	01
PARZHA_01_Solid Tissue_Primary Tumor	68.06	NA	NA	NBL, MYCN amplified	PARZHA	TARGET-30-PARZHA-01A-01R	01
PARZIP_01_Solid Tissue_Primary Tumor	53.23	3	loss	NBL, MYCN non-amplified	PARZIP	TARGET-30-PARZIP-01A-01D	01
PARZIP_01_Solid Tissue_Primary Tumor	53.23	3	loss	NBL, MYCN non-amplified	PARZIP	TARGET-30-PARZIP-01A-01D.M	01
PARZIP_01_Solid Tissue_Primary Tumor	53.23	3	loss	NBL, MYCN non-amplified	PARZIP	TARGET-30-PARZIP-01A-01R	01
PARZKK_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PARZKK	TARGET-30-PARZKK-09A-01D	09
PARZMY_06_Solid Tissue_Metastatic	NA	84	amplification	NBL, MYCN amplified	PARZMY	TARGET-30-PARZMY-06A-01D	06
PARZNV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARZNV	TARGET-30-PARZNV-01A-01D	01
PARZZC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARZZC	TARGET-30-PARZZC-01A-01D	01
PARZZD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PARZZD	TARGET-30-PARZZD-01A-01D	01
PASAAB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASAAB	TARGET-30-PASAAB-01A-01D	01
PASAAN_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PASAAN	TARGET-30-PASAAN-01A-01D	01
PASAEJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASAEJ	BS_AZ6KVKC4	01
PASAFG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASAFG	TARGET-30-PASAFG-01A-01D	01
PASAGA_01_Solid Tissue_Primary Tumor	11.82	NA	NA	NBL, MYCN non-amplified	PASAGA	BS_7MXT22QP	01
PASAGA_01_Solid Tissue_Primary Tumor	11.82	NA	NA	NBL, MYCN non-amplified	PASAGA	BS_9R8GFR36	01
PASAHC_01_Solid Tissue_Primary Tumor	20.59	NA	NA	NBL, MYCN amplified	PASAHC	BS_AFRGW493	01
PASAHC_01_Solid Tissue_Primary Tumor	20.59	NA	NA	NBL, MYCN amplified	PASAHC	BS_Z2G9EG1X	01
PASAHC_01_Solid Tissue_Primary Tumor	20.59	NA	NA	NBL, MYCN amplified	PASAHC	TARGET-30-PASAHC-01A-01D	01
PASAJU_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PASAJU	TARGET-30-PASAJU-01A-01D	01
PASAJY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASAJY	TARGET-30-PASAJY-01A-01D	01
PASALE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASALE	TARGET-30-PASALE-01A-01D	01
PASANE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASANE	TARGET-30-PASANE-01A-01D	01
PASATF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASATF	TARGET-30-PASATF-01A-01D	01
PASATK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASATK	TARGET-30-PASATK-01A-01D.M	01
PASAVJ_01_Solid Tissue_Primary Tumor	21.16	NA	NA	NBL, MYCN amplified	PASAVJ	BS_28ZRHXX8	01
PASAVJ_01_Solid Tissue_Primary Tumor	21.16	NA	NA	NBL, MYCN amplified	PASAVJ	BS_J3707KE2	01
PASAVJ_01_Solid Tissue_Primary Tumor	21.16	NA	NA	NBL, MYCN amplified	PASAVJ	TARGET-30-PASAVJ-01A-01D	01
PASAZJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASAZJ	TARGET-30-PASAZJ-01A-01D.M	01
PASAZZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASAZZ	TARGET-30-PASAZZ-01A-01D	01
PASBDN_01_Solid Tissue_Primary Tumor	31.15	NA	gain	NBL, MYCN non-amplified	PASBDN	BS_15ED4VDX	01
PASBDN_01_Solid Tissue_Primary Tumor	31.15	NA	gain	NBL, MYCN non-amplified	PASBDN	BS_JGVTE14P	01
PASBDN_01_Solid Tissue_Primary Tumor	31.15	NA	gain	NBL, MYCN non-amplified	PASBDN	TARGET-30-PASBDN-01A-01D	01
PASBEN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASBEN	TARGET-30-PASBEN-01A-01D.M	01
PASBGV_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PASBGV	TARGET-30-PASBGV-01A-01D	01
PASBHS_01_Solid Tissue_Primary Tumor	23.15	3	gain	NBL, MYCN non-amplified	PASBHS	BS_EF8F5GH8	01
PASBHS_01_Solid Tissue_Primary Tumor	23.15	3	gain	NBL, MYCN non-amplified	PASBHS	BS_SSHQFYA8	01
PASBJY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASBJY	TARGET-30-PASBJY-01A-01D	01
PASBKP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASBKP	TARGET-30-PASBKP-01A-01D	01
PASBMW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASBMW	TARGET-30-PASBMW-01A-01D	01
PASBPN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASBPN	BS_5PEA35TB	01
PASBPN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASBPN	TARGET-30-PASBPN-01A-01D	01
PASBYW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASBYW	TARGET-30-PASBYW-01A-01D	01
PASBZV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASBZV	TARGET-30-PASBZV-01A-01D	01
PASCDX_01_Solid Tissue_Primary Tumor	181.39	164	amplification	NBL, MYCN amplified	PASCDX	BS_97SKFHM4	01
PASCDX_01_Solid Tissue_Primary Tumor	181.39	164	amplification	NBL, MYCN amplified	PASCDX	BS_SYSZCYYZ	01
PASCDX_01_Solid Tissue_Primary Tumor	181.39	164	amplification	NBL, MYCN amplified	PASCDX	TARGET-30-PASCDX-01A-01D	01
PASCEW_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCEW	TARGET-30-PASCEW-09A-01D	09
PASCFA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCFA	TARGET-30-PASCFA-01A-01D	01
PASCFC_01_Solid Tissue_Primary Tumor	54.22	NA	NA	NBL, MYCN amplified	PASCFC	TARGET-30-PASCFC-01A-01D.M	01
PASCFC_01_Solid Tissue_Primary Tumor	54.22	NA	NA	NBL, MYCN amplified	PASCFC	TARGET-30-PASCFC-01A-01R	01
PASCFD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCFD	TARGET-30-PASCFD-01A-01D	01
PASCGM_01_Solid Tissue_Primary Tumor	5.56	3	neutral	NBL, MYCN non-amplified	PASCGM	BS_HYX0M8VM	01
PASCGM_01_Solid Tissue_Primary Tumor	5.56	3	neutral	NBL, MYCN non-amplified	PASCGM	BS_REGK1PS6	01
PASCIX_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCIX	TARGET-30-PASCIX-09A-01D	09
PASCJJ_01_Solid Tissue_Primary Tumor	NA	3	neutral	NBL, MYCN non-amplified	PASCJJ	TARGET-30-PASCJJ-01A-01D	01
PASCKI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCKI	TARGET-30-PASCKI-01A-01D.M	01
PASCLP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCLP	TARGET-30-PASCLP-01A-01D.M	01
PASCRK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCRK	TARGET-30-PASCRK-01A-01D	01
PASCTR_01_Solid Tissue_Primary Tumor	38.9	NA	NA	NBL, MYCN amplified	PASCTR	TARGET-30-PASCTR-01A-01D.M	01
PASCTR_01_Solid Tissue_Primary Tumor	38.9	NA	NA	NBL, MYCN amplified	PASCTR	TARGET-30-PASCTR-01A-01R	01
PASCUF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCUF	TARGET-30-PASCUF-01A-01D.M	01
PASCWD_01_Solid Tissue_Primary Tumor	310.39	NA	amplification	NBL, MYCN amplified	PASCWD	BS_DWYR5CTE	01
PASCWD_01_Solid Tissue_Primary Tumor	310.39	NA	amplification	NBL, MYCN amplified	PASCWD	BS_W5X4568N	01
PASCWD_01_Solid Tissue_Primary Tumor	310.39	NA	amplification	NBL, MYCN amplified	PASCWD	TARGET-30-PASCWD-01A-01D	01
PASCZY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASCZY	TARGET-30-PASCZY-01A-01D	01
PASDDP_01_Solid Tissue_Primary Tumor	19.57	NA	loss	NBL, MYCN non-amplified	PASDDP	BS_MAJ800Q0	01
PASDDP_01_Solid Tissue_Primary Tumor	19.57	NA	loss	NBL, MYCN non-amplified	PASDDP	BS_XA3KEKC6	01
PASDDP_01_Solid Tissue_Primary Tumor	19.57	NA	loss	NBL, MYCN non-amplified	PASDDP	TARGET-30-PASDDP-01A-01D	01
PASDNT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASDNT	BS_H18ZNTNR	01
PASDPN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASDPN	BS_W05MC7QG	01
PASDRV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASDRV	TARGET-30-PASDRV-01A-01D	01
PASDYT_01_Solid Tissue_Primary Tumor	17.46	NA	NA	NBL, MYCN amplified	PASDYT	BS_B6E0477K	01
PASDYT_01_Solid Tissue_Primary Tumor	17.46	NA	NA	NBL, MYCN amplified	PASDYT	BS_N13KZYRR	01
PASDYT_01_Solid Tissue_Primary Tumor	17.46	NA	NA	NBL, MYCN amplified	PASDYT	TARGET-30-PASDYT-01A-01D	01
PASDZJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASDZJ	TARGET-30-PASDZJ-01A-01D.M	01
PASEAR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASEAR	TARGET-30-PASEAR-01A-01D	01
PASEDP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASEDP	TARGET-30-PASEDP-01A-01D	01
PASEGA_01_Solid Tissue_Primary Tumor	16.44	2	neutral	NBL, MYCN non-amplified	PASEGA	TARGET-30-PASEGA-01A-01D	01
PASEGA_01_Solid Tissue_Primary Tumor	16.44	2	neutral	NBL, MYCN non-amplified	PASEGA	TARGET-30-PASEGA-01A-01D.M	01
PASEGA_01_Solid Tissue_Primary Tumor	16.44	2	neutral	NBL, MYCN non-amplified	PASEGA	TARGET-30-PASEGA-01A-01R	01
PASEGF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASEGF	TARGET-30-PASEGF-01A-01D	01
PASEJZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASEJZ	TARGET-30-PASEJZ-01A-01D	01
PASESX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASESX	TARGET-30-PASESX-01A-01D	01
PASEVK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASEVK	TARGET-30-PASEVK-01A-01D	01
PASEWX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASEWX	TARGET-30-PASEWX-01A-01D	01
PASEWZ_01_Solid Tissue_Primary Tumor	36.38	NA	gain	NBL, MYCN non-amplified	PASEWZ	BS_8VPBB5C2	01
PASEWZ_01_Solid Tissue_Primary Tumor	36.38	NA	gain	NBL, MYCN non-amplified	PASEWZ	BS_X2D8S1HY	01
PASEWZ_01_Solid Tissue_Primary Tumor	36.38	NA	gain	NBL, MYCN non-amplified	PASEWZ	TARGET-30-PASEWZ-01A-01D	01
PASEYW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASEYW	TARGET-30-PASEYW-01A-01D	01
PASFCG_01_Solid Tissue_Primary Tumor	24.8	NA	NA	NBL, MYCN amplified	PASFCG	BS_PQFKEKEW	01
PASFCG_01_Solid Tissue_Primary Tumor	24.8	NA	NA	NBL, MYCN amplified	PASFCG	BS_WR5VE59B	01
PASFCG_01_Solid Tissue_Primary Tumor	24.8	NA	NA	NBL, MYCN amplified	PASFCG	TARGET-30-PASFCG-01A-01D	01
PASFDJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASFDJ	TARGET-30-PASFDJ-01A-01D	01
PASFDU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASFDU	TARGET-30-PASFDU-01A-01D	01
PASFDV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASFDV	TARGET-30-PASFDV-01A-01D	01
PASFEU_01_Solid Tissue_Primary Tumor	1.62	NA	NA	NBL, MYCN non-amplified	PASFEU	BS_KE5D12KG	01
PASFEU_01_Solid Tissue_Primary Tumor	1.62	NA	NA	NBL, MYCN non-amplified	PASFEU	BS_W3ZSVEVP	01
PASFEV_01_Solid Tissue_Primary Tumor	32.76	NA	neutral	NBL, MYCN non-amplified	PASFEV	BS_MCCJ3EMF	01
PASFEV_01_Solid Tissue_Primary Tumor	32.76	NA	neutral	NBL, MYCN non-amplified	PASFEV	BS_Z0MTZA9K	01
PASFEV_01_Solid Tissue_Primary Tumor	32.76	NA	neutral	NBL, MYCN non-amplified	PASFEV	TARGET-30-PASFEV-01A-01D	01
PASFGD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASFGD	TARGET-30-PASFGD-01A-01D	01
PASFGG_01_Solid Tissue_Primary Tumor	18.94	2	neutral	NBL, MYCN non-amplified	PASFGG	TARGET-30-PASFGG-01A-01D	01
PASFGG_01_Solid Tissue_Primary Tumor	18.94	2	neutral	NBL, MYCN non-amplified	PASFGG	TARGET-30-PASFGG-01A-01D.M	01
PASFGG_01_Solid Tissue_Primary Tumor	18.94	2	neutral	NBL, MYCN non-amplified	PASFGG	TARGET-30-PASFGG-01A-01R	01
PASFHI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASFHI	BS_D8H43Q28	01
PASFIC_01_Solid Tissue_Primary Tumor	23.605	NA	NA	NBL, MYCN amplified	PASFIC	BS_DYHEFXJC	01
PASFIC_01_Solid Tissue_Primary Tumor	23.605	NA	NA	NBL, MYCN amplified	PASFIC	BS_W22EEJCZ	01
PASFIC_01_Solid Tissue_Primary Tumor	23.605	NA	NA	NBL, MYCN amplified	PASFIC	TARGET-30-PASFIC-01A-01D.M	01
PASFIC_01_Solid Tissue_Primary Tumor	23.605	NA	NA	NBL, MYCN amplified	PASFIC	TARGET-30-PASFIC-01A-01R	01
PASFKX_01_Solid Tissue_Primary Tumor	392.43	NA	loss	NBL, MYCN amplified	PASFKX	BS_2X9EVKZ0	01
PASFKX_01_Solid Tissue_Primary Tumor	392.43	NA	loss	NBL, MYCN amplified	PASFKX	BS_6N7RPHX9	01
PASFKX_01_Solid Tissue_Primary Tumor	392.43	NA	loss	NBL, MYCN amplified	PASFKX	TARGET-30-PASFKX-01A-01D	01
PASFNF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASFNF	TARGET-30-PASFNF-01A-01D	01
PASFNY_01_Solid Tissue_Primary Tumor	NA	86.5	amplification	NBL, MYCN amplified	PASFNY	BS_MTQ7F28J	01
PASFNY_01_Solid Tissue_Primary Tumor	NA	86.5	amplification	NBL, MYCN amplified	PASFNY	TARGET-30-PASFNY-01A-01D	01
PASFRV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASFRV	TARGET-30-PASFRV-01A-01D.M	01
PASFWL_01_Solid Tissue_Primary Tumor	34.59	NA	loss	NBL, MYCN non-amplified	PASFWL	BS_5BFNH9S6	01
PASFWL_01_Solid Tissue_Primary Tumor	34.59	NA	loss	NBL, MYCN non-amplified	PASFWL	BS_WHX83JW2	01
PASFWL_01_Solid Tissue_Primary Tumor	34.59	NA	loss	NBL, MYCN non-amplified	PASFWL	TARGET-30-PASFWL-01A-01D	01
PASFXC_01_Solid Tissue_Primary Tumor	21.59	NA	gain	NBL, MYCN non-amplified	PASFXC	BS_3KGHX57D	01
PASFXC_01_Solid Tissue_Primary Tumor	21.59	NA	gain	NBL, MYCN non-amplified	PASFXC	BS_T9VPRPVA	01
PASFXC_01_Solid Tissue_Primary Tumor	21.59	NA	gain	NBL, MYCN non-amplified	PASFXC	TARGET-30-PASFXC-01A-01D	01
PASFXS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASFXS	TARGET-30-PASFXS-01A-01D	01
PASGAP_01_Solid Tissue_Primary Tumor	5.34	2	loss	NBL, MYCN non-amplified	PASGAP	TARGET-30-PASGAP-01A-01D	01
PASGAP_01_Solid Tissue_Primary Tumor	5.34	2	loss	NBL, MYCN non-amplified	PASGAP	TARGET-30-PASGAP-01A-01D.M	01
PASGAP_01_Solid Tissue_Primary Tumor	5.34	2	loss	NBL, MYCN non-amplified	PASGAP	TARGET-30-PASGAP-01A-01R	01
PASGAP_02_Solid Tissue_Recurrence	10.98	NA	NA	NBL, MYCN non-amplified	PASGAP	TARGET-30-PASGAP-02A-01D.M	02
PASGAP_02_Solid Tissue_Recurrence	10.98	NA	NA	NBL, MYCN non-amplified	PASGAP	TARGET-30-PASGAP-02A-01R	02
PASGBE_01_Solid Tissue_Primary Tumor	2.34	NA	NA	NBL, MYCN amplified	PASGBE	BS_43R2B7DR	01
PASGCD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGCD	TARGET-30-PASGCD-01A-01D	01
PASGDB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGDB	TARGET-30-PASGDB-01A-01D	01
PASGEE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGEE	TARGET-30-PASGEE-01A-01D	01
PASGES_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGES	TARGET-30-PASGES-01A-01D	01
PASGGD_01_Solid Tissue_Primary Tumor	13.74	NA	NA	NBL, MYCN non-amplified	PASGGD	BS_A2HY1DZA	01
PASGGD_01_Solid Tissue_Primary Tumor	13.74	NA	NA	NBL, MYCN non-amplified	PASGGD	BS_QKTJ4QY9	01
PASGGI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGGI	BS_P8X3GAEP	01
PASGGI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGGI	TARGET-30-PASGGI-01A-01D	01
PASGHN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGHN	TARGET-30-PASGHN-01A-01D	01
PASGKP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGKP	TARGET-30-PASGKP-01A-01D	01
PASGNT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGNT	TARGET-30-PASGNT-01A-01D	01
PASGPY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASGPY	TARGET-30-PASGPY-01A-01D.M	01
PASGRL_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PASGRL	BS_EQE447QB	01
PASGUT_01_Solid Tissue_Primary Tumor	22.29	2	loss	NBL, MYCN non-amplified	PASGUT	TARGET-30-PASGUT-01A-01D	01
PASGUT_01_Solid Tissue_Primary Tumor	22.29	2	loss	NBL, MYCN non-amplified	PASGUT	TARGET-30-PASGUT-01A-01D.M	01
PASGUT_01_Solid Tissue_Primary Tumor	22.29	2	loss	NBL, MYCN non-amplified	PASGUT	TARGET-30-PASGUT-01A-01R	01
PASHEL_01_Solid Tissue_Primary Tumor	NA	53	amplification	NBL, MYCN amplified	PASHEL	BS_TR758MB1	01
PASHFA_01_Solid Tissue_Primary Tumor	422.71	NA	NA	NBL, MYCN amplified	PASHFA	TARGET-30-PASHFA-01A-01D.M	01
PASHFA_01_Solid Tissue_Primary Tumor	422.71	NA	NA	NBL, MYCN amplified	PASHFA	TARGET-30-PASHFA-01A-01R	01
PASHFA_02_Solid Tissue_Recurrence	NA	NA	NA	NBL, To be classified	PASHFA	TARGET-30-PASHFA-02A-01D.M	02
PASHLP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASHLP	BS_CGGJZ5Q1	01
PASIIB_01_Solid Tissue_Primary Tumor	13.32	3	gain	NBL, MYCN non-amplified	PASIIB	BS_30NT6PNA	01
PASIIB_01_Solid Tissue_Primary Tumor	13.32	3	gain	NBL, MYCN non-amplified	PASIIB	BS_6GSJCDCN	01
PASIIU_01_Solid Tissue_Primary Tumor	NA	622	amplification	NBL, MYCN amplified	PASIIU	BS_W2BC0CVT	01
PASIUJ_01_Solid Tissue_Primary Tumor	149.73	33	amplification	NBL, MYCN amplified	PASIUJ	BS_19PXZ71B	01
PASIUJ_01_Solid Tissue_Primary Tumor	149.73	33	amplification	NBL, MYCN amplified	PASIUJ	BS_SY6CCX4G	01
PASJBY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASJBY	BS_F3ZZ4BXE	01
PASJRT_01_Solid Tissue_Primary Tumor	NA	4	gain	NBL, To be classified	PASJRT	BS_WMM0MP1J	01
PASJTA_01_Solid Tissue_Primary Tumor	19.87	NA	gain	NBL, MYCN non-amplified	PASJTA	BS_DFJYRYV1	01
PASJTA_01_Solid Tissue_Primary Tumor	19.87	NA	gain	NBL, MYCN non-amplified	PASJTA	BS_WHBM0N3Y	01
PASJTA_01_Solid Tissue_Primary Tumor	19.87	NA	gain	NBL, MYCN non-amplified	PASJTA	TARGET-30-PASJTA-01A-01D	01
PASJUU_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PASJUU	BS_FV0C303D	01
PASJUU_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PASJUU	TARGET-30-PASJUU-01A-01D	01
PASJWA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASJWA	TARGET-30-PASJWA-01A-01D	01
PASJWG_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PASJWG	BS_VGAKW5G6	01
PASJWG_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PASJWG	TARGET-30-PASJWG-01A-01D	01
PASJWU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASJWU	TARGET-30-PASJWU-01A-01D	01
PASJYB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASJYB	TARGET-30-PASJYB-01A-01D.M	01
PASJZC_01_Solid Tissue_Primary Tumor	35.63	NA	NA	NBL, MYCN amplified	PASJZC	TARGET-30-PASJZC-01A-01D.M	01
PASJZC_01_Solid Tissue_Primary Tumor	35.63	NA	NA	NBL, MYCN amplified	PASJZC	TARGET-30-PASJZC-01A-01R	01
PASKCS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKCS	BS_1YD0ZQ4R	01
PASKCS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKCS	TARGET-30-PASKCS-01A-01D	01
PASKFM_01_Solid Tissue_Primary Tumor	50.58	NA	NA	NBL, MYCN amplified	PASKFM	BS_EE5Z0Z4J	01
PASKFM_01_Solid Tissue_Primary Tumor	50.58	NA	NA	NBL, MYCN amplified	PASKFM	BS_JQ0XD1K9	01
PASKFV_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, To be classified	PASKFV	TARGET-30-PASKFV-01A-01D	01
PASKIS_01_Solid Tissue_Primary Tumor	334.3	3	gain	NBL, MYCN amplified	PASKIS	BS_6WBAV14H	01
PASKIS_01_Solid Tissue_Primary Tumor	334.3	3	gain	NBL, MYCN amplified	PASKIS	BS_QDRHQSPZ	01
PASKJX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKJX	TARGET-30-PASKJX-01A-01D.M	01
PASKKZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKKZ	TARGET-30-PASKKZ-01A-01D	01
PASKNK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKNK	TARGET-30-PASKNK-01A-01D	01
PASKPC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKPC	TARGET-30-PASKPC-01A-01D	01
PASKRA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKRA	TARGET-30-PASKRA-01A-01D	01
PASKRS_01_Solid Tissue_Primary Tumor	11.07	NA	gain	NBL, MYCN non-amplified	PASKRS	BS_QS2NKZW3	01
PASKRS_01_Solid Tissue_Primary Tumor	11.07	NA	gain	NBL, MYCN non-amplified	PASKRS	BS_W41Y820G	01
PASKRS_01_Solid Tissue_Primary Tumor	11.07	NA	gain	NBL, MYCN non-amplified	PASKRS	TARGET-30-PASKRS-01A-01D	01
PASKRX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKRX	TARGET-30-PASKRX-01A-01D	01
PASKSR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKSR	TARGET-30-PASKSR-01A-01D	01
PASKSX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKSX	TARGET-30-PASKSX-01A-01D	01
PASKTB_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PASKTB	TARGET-30-PASKTB-01A-01D	01
PASKWI_01_Solid Tissue_Primary Tumor	0.86	NA	NA	NBL, MYCN non-amplified	PASKWI	BS_3V34S6KM	01
PASKYH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASKYH	TARGET-30-PASKYH-01A-01D	01
PASKZT_01_Solid Tissue_Primary Tumor	2.05	NA	NA	NBL, MYCN amplified	PASKZT	BS_CKVK1AYV	01
PASKZT_01_Solid Tissue_Primary Tumor	2.05	NA	NA	NBL, MYCN amplified	PASKZT	BS_CZ7DWCPE	01
PASKZT_01_Solid Tissue_Primary Tumor	2.05	NA	NA	NBL, MYCN amplified	PASKZT	TARGET-30-PASKZT-01A-01D	01
PASLAE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLAE	TARGET-30-PASLAE-01A-01D	01
PASLCD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLCD	TARGET-30-PASLCD-01A-01D	01
PASLDM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLDM	TARGET-30-PASLDM-01A-01D	01
PASLFG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLFG	TARGET-30-PASLFG-01A-01D	01
PASLGM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLGM	TARGET-30-PASLGM-01A-01D	01
PASLGS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLGS	TARGET-30-PASLGS-01A-01D.M	01
PASLIH_01_Solid Tissue_Primary Tumor	20.29	NA	NA	NBL, MYCN amplified	PASLIH	BS_6KH6CXMH	01
PASLIH_01_Solid Tissue_Primary Tumor	20.29	NA	NA	NBL, MYCN amplified	PASLIH	BS_HW9CGZ29	01
PASLIH_01_Solid Tissue_Primary Tumor	20.29	NA	NA	NBL, MYCN amplified	PASLIH	TARGET-30-PASLIH-01A-01D	01
PASLMN_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PASLMN	BS_3CVTNBQ3	01
PASLMN_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PASLMN	TARGET-30-PASLMN-01A-01D	01
PASLPG_01_Solid Tissue_Primary Tumor	8.53	NA	NA	NBL, MYCN amplified	PASLPG	BS_9C595Y9M	01
PASLPG_01_Solid Tissue_Primary Tumor	8.53	NA	NA	NBL, MYCN amplified	PASLPG	BS_V7B79J5R	01
PASLPG_01_Solid Tissue_Primary Tumor	8.53	NA	NA	NBL, MYCN amplified	PASLPG	TARGET-30-PASLPG-01A-01D	01
PASLRM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLRM	TARGET-30-PASLRM-01A-01D	01
PASLSS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLSS	TARGET-30-PASLSS-01A-01D	01
PASLTC_01_Solid Tissue_Primary Tumor	48.71	NA	gain	NBL, MYCN non-amplified	PASLTC	BS_AE718N55	01
PASLTC_01_Solid Tissue_Primary Tumor	48.71	NA	gain	NBL, MYCN non-amplified	PASLTC	BS_ZWRZRC4V	01
PASLTC_01_Solid Tissue_Primary Tumor	48.71	NA	gain	NBL, MYCN non-amplified	PASLTC	TARGET-30-PASLTC-01A-01D	01
PASLTH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLTH	BS_CPGZYTHM	01
PASLXS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLXS	TARGET-30-PASLXS-01A-01D	01
PASLYF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASLYF	TARGET-30-PASLYF-01A-01D	01
PASMCP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASMCP	TARGET-30-PASMCP-01A-01D	01
PASMDG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASMDG	TARGET-30-PASMDG-01A-01D	01
PASMDM_01_Solid Tissue_Primary Tumor	37.6	NA	NA	NBL, MYCN amplified	PASMDM	TARGET-30-PASMDM-01A-01D.M	01
PASMDM_01_Solid Tissue_Primary Tumor	37.6	NA	NA	NBL, MYCN amplified	PASMDM	TARGET-30-PASMDM-01A-01R	01
PASMET_01_Solid Tissue_Primary Tumor	86.26	NA	amplification	NBL, MYCN amplified	PASMET	BS_0SC4QNTM	01
PASMET_01_Solid Tissue_Primary Tumor	86.26	NA	amplification	NBL, MYCN amplified	PASMET	BS_RA5HNMDP	01
PASMET_01_Solid Tissue_Primary Tumor	86.26	NA	amplification	NBL, MYCN amplified	PASMET	TARGET-30-PASMET-01A-01D	01
PASMGS_01_Solid Tissue_Primary Tumor	28.29	3	loss	NBL, MYCN non-amplified	PASMGS	BS_59ZF7365	01
PASMGS_01_Solid Tissue_Primary Tumor	28.29	3	loss	NBL, MYCN non-amplified	PASMGS	BS_MJ2H7ZT3	01
PASMIU_01_Solid Tissue_Primary Tumor	48.41	3	gain	NBL, MYCN non-amplified	PASMIU	BS_0RBGK29M	01
PASMIU_01_Solid Tissue_Primary Tumor	48.41	3	gain	NBL, MYCN non-amplified	PASMIU	BS_KC02E200	01
PASMJG_01_Solid Tissue_Primary Tumor	1.73	2	neutral	NBL, MYCN non-amplified	PASMJG	TARGET-30-PASMJG-01A-01D	01
PASMJG_01_Solid Tissue_Primary Tumor	1.73	2	neutral	NBL, MYCN non-amplified	PASMJG	TARGET-30-PASMJG-01A-01D.M	01
PASMJG_01_Solid Tissue_Primary Tumor	1.73	2	neutral	NBL, MYCN non-amplified	PASMJG	TARGET-30-PASMJG-01A-01R	01
PASMNT_01_Solid Tissue_Primary Tumor	46.44	2	neutral	NBL, MYCN non-amplified	PASMNT	TARGET-30-PASMNT-01A-01D	01
PASMNT_01_Solid Tissue_Primary Tumor	46.44	2	neutral	NBL, MYCN non-amplified	PASMNT	TARGET-30-PASMNT-01A-01D.M	01
PASMNT_01_Solid Tissue_Primary Tumor	46.44	2	neutral	NBL, MYCN non-amplified	PASMNT	TARGET-30-PASMNT-01A-01R	01
PASMNU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASMNU	TARGET-30-PASMNU-01A-01D	01
PASMPT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASMPT	TARGET-30-PASMPT-01A-01D	01
PASMRC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASMRC	TARGET-30-PASMRC-01A-01D	01
PASMUB_01_Solid Tissue_Primary Tumor	10.97	NA	gain	NBL, MYCN non-amplified	PASMUB	BS_69KVWAWK	01
PASMUB_01_Solid Tissue_Primary Tumor	10.97	NA	gain	NBL, MYCN non-amplified	PASMUB	BS_H5RWQDCJ	01
PASMUB_01_Solid Tissue_Primary Tumor	10.97	NA	gain	NBL, MYCN non-amplified	PASMUB	TARGET-30-PASMUB-01A-01D	01
PASNEF_01_Solid Tissue_Primary Tumor	33.26	2	loss	NBL, MYCN non-amplified	PASNEF	TARGET-30-PASNEF-01A-01D	01
PASNEF_01_Solid Tissue_Primary Tumor	33.26	2	loss	NBL, MYCN non-amplified	PASNEF	TARGET-30-PASNEF-01A-01D.M	01
PASNEF_01_Solid Tissue_Primary Tumor	33.26	2	loss	NBL, MYCN non-amplified	PASNEF	TARGET-30-PASNEF-01A-01R	01
PASNHY_01_Solid Tissue_Primary Tumor	41.56	3	gain	NBL, MYCN non-amplified	PASNHY	BS_NVJJJ7MT	01
PASNHY_01_Solid Tissue_Primary Tumor	41.56	3	gain	NBL, MYCN non-amplified	PASNHY	BS_WKPG4MH1	01
PASNII_01_Solid Tissue_Primary Tumor	19.18	NA	NA	NBL, MYCN amplified	PASNII	BS_A3198WFE	01
PASNMJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASNMJ	TARGET-30-PASNMJ-01A-01D	01
PASNML_01_Solid Tissue_Primary Tumor	72.94	NA	NA	NBL, MYCN amplified	PASNML	TARGET-30-PASNML-01A-01D.M	01
PASNML_01_Solid Tissue_Primary Tumor	72.94	NA	NA	NBL, MYCN amplified	PASNML	TARGET-30-PASNML-01A-01R	01
PASNPG_01_Solid Tissue_Primary Tumor	39	NA	NA	NBL, MYCN amplified	PASNPG	TARGET-30-PASNPG-01A-01D.M	01
PASNPG_01_Solid Tissue_Primary Tumor	39	NA	NA	NBL, MYCN amplified	PASNPG	TARGET-30-PASNPG-01A-01R	01
PASNPG_02_Solid Tissue_Recurrence	24.6	NA	NA	NBL, MYCN amplified	PASNPG	TARGET-30-PASNPG-02A-01D.M	02
PASNPG_02_Solid Tissue_Recurrence	24.6	NA	NA	NBL, MYCN amplified	PASNPG	TARGET-30-PASNPG-02A-01R	02
PASNUI_01_Solid Tissue_Primary Tumor	407.97	NA	amplification	NBL, MYCN amplified	PASNUI	BS_3564XTTK	01
PASNUI_01_Solid Tissue_Primary Tumor	407.97	NA	amplification	NBL, MYCN amplified	PASNUI	BS_3CSY3JTN	01
PASNUI_01_Solid Tissue_Primary Tumor	407.97	NA	amplification	NBL, MYCN amplified	PASNUI	TARGET-30-PASNUI-01A-01D	01
PASNVM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASNVM	TARGET-30-PASNVM-01A-01D	01
PASNWH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASNWH	TARGET-30-PASNWH-01A-01D	01
PASNZU_01_Solid Tissue_Primary Tumor	1052.53	152	amplification	NBL, MYCN amplified	PASNZU	TARGET-30-PASNZU-01A-01D	01
PASNZU_01_Solid Tissue_Primary Tumor	1052.53	152	amplification	NBL, MYCN amplified	PASNZU	TARGET-30-PASNZU-01A-01D.M	01
PASNZU_01_Solid Tissue_Primary Tumor	1052.53	152	amplification	NBL, MYCN amplified	PASNZU	TARGET-30-PASNZU-01A-01R	01
PASPBY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPBY	TARGET-30-PASPBY-01A-01D	01
PASPBZ_01_Solid Tissue_Primary Tumor	16.63	NA	NA	NBL, MYCN amplified	PASPBZ	TARGET-30-PASPBZ-01A-01D.M	01
PASPBZ_01_Solid Tissue_Primary Tumor	16.63	NA	NA	NBL, MYCN amplified	PASPBZ	TARGET-30-PASPBZ-01A-01R	01
PASPER_01_Solid Tissue_Primary Tumor	14.89	2	neutral	NBL, MYCN non-amplified	PASPER	TARGET-30-PASPER-01A-01D	01
PASPER_01_Solid Tissue_Primary Tumor	14.89	2	neutral	NBL, MYCN non-amplified	PASPER	TARGET-30-PASPER-01A-01D.M	01
PASPER_01_Solid Tissue_Primary Tumor	14.89	2	neutral	NBL, MYCN non-amplified	PASPER	TARGET-30-PASPER-01A-01R	01
PASPGB_01_Solid Tissue_Primary Tumor	273.35	NA	gain	NBL, MYCN amplified	PASPGB	BS_94ZKC2SR	01
PASPGB_01_Solid Tissue_Primary Tumor	273.35	NA	gain	NBL, MYCN amplified	PASPGB	BS_ACCE0MEA	01
PASPGB_01_Solid Tissue_Primary Tumor	273.35	NA	gain	NBL, MYCN amplified	PASPGB	TARGET-30-PASPGB-01A-01D	01
PASPGU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPGU	TARGET-30-PASPGU-01A-01D	01
PASPIK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPIK	TARGET-30-PASPIK-01A-01D	01
PASPIU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPIU	BS_FK3DPAWA	01
PASPSE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPSE	TARGET-30-PASPSE-01A-01D	01
PASPTF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPTF	TARGET-30-PASPTF-01A-01D	01
PASPVR_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPVR	TARGET-30-PASPVR-09A-01D	09
PASPVZ_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPVZ	TARGET-30-PASPVZ-09A-01D	09
PASPXU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASPXU	TARGET-30-PASPXU-01A-01D	01
PASREV_09_Bone Marrow_Primary Tumor	NA	3	gain	NBL, To be classified	PASREV	BS_CH0ZV29W	09
PASREY_01_Solid Tissue_Primary Tumor	11.05	3	neutral	NBL, MYCN non-amplified	PASREY	BS_6Y5F3QGV	01
PASREY_01_Solid Tissue_Primary Tumor	11.05	3	neutral	NBL, MYCN non-amplified	PASREY	BS_QCP0VAZ7	01
PASREY_01_Solid Tissue_Primary Tumor	11.05	3	neutral	NBL, MYCN non-amplified	PASREY	TARGET-30-PASREY-01A-01D.M	01
PASRFS_01_Solid Tissue_Primary Tumor	45.74	2	neutral	NBL, MYCN non-amplified	PASRFS	TARGET-30-PASRFS-01A-01D	01
PASRFS_01_Solid Tissue_Primary Tumor	45.74	2	neutral	NBL, MYCN non-amplified	PASRFS	TARGET-30-PASRFS-01A-01D.M	01
PASRFS_01_Solid Tissue_Primary Tumor	45.74	2	neutral	NBL, MYCN non-amplified	PASRFS	TARGET-30-PASRFS-01A-01R	01
PASRIB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASRIB	TARGET-30-PASRIB-01A-01D	01
PASRLC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASRLC	TARGET-30-PASRLC-01A-01D	01
PASRRY_01_Solid Tissue_Primary Tumor	25.98	3	gain	NBL, MYCN non-amplified	PASRRY	BS_CD6KRB1K	01
PASRRY_01_Solid Tissue_Primary Tumor	25.98	3	gain	NBL, MYCN non-amplified	PASRRY	BS_GWN2F333	01
PASRSG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASRSG	TARGET-30-PASRSG-01A-01D	01
PASRTR_01_Solid Tissue_Primary Tumor	58.98	3	gain	NBL, MYCN non-amplified	PASRTR	BS_5Z1QJPG6	01
PASRTR_01_Solid Tissue_Primary Tumor	58.98	3	gain	NBL, MYCN non-amplified	PASRTR	BS_TS07B3TC	01
PASRUT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASRUT	BS_7ZT919XN	01
PASRWE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASRWE	TARGET-30-PASRWE-01A-01D	01
PASSEC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSEC	TARGET-30-PASSEC-01A-01D	01
PASSFD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSFD	BS_MQ6RKJCD	01
PASSGT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSGT	TARGET-30-PASSGT-01A-01D	01
PASSII_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSII	TARGET-30-PASSII-01A-01D	01
PASSJK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSJK	TARGET-30-PASSJK-01A-01D	01
PASSMV_01_Solid Tissue_Primary Tumor	7.74	NA	NA	NBL, MYCN amplified	PASSMV	BS_C9YD10Y4	01
PASSMV_01_Solid Tissue_Primary Tumor	7.74	NA	NA	NBL, MYCN amplified	PASSMV	BS_EXEE6TDK	01
PASSNN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSNN	TARGET-30-PASSNN-01A-01D	01
PASSPI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSPI	TARGET-30-PASSPI-01A-01D	01
PASSRN_01_Solid Tissue_Primary Tumor	738.94	522	amplification	NBL, MYCN amplified	PASSRN	TARGET-30-PASSRN-01A-01D	01
PASSRN_01_Solid Tissue_Primary Tumor	738.94	522	amplification	NBL, MYCN amplified	PASSRN	TARGET-30-PASSRN-01A-01D.M	01
PASSRN_01_Solid Tissue_Primary Tumor	738.94	522	amplification	NBL, MYCN amplified	PASSRN	TARGET-30-PASSRN-01A-01R	01
PASSRS_01_Solid Tissue_Primary Tumor	18.08	2	loss	NBL, MYCN non-amplified	PASSRS	TARGET-30-PASSRS-01A-01D	01
PASSRS_01_Solid Tissue_Primary Tumor	18.08	2	loss	NBL, MYCN non-amplified	PASSRS	TARGET-30-PASSRS-01A-01D.M	01
PASSRS_01_Solid Tissue_Primary Tumor	18.08	2	loss	NBL, MYCN non-amplified	PASSRS	TARGET-30-PASSRS-01A-01R	01
PASSUU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSUU	TARGET-30-PASSUU-01A-01D	01
PASSWB_01_Solid Tissue_Primary Tumor	NA	329	amplification	NBL, MYCN amplified	PASSWB	TARGET-30-PASSWB-01A-01D	01
PASSWW_01_Solid Tissue_Primary Tumor	13.53	NA	NA	NBL, MYCN non-amplified	PASSWW	BS_8S0EDFTP	01
PASSWW_01_Solid Tissue_Primary Tumor	13.53	NA	NA	NBL, MYCN non-amplified	PASSWW	BS_K9VNW7JD	01
PASSWW_01_Solid Tissue_Primary Tumor	13.53	NA	NA	NBL, MYCN non-amplified	PASSWW	TARGET-30-PASSWW-01A-01D.M	01
PASSWW_01_Solid Tissue_Primary Tumor	13.53	NA	NA	NBL, MYCN non-amplified	PASSWW	TARGET-30-PASSWW-01A-01R	01
PASSXA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSXA	TARGET-30-PASSXA-01A-01D	01
PASSZI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSZI	BS_X6BEG5J1	01
PASSZI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASSZI	TARGET-30-PASSZI-01A-01D	01
PASTCN_01_Solid Tissue_Primary Tumor	36.66	2	loss	NBL, MYCN non-amplified	PASTCN	TARGET-30-PASTCN-01A-01D	01
PASTCN_01_Solid Tissue_Primary Tumor	36.66	2	loss	NBL, MYCN non-amplified	PASTCN	TARGET-30-PASTCN-01A-01D.M	01
PASTCN_01_Solid Tissue_Primary Tumor	36.66	2	loss	NBL, MYCN non-amplified	PASTCN	TARGET-30-PASTCN-01A-01R	01
PASTDT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTDT	TARGET-30-PASTDT-01A-01D	01
PASTGD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTGD	TARGET-30-PASTGD-01A-01D	01
PASTGH_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTGH	TARGET-30-PASTGH-09A-01D	09
PASTHB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTHB	BS_CG9KDK95	01
PASTHF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTHF	TARGET-30-PASTHF-01A-01D	01
PASTIJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTIJ	TARGET-30-PASTIJ-01A-01D	01
PASTKC_01_Solid Tissue_Primary Tumor	24.11	2	loss	NBL, MYCN non-amplified	PASTKC	TARGET-30-PASTKC-01A-01D	01
PASTKC_01_Solid Tissue_Primary Tumor	24.11	2	loss	NBL, MYCN non-amplified	PASTKC	TARGET-30-PASTKC-01A-01D.M	01
PASTKC_01_Solid Tissue_Primary Tumor	24.11	2	loss	NBL, MYCN non-amplified	PASTKC	TARGET-30-PASTKC-01A-01R	01
PASTKW_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PASTKW	TARGET-30-PASTKW-01A-01D	01
PASTMW_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTMW	TARGET-30-PASTMW-09A-01D	09
PASTNT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTNT	TARGET-30-PASTNT-01A-01D	01
PASTRD_01_Solid Tissue_Primary Tumor	3.16	NA	NA	NBL, MYCN amplified	PASTRD	BS_RQZZ6T97	01
PASTRD_01_Solid Tissue_Primary Tumor	3.16	NA	NA	NBL, MYCN amplified	PASTRD	BS_S01DMJ5X	01
PASTSI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTSI	TARGET-30-PASTSI-01A-01D	01
PASTSY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTSY	TARGET-30-PASTSY-01A-01D	01
PASTTX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTTX	TARGET-30-PASTTX-01A-01D	01
PASTVV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTVV	BS_MYVQ8YDT	01
PASTWV_01_Solid Tissue_Primary Tumor	NA	1	loss	NBL, MYCN non-amplified	PASTWV	BS_A11S37GE	01
PASTWY_01_Solid Tissue_Primary Tumor	42.87	NA	NA	NBL, MYCN amplified	PASTWY	BS_8EX2H96N	01
PASTWY_01_Solid Tissue_Primary Tumor	42.87	NA	NA	NBL, MYCN amplified	PASTWY	BS_C3KT9THS	01
PASTWY_01_Solid Tissue_Primary Tumor	42.87	NA	NA	NBL, MYCN amplified	PASTWY	TARGET-30-PASTWY-01A-01D	01
PASTXR_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PASTXR	TARGET-30-PASTXR-01A-01D	01
PASTXV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASTXV	TARGET-30-PASTXV-01A-01D	01
PASTZR_01_Solid Tissue_Primary Tumor	23.06	NA	NA	NBL, MYCN amplified	PASTZR	BS_HA1N9VCX	01
PASTZR_01_Solid Tissue_Primary Tumor	23.06	NA	NA	NBL, MYCN amplified	PASTZR	BS_PS8TB6Z0	01
PASUCB_01_Solid Tissue_Primary Tumor	11.22	2	loss	NBL, MYCN non-amplified	PASUCB	TARGET-30-PASUCB-01A-01D	01
PASUCB_01_Solid Tissue_Primary Tumor	11.22	2	loss	NBL, MYCN non-amplified	PASUCB	TARGET-30-PASUCB-01A-01D.M	01
PASUCB_01_Solid Tissue_Primary Tumor	11.22	2	loss	NBL, MYCN non-amplified	PASUCB	TARGET-30-PASUCB-01A-01R	01
PASUCU_01_Solid Tissue_Primary Tumor	26.41	NA	gain	NBL, MYCN non-amplified	PASUCU	BS_4JVC08W2	01
PASUCU_01_Solid Tissue_Primary Tumor	26.41	NA	gain	NBL, MYCN non-amplified	PASUCU	BS_FAEHNS3Q	01
PASUCU_01_Solid Tissue_Primary Tumor	26.41	NA	gain	NBL, MYCN non-amplified	PASUCU	TARGET-30-PASUCU-01A-01D	01
PASUEA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASUEA	TARGET-30-PASUEA-01A-01D	01
PASUEZ_01_Solid Tissue_Primary Tumor	33.28	NA	neutral	NBL, MYCN non-amplified	PASUEZ	BS_9ND96NYZ	01
PASUEZ_01_Solid Tissue_Primary Tumor	33.28	NA	neutral	NBL, MYCN non-amplified	PASUEZ	BS_MDEQHB6J	01
PASUEZ_01_Solid Tissue_Primary Tumor	33.28	NA	neutral	NBL, MYCN non-amplified	PASUEZ	TARGET-30-PASUEZ-01A-01D	01
PASUFD_01_Solid Tissue_Primary Tumor	5.99	NA	NA	NBL, MYCN amplified	PASUFD	BS_2XTH5QRD	01
PASUFD_01_Solid Tissue_Primary Tumor	5.99	NA	NA	NBL, MYCN amplified	PASUFD	BS_Y4V9JXG4	01
PASUFL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASUFL	TARGET-30-PASUFL-01A-01D	01
PASUMG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASUMG	BS_WSK7MH3C	01
PASUMG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASUMG	TARGET-30-PASUMG-01A-01D	01
PASUMK_01_Solid Tissue_Primary Tumor	0.6	NA	NA	NBL, MYCN non-amplified	PASUMK	BS_9CPZ5R1T	01
PASUMK_01_Solid Tissue_Primary Tumor	0.6	NA	NA	NBL, MYCN non-amplified	PASUMK	BS_RW0JJ9BQ	01
PASUML_01_Solid Tissue_Primary Tumor	56.17	NA	NA	NBL, MYCN amplified	PASUML	TARGET-30-PASUML-01A-01D.M	01
PASUML_01_Solid Tissue_Primary Tumor	56.17	NA	NA	NBL, MYCN amplified	PASUML	TARGET-30-PASUML-01A-01R	01
PASUTC_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, To be classified	PASUTC	BS_B80Z459E	01
PASUTC_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, To be classified	PASUTC	TARGET-30-PASUTC-01A-01D	01
PASUVU_01_Solid Tissue_Primary Tumor	24.63	NA	NA	NBL, MYCN amplified	PASUVU	BS_9PRG9CJC	01
PASUVU_01_Solid Tissue_Primary Tumor	24.63	NA	NA	NBL, MYCN amplified	PASUVU	BS_MGHRCZEV	01
PASUXH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASUXH	TARGET-30-PASUXH-01A-01D	01
PASUYG_01_Solid Tissue_Primary Tumor	7.84	3	neutral	NBL, MYCN non-amplified	PASUYG	TARGET-30-PASUYG-01A-01D	01
PASUYG_01_Solid Tissue_Primary Tumor	7.84	3	neutral	NBL, MYCN non-amplified	PASUYG	TARGET-30-PASUYG-01A-01D.M	01
PASUYG_01_Solid Tissue_Primary Tumor	7.84	3	neutral	NBL, MYCN non-amplified	PASUYG	TARGET-30-PASUYG-01A-01R	01
PASUYL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASUYL	TARGET-30-PASUYL-01A-01D	01
PASVCU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASVCU	BS_9G2RB0V8	01
PASVKE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASVKE	TARGET-30-PASVKE-01A-01D	01
PASVKL_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASVKL	TARGET-30-PASVKL-09A-01D	09
PASVRU_01_Solid Tissue_Primary Tumor	473.38	121	amplification	NBL, MYCN amplified	PASVRU	TARGET-30-PASVRU-01A-01D	01
PASVRU_01_Solid Tissue_Primary Tumor	473.38	121	amplification	NBL, MYCN amplified	PASVRU	TARGET-30-PASVRU-01A-01D.M	01
PASVRU_01_Solid Tissue_Primary Tumor	473.38	121	amplification	NBL, MYCN amplified	PASVRU	TARGET-30-PASVRU-01A-01R	01
PASVSU_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASVSU	TARGET-30-PASVSU-09A-01D	09
PASVWG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASVWG	TARGET-30-PASVWG-01A-01D	01
PASVXS_01_Solid Tissue_Primary Tumor	9.01	NA	NA	NBL, MYCN amplified	PASVXS	BS_2SFR8Z1P	01
PASVXS_01_Solid Tissue_Primary Tumor	9.01	NA	NA	NBL, MYCN amplified	PASVXS	BS_8T0AKNMJ	01
PASVYV_01_Solid Tissue_Primary Tumor	32.32	NA	gain	NBL, MYCN non-amplified	PASVYV	BS_QDMDQ3E3	01
PASVYV_01_Solid Tissue_Primary Tumor	32.32	NA	gain	NBL, MYCN non-amplified	PASVYV	BS_T4KS08ND	01
PASVYV_01_Solid Tissue_Primary Tumor	32.32	NA	gain	NBL, MYCN non-amplified	PASVYV	TARGET-30-PASVYV-01A-01D	01
PASWAU_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PASWAU	TARGET-30-PASWAU-01A-01D	01
PASWCY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASWCY	TARGET-30-PASWCY-01A-01D	01
PASWEE_01_Solid Tissue_Primary Tumor	32.65	3	gain	NBL, MYCN non-amplified	PASWEE	BS_A70FPYSH	01
PASWEE_01_Solid Tissue_Primary Tumor	32.65	3	gain	NBL, MYCN non-amplified	PASWEE	BS_APY3G22J	01
PASWFB_01_Solid Tissue_Primary Tumor	1034.06	195	amplification	NBL, MYCN amplified	PASWFB	TARGET-30-PASWFB-01A-01D	01
PASWFB_01_Solid Tissue_Primary Tumor	1034.06	195	amplification	NBL, MYCN amplified	PASWFB	TARGET-30-PASWFB-01A-01D.M	01
PASWFB_01_Solid Tissue_Primary Tumor	1034.06	195	amplification	NBL, MYCN amplified	PASWFB	TARGET-30-PASWFB-01A-01R	01
PASWIJ_01_Solid Tissue_Primary Tumor	57.63	3	neutral	NBL, MYCN non-amplified	PASWIJ	TARGET-30-PASWIJ-01A-01D	01
PASWIJ_01_Solid Tissue_Primary Tumor	57.63	3	neutral	NBL, MYCN non-amplified	PASWIJ	TARGET-30-PASWIJ-01A-01D.M	01
PASWIJ_01_Solid Tissue_Primary Tumor	57.63	3	neutral	NBL, MYCN non-amplified	PASWIJ	TARGET-30-PASWIJ-01A-01R	01
PASWKI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASWKI	TARGET-30-PASWKI-01A-01D	01
PASWLY_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PASWLY	TARGET-30-PASWLY-01A-01D	01
PASWMY_01_Solid Tissue_Primary Tumor	13	NA	NA	NBL, MYCN non-amplified	PASWMY	BS_3CTRC269	01
PASWMY_01_Solid Tissue_Primary Tumor	13	NA	NA	NBL, MYCN non-amplified	PASWMY	BS_TT4PHFV7	01
PASWNG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASWNG	TARGET-30-PASWNG-01A-01D	01
PASWSZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASWSZ	TARGET-30-PASWSZ-01A-01D	01
PASWVD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASWVD	TARGET-30-PASWVD-01A-01D	01
PASWVE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASWVE	TARGET-30-PASWVE-01A-01D	01
PASWVY_01_Solid Tissue_Primary Tumor	77.32	4	gain	NBL, MYCN non-amplified	PASWVY	TARGET-30-PASWVY-01A-01D	01
PASWVY_01_Solid Tissue_Primary Tumor	77.32	4	gain	NBL, MYCN non-amplified	PASWVY	TARGET-30-PASWVY-01A-01D.M	01
PASWVY_01_Solid Tissue_Primary Tumor	77.32	4	gain	NBL, MYCN non-amplified	PASWVY	TARGET-30-PASWVY-01A-01R	01
PASWXG_01_Solid Tissue_Primary Tumor	379.57	NA	amplification	NBL, MYCN amplified	PASWXG	BS_GMH5C45K	01
PASWXG_01_Solid Tissue_Primary Tumor	379.57	NA	amplification	NBL, MYCN amplified	PASWXG	BS_R13WNSAR	01
PASWXG_01_Solid Tissue_Primary Tumor	379.57	NA	amplification	NBL, MYCN amplified	PASWXG	TARGET-30-PASWXG-01A-01D	01
PASWYR_01_Solid Tissue_Primary Tumor	NA	93	gain, amplification	NBL, MYCN amplified	PASWYR	BS_8XDZQKSD	01
PASWYR_01_Solid Tissue_Primary Tumor	NA	93	gain, amplification	NBL, MYCN amplified	PASWYR	BS_MPE34NYZ	01
PASWYR_01_Solid Tissue_Primary Tumor	NA	93	gain, amplification	NBL, MYCN amplified	PASWYR	TARGET-30-PASWYR-01A-01D	01
PASWYR_01_Solid Tissue_Primary Tumor	NA	93	gain, amplification	NBL, MYCN amplified	PASWYR	TARGET-30-PASWYR-01A-01D.M	01
PASWYR_01_Solid Tissue_Primary Tumor	NA	93	gain, amplification	NBL, MYCN amplified	PASWYR	TARGET-30-PASWYR-01A-01R	01
PASXCG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASXCG	TARGET-30-PASXCG-01A-01D	01
PASXGP_01_Solid Tissue_Primary Tumor	53.89	2	neutral	NBL, MYCN non-amplified	PASXGP	TARGET-30-PASXGP-01A-01D	01
PASXGP_01_Solid Tissue_Primary Tumor	53.89	2	neutral	NBL, MYCN non-amplified	PASXGP	TARGET-30-PASXGP-01A-01D.M	01
PASXGP_01_Solid Tissue_Primary Tumor	53.89	2	neutral	NBL, MYCN non-amplified	PASXGP	TARGET-30-PASXGP-01A-01R	01
PASXHE_01_Solid Tissue_Primary Tumor	54.185	3	gain	NBL, MYCN non-amplified	PASXHE	BS_EZRVK9ZQ	01
PASXHE_01_Solid Tissue_Primary Tumor	54.185	3	gain	NBL, MYCN non-amplified	PASXHE	BS_V4VGG98Y	01
PASXHE_01_Solid Tissue_Primary Tumor	54.185	3	gain	NBL, MYCN non-amplified	PASXHE	TARGET-30-PASXHE-01A-01D	01
PASXHE_01_Solid Tissue_Primary Tumor	54.185	3	gain	NBL, MYCN non-amplified	PASXHE	TARGET-30-PASXHE-01A-01D.M	01
PASXHE_01_Solid Tissue_Primary Tumor	54.185	3	gain	NBL, MYCN non-amplified	PASXHE	TARGET-30-PASXHE-01A-01R	01
PASXIE_01_Solid Tissue_Primary Tumor	NA	5	gain	NBL, To be classified	PASXIE	BS_2N95EW0G	01
PASXIE_01_Solid Tissue_Primary Tumor	NA	5	gain	NBL, To be classified	PASXIE	BS_9TKGBJH7	01
PASXIE_01_Solid Tissue_Primary Tumor	NA	5	gain	NBL, To be classified	PASXIE	TARGET-30-PASXIE-01A-01D	01
PASXIE_01_Solid Tissue_Primary Tumor	NA	5	gain	NBL, To be classified	PASXIE	TARGET-30-PASXIE-01A-01D.M	01
PASXIE_01_Solid Tissue_Primary Tumor	NA	5	gain	NBL, To be classified	PASXIE	TARGET-30-PASXIE-01A-01R	01
PASXMI_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PASXMI	TARGET-30-PASXMI-09A-01D	09
PASXNN_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PASXNN	TARGET-30-PASXNN-01A-01D	01
PASXRG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASXRG	BS_9JBYGRQW	01
PASXRG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASXRG	BS_P6FPBJM8	01
PASXRG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASXRG	TARGET-30-PASXRG-01A-01D	01
PASXRG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASXRG	TARGET-30-PASXRG-01A-01D.M	01
PASXRG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASXRG	TARGET-30-PASXRG-01A-01R	01
PASXRJ_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PASXRJ	BS_1BKHK7AY	01
PASXRJ_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PASXRJ	BS_KXRFQF5N	01
PASXRJ_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PASXRJ	TARGET-30-PASXRJ-01A-01D	01
PASXRJ_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PASXRJ	TARGET-30-PASXRJ-01A-01D.M	01
PASXRJ_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PASXRJ	TARGET-30-PASXRJ-01A-01R	01
PASXSJ_01_Solid Tissue_Primary Tumor	261.14	106	amplification	NBL, MYCN amplified	PASXSJ	BS_9ZDR2H7D	01
PASXSJ_01_Solid Tissue_Primary Tumor	261.14	106	amplification	NBL, MYCN amplified	PASXSJ	BS_XZQE9FBM	01
PASXVW_01_Solid Tissue_Primary Tumor	NA	3	loss	NBL, MYCN non-amplified	PASXVW	BS_4G4PK2D4	01
PASXWF_01_Solid Tissue_Primary Tumor	2.17	NA	NA	NBL, MYCN amplified	PASXWF	BS_CD6WEHG9	01
PASXWF_01_Solid Tissue_Primary Tumor	2.17	NA	NA	NBL, MYCN amplified	PASXWF	BS_SPGHWHXY	01
PASYHS_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PASYHS	BS_H68W3CE8	01
PASYIP_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASYIP	BS_XH6P7BY8	01
PASYIP_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASYIP	TARGET-30-PASYIP-01A-01D	01
PASYJF_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PASYJF	BS_SGRCCAVT	01
PASYJF_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PASYJF	TARGET-30-PASYJF-01A-01D	01
PASYLD_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PASYLD	TARGET-30-PASYLD-01A-01D	01
PASYLD_01_Solid Tissue_Primary Tumor	NA	2	neutral	NBL, MYCN non-amplified	PASYLD	TARGET-30-PASYLD-01A-01D.M	01
PASYMX_01_Solid Tissue_Primary Tumor	NA	3	loss	NBL, MYCN non-amplified	PASYMX	TARGET-30-PASYMX-01A-01D	01
PASYPX_01_Solid Tissue_Primary Tumor	31.64	3	neutral	NBL, MYCN non-amplified	PASYPX	TARGET-30-PASYPX-01A-01D	01
PASYPX_01_Solid Tissue_Primary Tumor	31.64	3	neutral	NBL, MYCN non-amplified	PASYPX	TARGET-30-PASYPX-01A-01D.M	01
PASYPX_01_Solid Tissue_Primary Tumor	31.64	3	neutral	NBL, MYCN non-amplified	PASYPX	TARGET-30-PASYPX-01A-01R	01
PASYTP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASYTP	TARGET-30-PASYTP-01A-01D	01
PASYVV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASYVV	BS_B4GBBM0J	01
PASYYM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASYYM	TARGET-30-PASYYM-01A-01D	01
PASYYX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASYYX	TARGET-30-PASYYX-01A-01D	01
PASYYZ_01_Solid Tissue_Primary Tumor	1.27	NA	NA	NBL, MYCN non-amplified	PASYYZ	BS_EPZ2H50J	01
PASYYZ_01_Solid Tissue_Primary Tumor	1.27	NA	NA	NBL, MYCN non-amplified	PASYYZ	BS_XQSEQPAZ	01
PASZFX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASZFX	TARGET-30-PASZFX-01A-01D	01
PASZGB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASZGB	TARGET-30-PASZGB-01A-01D	01
PASZJB_01_Solid Tissue_Primary Tumor	18.88	NA	loss	NBL, MYCN non-amplified	PASZJB	BS_CXGWN1W5	01
PASZJB_01_Solid Tissue_Primary Tumor	18.88	NA	loss	NBL, MYCN non-amplified	PASZJB	BS_ZRG2V7T2	01
PASZJB_01_Solid Tissue_Primary Tumor	18.88	NA	loss	NBL, MYCN non-amplified	PASZJB	TARGET-30-PASZJB-01A-01D	01
PASZKE_01_Solid Tissue_Primary Tumor	16.17	NA	NA	NBL, MYCN amplified	PASZKE	BS_XPTREBJD	01
PASZKE_01_Solid Tissue_Primary Tumor	16.17	NA	NA	NBL, MYCN amplified	PASZKE	TARGET-30-PASZKE-01A-01D.M	01
PASZKE_01_Solid Tissue_Primary Tumor	16.17	NA	NA	NBL, MYCN amplified	PASZKE	TARGET-30-PASZKE-01A-01R	01
PASZPI_01_Solid Tissue_Primary Tumor	894.63	44	amplification	NBL, MYCN amplified	PASZPI	TARGET-30-PASZPI-01A-01D	01
PASZPI_01_Solid Tissue_Primary Tumor	894.63	44	amplification	NBL, MYCN amplified	PASZPI	TARGET-30-PASZPI-01A-01R	01
PASZRF_01_Solid Tissue_Primary Tumor	17.59	NA	NA	NBL, MYCN amplified	PASZRF	BS_FRY5NFRY	01
PASZRF_01_Solid Tissue_Primary Tumor	17.59	NA	NA	NBL, MYCN amplified	PASZRF	BS_Y9BHAPG3	01
PASZST_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASZST	TARGET-30-PASZST-01A-01D	01
PASZTC_01_Solid Tissue_Primary Tumor	19.89	3	gain	NBL, MYCN non-amplified	PASZTC	BS_DGV11G69	01
PASZTC_01_Solid Tissue_Primary Tumor	19.89	3	gain	NBL, MYCN non-amplified	PASZTC	BS_RZEEJETF	01
PASZTV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PASZTV	TARGET-30-PASZTV-01A-01D	01
PASZYY_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASZYY	BS_BHKAK446	01
PASZYY_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PASZYY	TARGET-30-PASZYY-01A-01D	01
PATAAV_01_Solid Tissue_Primary Tumor	8.73	NA	gain	NBL, MYCN non-amplified	PATAAV	BS_PKHXM1NB	01
PATAAV_01_Solid Tissue_Primary Tumor	8.73	NA	gain	NBL, MYCN non-amplified	PATAAV	BS_XJDB3R9K	01
PATAAV_01_Solid Tissue_Primary Tumor	8.73	NA	gain	NBL, MYCN non-amplified	PATAAV	TARGET-30-PATAAV-01A-01D	01
PATACA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATACA	TARGET-30-PATACA-01A-01D	01
PATAFE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATAFE	TARGET-30-PATAFE-01A-01D	01
PATAFI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATAFI	TARGET-30-PATAFI-01A-01D	01
PATAKH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATAKH	TARGET-30-PATAKH-01A-01D	01
PATAYJ_01_Solid Tissue_Primary Tumor	40.96	NA	NA	NBL, MYCN amplified	PATAYJ	TARGET-30-PATAYJ-01A-01D.M	01
PATAYJ_01_Solid Tissue_Primary Tumor	40.96	NA	NA	NBL, MYCN amplified	PATAYJ	TARGET-30-PATAYJ-01A-01R	01
PATBAC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATBAC	TARGET-30-PATBAC-01A-01D	01
PATBBF_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATBBF	BS_S0T1WT6R	01
PATBCM_01_Solid Tissue_Primary Tumor	5.2	NA	NA	NBL, MYCN amplified	PATBCM	BS_FE3BY6DT	01
PATBCM_01_Solid Tissue_Primary Tumor	5.2	NA	NA	NBL, MYCN amplified	PATBCM	BS_W09W6AAS	01
PATBFN_01_Solid Tissue_Primary Tumor	33.83	NA	NA	NBL, MYCN amplified	PATBFN	BS_HCWEF4QN	01
PATBFN_01_Solid Tissue_Primary Tumor	33.83	NA	NA	NBL, MYCN amplified	PATBFN	BS_Z3BZ01S1	01
PATBGF_01_Solid Tissue_Primary Tumor	6.68	NA	NA	NBL, MYCN amplified	PATBGF	BS_7W42FH5A	01
PATBGF_01_Solid Tissue_Primary Tumor	6.68	NA	NA	NBL, MYCN amplified	PATBGF	BS_M462FWS9	01
PATBHY_01_Solid Tissue_Primary Tumor	16.32	NA	NA	NBL, MYCN amplified	PATBHY	BS_NQP7B1SY	01
PATBHY_01_Solid Tissue_Primary Tumor	16.32	NA	NA	NBL, MYCN amplified	PATBHY	TARGET-30-PATBHY-01A-01D	01
PATBJI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATBJI	TARGET-30-PATBJI-01A-01D	01
PATBKX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATBKX	TARGET-30-PATBKX-01A-01D	01
PATBLZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATBLZ	BS_7S8KSFRC	01
PATBMM_01_Solid Tissue_Primary Tumor	NA	NA	loss	NBL, MYCN non-amplified	PATBMM	BS_3DJBSNGE	01
PATBMM_01_Solid Tissue_Primary Tumor	NA	NA	loss	NBL, MYCN non-amplified	PATBMM	BS_D7442ACV	01
PATBMM_01_Solid Tissue_Primary Tumor	NA	NA	loss	NBL, MYCN non-amplified	PATBMM	TARGET-30-PATBMM-01A-01D	01
PATBMM_01_Solid Tissue_Primary Tumor	NA	NA	loss	NBL, MYCN non-amplified	PATBMM	TARGET-30-PATBMM-01A-01D.M	01
PATBMM_01_Solid Tissue_Primary Tumor	NA	NA	loss	NBL, MYCN non-amplified	PATBMM	TARGET-30-PATBMM-01A-01R	01
PATBPG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATBPG	TARGET-30-PATBPG-01A-01D	01
PATBRX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATBRX	TARGET-30-PATBRX-01A-01D	01
PATCDJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATCDJ	TARGET-30-PATCDJ-01A-01D	01
PATCEM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATCEM	TARGET-30-PATCEM-01A-01D	01
PATCFL_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PATCFL	BS_D3N3FG7Y	01
PATCFL_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PATCFL	BS_N05R3CT2	01
PATCFL_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PATCFL	TARGET-30-PATCFL-01A-01D	01
PATCFL_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PATCFL	TARGET-30-PATCFL-01A-01D.M	01
PATCFL_01_Solid Tissue_Primary Tumor	NA	NA	neutral	NBL, MYCN non-amplified	PATCFL	TARGET-30-PATCFL-01A-01R	01
PATCJF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATCJF	TARGET-30-PATCJF-01A-01D	01
PATCJP_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATCJP	TARGET-30-PATCJP-09A-01D	09
PATCKU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATCKU	TARGET-30-PATCKU-01A-01D	01
PATCMD_01_Solid Tissue_Primary Tumor	43.2	NA	NA	NBL, MYCN amplified	PATCMD	BS_MYNJDVWV	01
PATCVK_01_Solid Tissue_Primary Tumor	15.78	NA	NA	NBL, MYCN amplified	PATCVK	BS_F92J3KBA	01
PATCVK_01_Solid Tissue_Primary Tumor	15.78	NA	NA	NBL, MYCN amplified	PATCVK	BS_JWXQFZY9	01
PATDBR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATDBR	TARGET-30-PATDBR-01A-01D	01
PATDCJ_01_Solid Tissue_Primary Tumor	13.3	NA	gain	NBL, MYCN non-amplified	PATDCJ	BS_BBD7XS5N	01
PATDCJ_01_Solid Tissue_Primary Tumor	13.3	NA	gain	NBL, MYCN non-amplified	PATDCJ	BS_DZ998H9P	01
PATDCJ_01_Solid Tissue_Primary Tumor	13.3	NA	gain	NBL, MYCN non-amplified	PATDCJ	TARGET-30-PATDCJ-01A-01D	01
PATDFU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATDFU	TARGET-30-PATDFU-01A-01D	01
PATDKL_01_Solid Tissue_Primary Tumor	3.77	NA	NA	NBL, MYCN amplified	PATDKL	BS_TWN989ZD	01
PATDKL_01_Solid Tissue_Primary Tumor	3.77	NA	NA	NBL, MYCN amplified	PATDKL	BS_YF5NCTGA	01
PATDSY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATDSY	TARGET-30-PATDSY-01A-01D	01
PATDVF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATDVF	TARGET-30-PATDVF-01A-01D	01
PATDWN_01_Solid Tissue_Primary Tumor	1540.66	238	amplification	NBL, MYCN amplified	PATDWN	TARGET-30-PATDWN-01A-01D	01
PATDWN_01_Solid Tissue_Primary Tumor	1540.66	238	amplification	NBL, MYCN amplified	PATDWN	TARGET-30-PATDWN-01A-01D.M	01
PATDWN_01_Solid Tissue_Primary Tumor	1540.66	238	amplification	NBL, MYCN amplified	PATDWN	TARGET-30-PATDWN-01A-01R	01
PATDWR_01_Solid Tissue_Primary Tumor	15.89	NA	NA	NBL, MYCN amplified	PATDWR	BS_4A1CKAXN	01
PATDWR_01_Solid Tissue_Primary Tumor	15.89	NA	NA	NBL, MYCN amplified	PATDWR	BS_XWKDJ2M6	01
PATDXC_01_Solid Tissue_Primary Tumor	58.6	3	neutral	NBL, MYCN non-amplified	PATDXC	TARGET-30-PATDXC-01A-01D	01
PATDXC_01_Solid Tissue_Primary Tumor	58.6	3	neutral	NBL, MYCN non-amplified	PATDXC	TARGET-30-PATDXC-01A-01D.M	01
PATDXC_01_Solid Tissue_Primary Tumor	58.6	3	neutral	NBL, MYCN non-amplified	PATDXC	TARGET-30-PATDXC-01A-01R	01
PATDXG_01_Solid Tissue_Primary Tumor	1449.04	118	amplification	NBL, MYCN amplified	PATDXG	TARGET-30-PATDXG-01A-01D	01
PATDXG_01_Solid Tissue_Primary Tumor	1449.04	118	amplification	NBL, MYCN amplified	PATDXG	TARGET-30-PATDXG-01A-01R	01
PATECM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATECM	TARGET-30-PATECM-01A-01D	01
PATEEE_01_Solid Tissue_Primary Tumor	8.55	NA	NA	NBL, MYCN amplified	PATEEE	BS_WFZG82XZ	01
PATEEE_01_Solid Tissue_Primary Tumor	8.55	NA	NA	NBL, MYCN amplified	PATEEE	BS_XFFQR05Z	01
PATEKG_01_Solid Tissue_Primary Tumor	5.33	2	neutral	NBL, MYCN non-amplified	PATEKG	TARGET-30-PATEKG-01A-01D	01
PATEKG_01_Solid Tissue_Primary Tumor	5.33	2	neutral	NBL, MYCN non-amplified	PATEKG	TARGET-30-PATEKG-01A-01R	01
PATEPF_01_Solid Tissue_Primary Tumor	40.48	2	neutral	NBL, MYCN non-amplified	PATEPF	TARGET-30-PATEPF-01A-01D	01
PATEPF_01_Solid Tissue_Primary Tumor	40.48	2	neutral	NBL, MYCN non-amplified	PATEPF	TARGET-30-PATEPF-01A-01D.M	01
PATEPF_01_Solid Tissue_Primary Tumor	40.48	2	neutral	NBL, MYCN non-amplified	PATEPF	TARGET-30-PATEPF-01A-01R	01
PATESI_01_Solid Tissue_Primary Tumor	1278.85	105	amplification	NBL, MYCN amplified	PATESI	TARGET-30-PATESI-01A-01D	01
PATESI_01_Solid Tissue_Primary Tumor	1278.85	105	amplification	NBL, MYCN amplified	PATESI	TARGET-30-PATESI-01A-01D.M	01
PATESI_01_Solid Tissue_Primary Tumor	1278.85	105	amplification	NBL, MYCN amplified	PATESI	TARGET-30-PATESI-01A-01R	01
PATETW_01_Solid Tissue_Primary Tumor	17.35	NA	NA	NBL, MYCN amplified	PATETW	BS_3GRJH3PS	01
PATETW_01_Solid Tissue_Primary Tumor	17.35	NA	NA	NBL, MYCN amplified	PATETW	BS_K5DHTP34	01
PATEUC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATEUC	TARGET-30-PATEUC-01A-01D	01
PATEWM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATEWM	TARGET-30-PATEWM-01A-01D	01
PATFCY_01_Solid Tissue_Primary Tumor	60.56	2	loss	NBL, MYCN non-amplified	PATFCY	TARGET-30-PATFCY-01A-01D	01
PATFCY_01_Solid Tissue_Primary Tumor	60.56	2	loss	NBL, MYCN non-amplified	PATFCY	TARGET-30-PATFCY-01A-01D.M	01
PATFCY_01_Solid Tissue_Primary Tumor	60.56	2	loss	NBL, MYCN non-amplified	PATFCY	TARGET-30-PATFCY-01A-01R	01
PATFES_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATFES	TARGET-30-PATFES-01A-01D	01
PATFIK_01_Solid Tissue_Primary Tumor	41.21	3	gain	NBL, MYCN non-amplified	PATFIK	BS_64P50TAP	01
PATFIK_01_Solid Tissue_Primary Tumor	41.21	3	gain	NBL, MYCN non-amplified	PATFIK	BS_CZMY8CVE	01
PATFIN_01_Solid Tissue_Primary Tumor	NA	128	amplification	NBL, MYCN amplified	PATFIN	TARGET-30-PATFIN-01A-01D	01
PATFMU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATFMU	TARGET-30-PATFMU-01A-01D	01
PATFPK_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATFPK	BS_2F5KDZ93	09
PATFPS_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATFPS	TARGET-30-PATFPS-09A-01D	09
PATFTN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATFTN	TARGET-30-PATFTN-01A-01D	01
PATFTR_01_Solid Tissue_Primary Tumor	27.57	NA	NA	NBL, MYCN amplified	PATFTR	BS_GTFHNG3R	01
PATFTR_01_Solid Tissue_Primary Tumor	27.57	NA	NA	NBL, MYCN amplified	PATFTR	BS_XQC9PNZP	01
PATFTR_01_Solid Tissue_Primary Tumor	27.57	NA	NA	NBL, MYCN amplified	PATFTR	TARGET-30-PATFTR-01A-01D	01
PATFTY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATFTY	TARGET-30-PATFTY-01A-01D	01
PATFXV_01_Solid Tissue_Primary Tumor	1554.55	188	amplification	NBL, MYCN amplified	PATFXV	TARGET-30-PATFXV-01A-01D	01
PATFXV_01_Solid Tissue_Primary Tumor	1554.55	188	amplification	NBL, MYCN amplified	PATFXV	TARGET-30-PATFXV-01A-01D.M	01
PATFXV_01_Solid Tissue_Primary Tumor	1554.55	188	amplification	NBL, MYCN amplified	PATFXV	TARGET-30-PATFXV-01A-01R	01
PATGIW_01_Solid Tissue_Primary Tumor	6.43	NA	NA	NBL, MYCN amplified	PATGIW	BS_JBKQ59CW	01
PATGIW_01_Solid Tissue_Primary Tumor	6.43	NA	NA	NBL, MYCN amplified	PATGIW	BS_VKK21QBZ	01
PATGJU_01_Solid Tissue_Primary Tumor	26.34	NA	NA	NBL, MYCN amplified	PATGJU	TARGET-30-PATGJU-01A-01D.M	01
PATGJU_01_Solid Tissue_Primary Tumor	26.34	NA	NA	NBL, MYCN amplified	PATGJU	TARGET-30-PATGJU-01A-01R	01
PATGLU_01_Solid Tissue_Primary Tumor	50.36	3	gain	NBL, MYCN non-amplified	PATGLU	BS_2P6MH05V	01
PATGLU_01_Solid Tissue_Primary Tumor	50.36	3	gain	NBL, MYCN non-amplified	PATGLU	TARGET-30-PATGLU-01A-01D	01
PATGLU_01_Solid Tissue_Primary Tumor	50.36	3	gain	NBL, MYCN non-amplified	PATGLU	TARGET-30-PATGLU-01A-01D.M	01
PATGLU_01_Solid Tissue_Primary Tumor	50.36	3	gain	NBL, MYCN non-amplified	PATGLU	TARGET-30-PATGLU-01A-01R	01
PATGWT_01_Solid Tissue_Primary Tumor	NA	129	amplification	NBL, MYCN amplified	PATGWT	TARGET-30-PATGWT-01A-01D	01
PATGWT_01_Solid Tissue_Primary Tumor	NA	129	amplification	NBL, MYCN amplified	PATGWT	TARGET-30-PATGWT-01A-01D.M	01
PATGWU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATGWU	TARGET-30-PATGWU-01A-01D	01
PATHJU_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATHJU	TARGET-30-PATHJU-09A-01D	09
PATHJZ_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PATHJZ	BS_89V49XKJ	01
PATHJZ_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PATHJZ	TARGET-30-PATHJZ-01A-01D	01
PATHKB_01_Solid Tissue_Primary Tumor	88.44	NA	NA	NBL, MYCN amplified	PATHKB	TARGET-30-PATHKB-01A-01D.M	01
PATHKB_01_Solid Tissue_Primary Tumor	88.44	NA	NA	NBL, MYCN amplified	PATHKB	TARGET-30-PATHKB-01A-01R	01
PATHUU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATHUU	TARGET-30-PATHUU-01A-01D	01
PATHVK_01_Solid Tissue_Primary Tumor	25.72	4	neutral	NBL, MYCN non-amplified	PATHVK	TARGET-30-PATHVK-01A-01D	01
PATHVK_01_Solid Tissue_Primary Tumor	25.72	4	neutral	NBL, MYCN non-amplified	PATHVK	TARGET-30-PATHVK-01A-01D.M	01
PATHVK_01_Solid Tissue_Primary Tumor	25.72	4	neutral	NBL, MYCN non-amplified	PATHVK	TARGET-30-PATHVK-01A-01R	01
PATHYD_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATHYD	BS_JXVVZ2S8	01
PATHYK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATHYK	TARGET-30-PATHYK-01A-01D	01
PATIHB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATIHB	TARGET-30-PATIHB-01A-01D	01
PATIIT_01_Solid Tissue_Primary Tumor	42.43	NA	NA	NBL, MYCN amplified	PATIIT	BS_2480EHNY	01
PATIIT_01_Solid Tissue_Primary Tumor	42.43	NA	NA	NBL, MYCN amplified	PATIIT	BS_GFN4FETJ	01
PATILE_01_Solid Tissue_Primary Tumor	NA	2	loss	NBL, MYCN non-amplified	PATILE	TARGET-30-PATILE-01A-01D	01
PATINJ_01_Solid Tissue_Primary Tumor	52.26	2	neutral	NBL, MYCN non-amplified	PATINJ	TARGET-30-PATINJ-01A-01D	01
PATINJ_01_Solid Tissue_Primary Tumor	52.26	2	neutral	NBL, MYCN non-amplified	PATINJ	TARGET-30-PATINJ-01A-01R	01
PATIRK_01_Solid Tissue_Primary Tumor	6.42	NA	NA	NBL, MYCN amplified	PATIRK	BS_NR090DDV	01
PATIRK_01_Solid Tissue_Primary Tumor	6.42	NA	NA	NBL, MYCN amplified	PATIRK	BS_WCEHT7D0	01
PATISU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATISU	TARGET-30-PATISU-01A-01D	01
PATIWH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATIWH	TARGET-30-PATIWH-01A-01D	01
PATIYD_09_Bone Marrow_Primary Tumor	NA	NA	gain	NBL, To be classified	PATIYD	BS_E4V8XN3G	09
PATIYD_09_Bone Marrow_Primary Tumor	NA	NA	gain	NBL, To be classified	PATIYD	TARGET-30-PATIYD-09A-01D	09
PATIYR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATIYR	BS_H915DJY3	01
PATJDG_01_Solid Tissue_Primary Tumor	1.7	NA	NA	NBL, MYCN non-amplified	PATJDG	BS_ETC8R0TD	01
PATJDG_01_Solid Tissue_Primary Tumor	1.7	NA	NA	NBL, MYCN non-amplified	PATJDG	BS_JZFMHGNX	01
PATJET_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJET	TARGET-30-PATJET-01A-01D	01
PATJEY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJEY	TARGET-30-PATJEY-01A-01D	01
PATJGB_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATJGB	BS_7NXB23C9	01
PATJHU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJHU	TARGET-30-PATJHU-01A-01D	01
PATJIN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJIN	TARGET-30-PATJIN-01A-01D	01
PATJIV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJIV	BS_T62SHZA7	01
PATJPI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJPI	TARGET-30-PATJPI-01A-01D	01
PATJXV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJXV	TARGET-30-PATJXV-01A-01D	01
PATJZC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJZC	TARGET-30-PATJZC-01A-01D	01
PATJZF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATJZF	TARGET-30-PATJZF-01A-01D	01
PATKGB_01_Solid Tissue_Primary Tumor	40.95	NA	loss	NBL, MYCN non-amplified	PATKGB	BS_9BYP1GZS	01
PATKGB_01_Solid Tissue_Primary Tumor	40.95	NA	loss	NBL, MYCN non-amplified	PATKGB	BS_YK9W04XG	01
PATKGB_01_Solid Tissue_Primary Tumor	40.95	NA	loss	NBL, MYCN non-amplified	PATKGB	TARGET-30-PATKGB-01A-01D	01
PATKHS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATKHS	TARGET-30-PATKHS-01A-01D	01
PATKPD_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, To be classified	PATKPD	BS_4WSW3X49	01
PATKPD_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, To be classified	PATKPD	TARGET-30-PATKPD-01A-01D	01
PATKSX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATKSX	TARGET-30-PATKSX-01A-01D	01
PATLBP_01_Solid Tissue_Primary Tumor	14.18	NA	NA	NBL, MYCN non-amplified	PATLBP	BS_38SSRZJ1	01
PATLBP_01_Solid Tissue_Primary Tumor	14.18	NA	NA	NBL, MYCN non-amplified	PATLBP	BS_Y2DSNJ1E	01
PATLCM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATLCM	TARGET-30-PATLCM-01A-01D	01
PATLFF_01_Solid Tissue_Primary Tumor	18.12	3	gain	NBL, MYCN non-amplified	PATLFF	BS_JFJYEHFM	01
PATLFF_01_Solid Tissue_Primary Tumor	18.12	3	gain	NBL, MYCN non-amplified	PATLFF	BS_WRZATZQF	01
PATLFX_01_Solid Tissue_Primary Tumor	26.59	3	gain	NBL, MYCN non-amplified	PATLFX	BS_3AKS23A0	01
PATLFX_01_Solid Tissue_Primary Tumor	26.59	3	gain	NBL, MYCN non-amplified	PATLFX	BS_F2F7BXT5	01
PATLKI_01_Solid Tissue_Primary Tumor	29.28	NA	gain	NBL, MYCN amplified	PATLKI	BS_A5AQFAFA	01
PATLKI_01_Solid Tissue_Primary Tumor	29.28	NA	gain	NBL, MYCN amplified	PATLKI	BS_QJ3XB7XZ	01
PATLKI_01_Solid Tissue_Primary Tumor	29.28	NA	gain	NBL, MYCN amplified	PATLKI	TARGET-30-PATLKI-01A-01D	01
PATLLI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATLLI	TARGET-30-PATLLI-01A-01D	01
PATLNM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATLNM	TARGET-30-PATLNM-01A-01D	01
PATLSY_01_Solid Tissue_Primary Tumor	3.7	NA	NA	NBL, MYCN amplified	PATLSY	BS_4VKRBRJC	01
PATLSY_01_Solid Tissue_Primary Tumor	3.7	NA	NA	NBL, MYCN amplified	PATLSY	BS_F9ZXCH60	01
PATLUI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATLUI	TARGET-30-PATLUI-01A-01D	01
PATLXP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATLXP	TARGET-30-PATLXP-01A-01D	01
PATMAJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMAJ	TARGET-30-PATMAJ-01A-01D	01
PATMAW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMAW	TARGET-30-PATMAW-01A-01D	01
PATMDE_01_Solid Tissue_Primary Tumor	2.09	NA	NA	NBL, MYCN amplified	PATMDE	BS_5W25GMQ1	01
PATMDE_01_Solid Tissue_Primary Tumor	2.09	NA	NA	NBL, MYCN amplified	PATMDE	BS_BPXHZ3Y0	01
PATMFH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMFH	BS_H7T26DMD	01
PATMFL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMFL	TARGET-30-PATMFL-01A-01D	01
PATMJV_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMJV	TARGET-30-PATMJV-09A-01D	09
PATMPC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMPC	TARGET-30-PATMPC-01A-01D	01
PATMRZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMRZ	BS_1GQJVG9Q	01
PATMRZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMRZ	TARGET-30-PATMRZ-01A-01D	01
PATMSI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMSI	TARGET-30-PATMSI-01A-01D	01
PATMSR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMSR	TARGET-30-PATMSR-01A-01D	01
PATMTX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMTX	TARGET-30-PATMTX-01A-01D	01
PATMVN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMVN	BS_4J4MVGTR	01
PATMXC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMXC	TARGET-30-PATMXC-01A-01D	01
PATMZJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATMZJ	BS_35DBPYMN	01
PATNBK_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATNBK	BS_SXVVN52M	01
PATNCI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATNCI	TARGET-30-PATNCI-01A-01D	01
PATNEA_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PATNEA	BS_8DB19DYW	01
PATNEA_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PATNEA	TARGET-30-PATNEA-01A-01D	01
PATNGD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATNGD	TARGET-30-PATNGD-01A-01D	01
PATNKP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATNKP	TARGET-30-PATNKP-01A-01D.M	01
PATNKP_02_Solid Tissue_Recurrence	35.73	NA	NA	NBL, MYCN amplified	PATNKP	TARGET-30-PATNKP-02A-01D.M	02
PATNKP_02_Solid Tissue_Recurrence	35.73	NA	NA	NBL, MYCN amplified	PATNKP	TARGET-30-PATNKP-02A-01R	02
PATNPW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATNPW	TARGET-30-PATNPW-01A-01D	01
PATNRI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATNRI	TARGET-30-PATNRI-01A-01D	01
PATNRK_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATNRK	TARGET-30-PATNRK-09A-01D	09
PATNUK_01_Solid Tissue_Primary Tumor	11.42	NA	NA	NBL, MYCN non-amplified	PATNUK	BS_NK1FJNRG	01
PATNUK_01_Solid Tissue_Primary Tumor	11.42	NA	NA	NBL, MYCN non-amplified	PATNUK	BS_XHSRBERM	01
PATNVA_01_Solid Tissue_Primary Tumor	12.14	NA	NA	NBL, MYCN non-amplified	PATNVA	BS_KYGRX01W	01
PATNVA_01_Solid Tissue_Primary Tumor	12.14	NA	NA	NBL, MYCN non-amplified	PATNVA	BS_S4R97RNZ	01
PATNWL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATNWL	TARGET-30-PATNWL-01A-01D	01
PATNWM_01_Solid Tissue_Primary Tumor	22.37	NA	NA	NBL, MYCN amplified	PATNWM	BS_HEKMP7BH	01
PATNWM_01_Solid Tissue_Primary Tumor	22.37	NA	NA	NBL, MYCN amplified	PATNWM	BS_R0WH31Q0	01
PATNXJ_01_Solid Tissue_Primary Tumor	28.29	NA	NA	NBL, MYCN amplified	PATNXJ	BS_GAA781GQ	01
PATNXJ_01_Solid Tissue_Primary Tumor	28.29	NA	NA	NBL, MYCN amplified	PATNXJ	BS_MH01GQ2B	01
PATNXK_01_Solid Tissue_Primary Tumor	23.59	NA	NA	NBL, MYCN amplified	PATNXK	BS_6FA0NNF1	01
PATNXK_01_Solid Tissue_Primary Tumor	23.59	NA	NA	NBL, MYCN amplified	PATNXK	BS_S0SM38BZ	01
PATNXK_01_Solid Tissue_Primary Tumor	23.59	NA	NA	NBL, MYCN amplified	PATNXK	TARGET-30-PATNXK-01A-01D	01
PATNZJ_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PATNZJ	BS_4D9SK48F	01
PATNZJ_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PATNZJ	TARGET-30-PATNZJ-01A-01D	01
PATNZR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATNZR	BS_P9FWPEYY	01
PATPET_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPET	TARGET-30-PATPET-01A-01D	01
PATPFG_01_Solid Tissue_Primary Tumor	22.7	3	gain	NBL, MYCN non-amplified	PATPFG	BS_9PEJSEZG	01
PATPFG_01_Solid Tissue_Primary Tumor	22.7	3	gain	NBL, MYCN non-amplified	PATPFG	BS_AYDD070S	01
PATPHR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPHR	TARGET-30-PATPHR-01A-01D	01
PATPIU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPIU	BS_ZYXTC212	01
PATPJD_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPJD	TARGET-30-PATPJD-09A-01D	09
PATPNR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPNR	TARGET-30-PATPNR-01A-01D	01
PATPPK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPPK	TARGET-30-PATPPK-01A-01D	01
PATPPU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPPU	TARGET-30-PATPPU-01A-01D	01
PATPPY_01_Solid Tissue_Primary Tumor	20.82	NA	NA	NBL, MYCN amplified	PATPPY	BS_8NQWYZHR	01
PATPPY_01_Solid Tissue_Primary Tumor	20.82	NA	NA	NBL, MYCN amplified	PATPPY	BS_T9KJYH7M	01
PATPXF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPXF	BS_EE2YW499	01
PATPXF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPXF	TARGET-30-PATPXF-01A-01D	01
PATPXJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPXJ	TARGET-30-PATPXJ-01A-01D	01
PATPYK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATPYK	TARGET-30-PATPYK-01A-01D	01
PATRHD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATRHD	TARGET-30-PATRHD-01A-01D	01
PATRJG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATRJG	TARGET-30-PATRJG-01A-01D	01
PATRJK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATRJK	TARGET-30-PATRJK-01A-01D	01
PATRMB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATRMB	TARGET-30-PATRMB-01A-01D	01
PATRNL_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATRNL	BS_CP8741SX	01
PATRUL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATRUL	TARGET-30-PATRUL-01A-01D	01
PATRUX_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATRUX	TARGET-30-PATRUX-09A-01D	09
PATRVB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATRVB	BS_WSD8PV27	01
PATRXC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATRXC	TARGET-30-PATRXC-01A-01D	01
PATRZM_01_Solid Tissue_Primary Tumor	NA	4	gain	NBL, MYCN non-amplified	PATRZM	BS_55PH1SAS	01
PATSCT_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATSCT	BS_BF83XX7P	01
PATSDR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSDR	TARGET-30-PATSDR-01A-01D	01
PATSEC_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSEC	BS_K9P9N35B	09
PATSIJ_01_Solid Tissue_Primary Tumor	19.48	NA	NA	NBL, MYCN amplified	PATSIJ	BS_DERH44Z2	01
PATSIJ_01_Solid Tissue_Primary Tumor	19.48	NA	NA	NBL, MYCN amplified	PATSIJ	BS_X3AFTRNM	01
PATSJV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSJV	TARGET-30-PATSJV-01A-01D	01
PATSKE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSKE	TARGET-30-PATSKE-01A-01D	01
PATSNC_01_Solid Tissue_Primary Tumor	8.33	NA	NA	NBL, MYCN amplified	PATSNC	BS_FXG6F3NN	01
PATSNC_01_Solid Tissue_Primary Tumor	8.33	NA	NA	NBL, MYCN amplified	PATSNC	BS_WKC3GR0D	01
PATSPZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSPZ	TARGET-30-PATSPZ-01A-01D	01
PATSRD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSRD	TARGET-30-PATSRD-01A-01D	01
PATSRY_01_Solid Tissue_Primary Tumor	29.52	3	loss	NBL, MYCN non-amplified	PATSRY	BS_K62HBS01	01
PATSRY_01_Solid Tissue_Primary Tumor	29.52	3	loss	NBL, MYCN non-amplified	PATSRY	BS_WFCVBVDS	01
PATSSA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSSA	BS_XDH1Y1TQ	01
PATSSA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSSA	TARGET-30-PATSSA-01A-01D	01
PATSSG_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATSSG	BS_P69A72G2	01
PATSTU_01_Solid Tissue_Primary Tumor	4.33	NA	NA	NBL, MYCN amplified	PATSTU	BS_255803B6	01
PATSTU_01_Solid Tissue_Primary Tumor	4.33	NA	NA	NBL, MYCN amplified	PATSTU	BS_3D1XTG0K	01
PATSUB_01_Solid Tissue_Primary Tumor	24.04	3	gain	NBL, MYCN non-amplified	PATSUB	BS_NN42N0XB	01
PATSUB_01_Solid Tissue_Primary Tumor	24.04	3	gain	NBL, MYCN non-amplified	PATSUB	BS_QZAV7XVF	01
PATSUL_01_Solid Tissue_Primary Tumor	8.57	NA	NA	NBL, MYCN amplified	PATSUL	BS_ACDQRWMY	01
PATSUL_01_Solid Tissue_Primary Tumor	8.57	NA	NA	NBL, MYCN amplified	PATSUL	BS_MG1N76FY	01
PATSVA_01_Solid Tissue_Primary Tumor	NA	23	amplification	NBL, MYCN amplified	PATSVA	BS_CQ40NN4X	01
PATSXC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATSXC	TARGET-30-PATSXC-01A-01D	01
PATTCU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTCU	BS_NB0ESCXK	01
PATTDY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTDY	BS_HEP8QTNN	01
PATTDY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTDY	TARGET-30-PATTDY-01A-01D	01
PATTEF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTEF	TARGET-30-PATTEF-01A-01D	01
PATTFB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTFB	TARGET-30-PATTFB-01A-01D	01
PATTFS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTFS	BS_WVMWHF4P	01
PATTHA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTHA	TARGET-30-PATTHA-01A-01D	01
PATTHB_01_Solid Tissue_Primary Tumor	25.6	3	gain	NBL, MYCN non-amplified	PATTHB	BS_B2RYV4GG	01
PATTHB_01_Solid Tissue_Primary Tumor	25.6	3	gain	NBL, MYCN non-amplified	PATTHB	BS_S32M2YTY	01
PATTMM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTMM	TARGET-30-PATTMM-01A-01D	01
PATTNA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTNA	TARGET-30-PATTNA-01A-01D	01
PATTNX_01_Solid Tissue_Primary Tumor	36.26	3	gain	NBL, MYCN non-amplified	PATTNX	BS_DHXNWXP6	01
PATTNX_01_Solid Tissue_Primary Tumor	36.26	3	gain	NBL, MYCN non-amplified	PATTNX	BS_G4W213NW	01
PATTPC_01_Solid Tissue_Primary Tumor	393.89	NA	amplification	NBL, MYCN amplified	PATTPC	BS_GBS4JMAZ	01
PATTPC_01_Solid Tissue_Primary Tumor	393.89	NA	amplification	NBL, MYCN amplified	PATTPC	BS_NKGRBE18	01
PATTPC_01_Solid Tissue_Primary Tumor	393.89	NA	amplification	NBL, MYCN amplified	PATTPC	TARGET-30-PATTPC-01A-01D	01
PATTPL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTPL	TARGET-30-PATTPL-01A-01D	01
PATTPW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTPW	TARGET-30-PATTPW-01A-01D	01
PATTTS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTTS	BS_ABZC437A	01
PATTWT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATTWT	BS_D9BP1QN2	01
PATUAI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATUAI	BS_XX68G6KE	01
PATUBI_01_Solid Tissue_Primary Tumor	26.85	NA	NA	NBL, MYCN amplified	PATUBI	BS_E359X3QV	01
PATUBI_01_Solid Tissue_Primary Tumor	26.85	NA	NA	NBL, MYCN amplified	PATUBI	BS_E4N511ZX	01
PATUEH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATUEH	TARGET-30-PATUEH-01A-01D	01
PATUNK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATUNK	TARGET-30-PATUNK-01A-01D	01
PATUNX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATUNX	TARGET-30-PATUNX-01A-01D	01
PATUNZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATUNZ	TARGET-30-PATUNZ-01A-01D	01
PATUPN_01_Solid Tissue_Primary Tumor	13.36	NA	NA	NBL, MYCN non-amplified	PATUPN	BS_10MQQC5C	01
PATUPN_01_Solid Tissue_Primary Tumor	13.36	NA	NA	NBL, MYCN non-amplified	PATUPN	BS_NNH2A86D	01
PATUPR_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATUPR	TARGET-30-PATUPR-09A-01D	09
PATUVB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATUVB	TARGET-30-PATUVB-01A-01D	01
PATUWG_01_Solid Tissue_Primary Tumor	NA	NA	loss	NBL, MYCN non-amplified	PATUWG	BS_STK02B14	01
PATUWG_01_Solid Tissue_Primary Tumor	NA	NA	loss	NBL, MYCN non-amplified	PATUWG	TARGET-30-PATUWG-01A-01D	01
PATUZF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATUZF	TARGET-30-PATUZF-01A-01D	01
PATVDI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVDI	TARGET-30-PATVDI-01A-01D	01
PATVDP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVDP	TARGET-30-PATVDP-01A-01D	01
PATVDY_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVDY	TARGET-30-PATVDY-09A-01D	09
PATVER_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVER	BS_SYQG48V0	01
PATVHJ_01_Solid Tissue_Primary Tumor	16.33	NA	NA	NBL, MYCN amplified	PATVHJ	BS_8GD69HHF	01
PATVHJ_01_Solid Tissue_Primary Tumor	16.33	NA	NA	NBL, MYCN amplified	PATVHJ	BS_EDGSP4V6	01
PATVJX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVJX	TARGET-30-PATVJX-01A-01D	01
PATVKG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVKG	BS_0Y4VHCMS	01
PATVKI_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATVKI	BS_6S50RDHT	01
PATVKN_01_Solid Tissue_Primary Tumor	11.39	NA	NA	NBL, MYCN non-amplified	PATVKN	BS_6AENZKKA	01
PATVKN_01_Solid Tissue_Primary Tumor	11.39	NA	NA	NBL, MYCN non-amplified	PATVKN	BS_Z36F6GKX	01
PATVMF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVMF	BS_8JTH2X5Z	01
PATVMF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVMF	TARGET-30-PATVMF-01A-01D	01
PATVNW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVNW	TARGET-30-PATVNW-01A-01D	01
PATVRG_01_Solid Tissue_Primary Tumor	11.96	3	gain	NBL, MYCN non-amplified	PATVRG	BS_83RF7CY6	01
PATVRG_01_Solid Tissue_Primary Tumor	11.96	3	gain	NBL, MYCN non-amplified	PATVRG	BS_YPKSF86W	01
PATVSU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVSU	TARGET-30-PATVSU-01A-01D	01
PATVTL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVTL	TARGET-30-PATVTL-01A-01D	01
PATVVB_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATVVB	BS_PDWEETXG	01
PATVWA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVWA	TARGET-30-PATVWA-01A-01D	01
PATVYZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVYZ	BS_NGBKDYFB	01
PATVYZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVYZ	TARGET-30-PATVYZ-01A-01D	01
PATVZB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATVZB	TARGET-30-PATVZB-01A-01D	01
PATWAG_09_Bone Marrow_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATWAG	BS_SSS5J8P5	09
PATWDV_01_Solid Tissue_Primary Tumor	NA	3	loss	NBL, MYCN non-amplified	PATWDV	BS_588QYDB1	01
PATWED_01_Solid Tissue_Primary Tumor	82.09	NA	amplification	NBL, MYCN amplified	PATWED	BS_HZKJMB0D	01
PATWED_01_Solid Tissue_Primary Tumor	82.09	NA	amplification	NBL, MYCN amplified	PATWED	BS_YA56YE71	01
PATWED_01_Solid Tissue_Primary Tumor	82.09	NA	amplification	NBL, MYCN amplified	PATWED	TARGET-30-PATWED-01A-01D	01
PATWEJ_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATWEJ	BS_QNQDTDCS	01
PATWGC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATWGC	TARGET-30-PATWGC-01A-01D	01
PATWGR_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PATWGR	BS_1FR8GJ7N	01
PATWGR_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PATWGR	TARGET-30-PATWGR-01A-01D	01
PATWIL_01_Solid Tissue_Primary Tumor	19.1	NA	NA	NBL, MYCN amplified	PATWIL	BS_KBXSSXWF	01
PATWIL_01_Solid Tissue_Primary Tumor	19.1	NA	NA	NBL, MYCN amplified	PATWIL	BS_R66Z3ENM	01
PATWIL_01_Solid Tissue_Primary Tumor	19.1	NA	NA	NBL, MYCN amplified	PATWIL	TARGET-30-PATWIL-01A-01D	01
PATWMX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATWMX	TARGET-30-PATWMX-01A-01D	01
PATWNB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATWNB	TARGET-30-PATWNB-01A-01D	01
PATWPC_01_Solid Tissue_Primary Tumor	10.85	NA	NA	NBL, MYCN non-amplified	PATWPC	BS_25EXB29C	01
PATWPC_01_Solid Tissue_Primary Tumor	10.85	NA	NA	NBL, MYCN non-amplified	PATWPC	BS_8V59CEJJ	01
PATWPL_01_Solid Tissue_Primary Tumor	34.48	3	neutral	NBL, MYCN non-amplified	PATWPL	BS_7HRQNWJY	01
PATWPL_01_Solid Tissue_Primary Tumor	34.48	3	neutral	NBL, MYCN non-amplified	PATWPL	BS_STTGK8V4	01
PATWTJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATWTJ	BS_YTQ6Y7FQ	01
PATWTW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATWTW	TARGET-30-PATWTW-01A-01D	01
PATWWJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATWWJ	TARGET-30-PATWWJ-01A-01D	01
PATWZB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATWZB	TARGET-30-PATWZB-01A-01D	01
PATWZZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATWZZ	TARGET-30-PATWZZ-01A-01D	01
PATXDV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXDV	TARGET-30-PATXDV-01A-01D	01
PATXGG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXGG	BS_J8YAY1HM	01
PATXHB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXHB	BS_E7CRT00M	01
PATXHC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXHC	TARGET-30-PATXHC-01A-01D	01
PATXHT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXHT	TARGET-30-PATXHT-01A-01D	01
PATXHW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXHW	TARGET-30-PATXHW-01A-01D	01
PATXKG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PATXKG	BS_01BDZ0TW	01
PATXKG_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PATXKG	TARGET-30-PATXKG-01A-01D	01
PATXKN_01_Solid Tissue_Primary Tumor	9.08	3	gain	NBL, MYCN non-amplified	PATXKN	BS_0D3SCV7P	01
PATXKN_01_Solid Tissue_Primary Tumor	9.08	3	gain	NBL, MYCN non-amplified	PATXKN	BS_SMJRCVQB	01
PATXTF_01_Solid Tissue_Primary Tumor	36.56	NA	gain	NBL, MYCN non-amplified	PATXTF	BS_76SQJSHP	01
PATXTF_01_Solid Tissue_Primary Tumor	36.56	NA	gain	NBL, MYCN non-amplified	PATXTF	BS_BW9QBKEQ	01
PATXTF_01_Solid Tissue_Primary Tumor	36.56	NA	gain	NBL, MYCN non-amplified	PATXTF	TARGET-30-PATXTF-01A-01D	01
PATXUG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXUG	TARGET-30-PATXUG-01A-01D	01
PATXWS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXWS	TARGET-30-PATXWS-01A-01D	01
PATXWY_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXWY	TARGET-30-PATXWY-09A-01D	09
PATXXF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXXF	TARGET-30-PATXXF-01A-01D	01
PATXXI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATXXI	TARGET-30-PATXXI-01A-01D	01
PATYAU_01_Solid Tissue_Primary Tumor	NA	25	amplification	NBL, MYCN amplified	PATYAU	BS_GPXZ2NQB	01
PATYCM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYCM	TARGET-30-PATYCM-01A-01D	01
PATYDC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYDC	TARGET-30-PATYDC-01A-01D	01
PATYEJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYEJ	TARGET-30-PATYEJ-01A-01D	01
PATYGV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYGV	BS_FSNCPJJF	01
PATYIL_01_Solid Tissue_Primary Tumor	561.5	NA	NA	NBL, MYCN amplified	PATYIL	TARGET-30-PATYIL-01A-01D.M	01
PATYIL_01_Solid Tissue_Primary Tumor	561.5	NA	NA	NBL, MYCN amplified	PATYIL	TARGET-30-PATYIL-01A-01R	01
PATYIL_02_Solid Tissue_Recurrence	637.82	NA	NA	NBL, MYCN amplified	PATYIL	TARGET-30-PATYIL-02A-01D.M	02
PATYIL_02_Solid Tissue_Recurrence	637.82	NA	NA	NBL, MYCN amplified	PATYIL	TARGET-30-PATYIL-02A-01R	02
PATYMK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYMK	TARGET-30-PATYMK-01A-01D	01
PATYMS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYMS	TARGET-30-PATYMS-01A-01D	01
PATYMZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYMZ	TARGET-30-PATYMZ-01A-01D	01
PATYNP_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATYNP	BS_QSTNH2MJ	01
PATYPH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYPH	TARGET-30-PATYPH-01A-01D	01
PATYRV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYRV	BS_PWXXZMSR	01
PATYWG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYWG	BS_A3K94FCY	01
PATYWM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYWM	TARGET-30-PATYWM-01A-01D	01
PATYWX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYWX	TARGET-30-PATYWX-01A-01D	01
PATYXS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATYXS	BS_1HXG4A7B	01
PATZBH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATZBH	TARGET-30-PATZBH-01A-01D	01
PATZIG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATZIG	TARGET-30-PATZIG-01A-01D	01
PATZRF_01_Solid Tissue_Primary Tumor	235.02	NA	amplification	NBL, MYCN amplified	PATZRF	BS_A527Y2QF	01
PATZRF_01_Solid Tissue_Primary Tumor	235.02	NA	amplification	NBL, MYCN amplified	PATZRF	BS_S4WH99C9	01
PATZRF_01_Solid Tissue_Primary Tumor	235.02	NA	amplification	NBL, MYCN amplified	PATZRF	TARGET-30-PATZRF-01A-01D	01
PATZRU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PATZRU	TARGET-30-PATZRU-01A-01D	01
PATZZJ_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PATZZJ	BS_0QTY32QA	01
PAUAEE_01_Solid Tissue_Primary Tumor	31.89	3	loss	NBL, MYCN non-amplified	PAUAEE	BS_0JBZPAGN	01
PAUAEE_01_Solid Tissue_Primary Tumor	31.89	3	loss	NBL, MYCN non-amplified	PAUAEE	BS_HQC1EKZ8	01
PAUAEK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUAEK	BS_A2Z4DDQS	01
PAUAFH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUAFH	BS_EWNSDJ7V	01
PAUAKC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUAKC	BS_WKPJ7S74	01
PAUAKT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUAKT	TARGET-30-PAUAKT-01A-01D	01
PAUALH_01_Solid Tissue_Primary Tumor	NA	3	loss	NBL, MYCN non-amplified	PAUALH	BS_QEKBZRMD	01
PAUATG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUATG	TARGET-30-PAUATG-01A-01D	01
PAUAZA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUAZA	BS_MMCZHZE6	01
PAUAZA_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUAZA	TARGET-30-PAUAZA-01A-01D	01
PAUAZW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUAZW	BS_TDV0SYNR	01
PAUBDC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBDC	TARGET-30-PAUBDC-01A-01D	01
PAUBEC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBEC	TARGET-30-PAUBEC-01A-01D	01
PAUBFU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBFU	TARGET-30-PAUBFU-01A-01D	01
PAUBGW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBGW	TARGET-30-PAUBGW-01A-01D	01
PAUBHV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBHV	TARGET-30-PAUBHV-01A-01D	01
PAUBPW_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBPW	TARGET-30-PAUBPW-09A-01D	09
PAUBRR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBRR	TARGET-30-PAUBRR-01A-01D	01
PAUBSW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBSW	TARGET-30-PAUBSW-01A-01D	01
PAUBVN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBVN	BS_M0N8YXTA	01
PAUBVN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBVN	TARGET-30-PAUBVN-01A-01D	01
PAUBWP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBWP	TARGET-30-PAUBWP-01A-01D	01
PAUBYW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUBYW	TARGET-30-PAUBYW-01A-01D	01
PAUCFI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUCFI	TARGET-30-PAUCFI-01A-01D	01
PAUCGP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUCGP	TARGET-30-PAUCGP-01A-01D	01
PAUCIK_01_Solid Tissue_Primary Tumor	12.05	NA	NA	NBL, MYCN non-amplified	PAUCIK	BS_FR9R7VFY	01
PAUCIK_01_Solid Tissue_Primary Tumor	12.05	NA	NA	NBL, MYCN non-amplified	PAUCIK	BS_YMWFA93F	01
PAUCKF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUCKF	TARGET-30-PAUCKF-01A-01D	01
PAUCMD_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAUCMD	BS_HQYHVPC9	01
PAUCNL_01_Solid Tissue_Primary Tumor	22.84	NA	NA	NBL, MYCN amplified	PAUCNL	BS_HEJAPS03	01
PAUCNL_01_Solid Tissue_Primary Tumor	22.84	NA	NA	NBL, MYCN amplified	PAUCNL	BS_KTHF096D	01
PAUCRL_01_Solid Tissue_Primary Tumor	10.42	NA	NA	NBL, MYCN non-amplified	PAUCRL	BS_PGBR1H2A	01
PAUCRL_01_Solid Tissue_Primary Tumor	10.42	NA	NA	NBL, MYCN non-amplified	PAUCRL	BS_SM1QE9FJ	01
PAUCRL_01_Solid Tissue_Primary Tumor	10.42	NA	NA	NBL, MYCN non-amplified	PAUCRL	TARGET-30-PAUCRL-01A-01D	01
PAUCXF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUCXF	BS_GPNWSW71	01
PAUCXG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUCXG	BS_G6ASNYWP	01
PAUCYI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUCYI	BS_9YMT5HB4	01
PAUDBX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDBX	TARGET-30-PAUDBX-01A-01D	01
PAUDDK_01_Solid Tissue_Primary Tumor	13.43	NA	NA	NBL, MYCN non-amplified	PAUDDK	TARGET-30-PAUDDK-01A-01D.M	01
PAUDDK_01_Solid Tissue_Primary Tumor	13.43	NA	NA	NBL, MYCN non-amplified	PAUDDK	TARGET-30-PAUDDK-01A-01R	01
PAUDDK_02_Solid Tissue_Recurrence	41.56	NA	NA	NBL, MYCN amplified	PAUDDK	TARGET-30-PAUDDK-02A-01D.M	02
PAUDDK_02_Solid Tissue_Recurrence	41.56	NA	NA	NBL, MYCN amplified	PAUDDK	TARGET-30-PAUDDK-02A-01R	02
PAUDDZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDDZ	TARGET-30-PAUDDZ-01A-01D	01
PAUDEK_01_Solid Tissue_Primary Tumor	NA	3	loss	NBL, MYCN non-amplified	PAUDEK	BS_4ZE1R1FW	01
PAUDFJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDFJ	BS_QXZZY4SJ	01
PAUDFR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDFR	BS_VCXG53E7	01
PAUDFR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDFR	TARGET-30-PAUDFR-01A-01D	01
PAUDIK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDIK	TARGET-30-PAUDIK-01A-01D	01
PAUDMU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDMU	TARGET-30-PAUDMU-01A-01D	01
PAUDPP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDPP	TARGET-30-PAUDPP-01A-01D	01
PAUDVA_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUDVA	TARGET-30-PAUDVA-09A-01D	09
PAUEKP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUEKP	BS_EXDY4JFF	01
PAUELT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUELT	TARGET-30-PAUELT-01A-01D	01
PAUEWF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUEWF	BS_NWCPQC60	01
PAUEXM_01_Solid Tissue_Primary Tumor	40.38	4	gain	NBL, MYCN non-amplified	PAUEXM	BS_6YYC47K2	01
PAUEXM_01_Solid Tissue_Primary Tumor	40.38	4	gain	NBL, MYCN non-amplified	PAUEXM	BS_WBZBDN0A	01
PAUEYW_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUEYW	TARGET-30-PAUEYW-09A-01D	09
PAUEZU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUEZU	TARGET-30-PAUEZU-01A-01D	01
PAUFFP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFFP	TARGET-30-PAUFFP-01A-01D	01
PAUFHY_01_Solid Tissue_Primary Tumor	1.54	NA	NA	NBL, MYCN non-amplified	PAUFHY	BS_FXDGYFBR	01
PAUFHY_01_Solid Tissue_Primary Tumor	1.54	NA	NA	NBL, MYCN non-amplified	PAUFHY	BS_ZK0GRMB1	01
PAUFIM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFIM	TARGET-30-PAUFIM-01A-01D	01
PAUFIT_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFIT	BS_S8STY9B1	09
PAUFKP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFKP	BS_R2G2TPBV	01
PAUFPG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFPG	TARGET-30-PAUFPG-01A-01D	01
PAUFSR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFSR	TARGET-30-PAUFSR-01A-01D	01
PAUFSZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFSZ	BS_8ZFK0D8Z	01
PAUFUS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFUS	TARGET-30-PAUFUS-01A-01D	01
PAUFVW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFVW	TARGET-30-PAUFVW-01A-01D	01
PAUFYH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUFYH	BS_8D7YYP13	01
PAUGGK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUGGK	TARGET-30-PAUGGK-01A-01D	01
PAUGIP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUGIP	TARGET-30-PAUGIP-01A-01D	01
PAUGJI_01_Solid Tissue_Primary Tumor	266.48	NA	amplification	NBL, MYCN amplified	PAUGJI	BS_8MYS5HP4	01
PAUGJI_01_Solid Tissue_Primary Tumor	266.48	NA	amplification	NBL, MYCN amplified	PAUGJI	BS_T5BAS1JN	01
PAUGJI_01_Solid Tissue_Primary Tumor	266.48	NA	amplification	NBL, MYCN amplified	PAUGJI	TARGET-30-PAUGJI-01A-01D	01
PAUGNL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUGNL	TARGET-30-PAUGNL-01A-01D	01
PAUGRP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUGRP	TARGET-30-PAUGRP-01A-01D	01
PAUGVU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUGVU	BS_1BR81RGD	01
PAUGVZ_01_Solid Tissue_Primary Tumor	15.43	NA	NA	NBL, MYCN amplified	PAUGVZ	BS_J9EH31NM	01
PAUGVZ_01_Solid Tissue_Primary Tumor	15.43	NA	NA	NBL, MYCN amplified	PAUGVZ	BS_NQN1P6QY	01
PAUGVZ_01_Solid Tissue_Primary Tumor	15.43	NA	NA	NBL, MYCN amplified	PAUGVZ	TARGET-30-PAUGVZ-01A-01D	01
PAUGWT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUGWT	TARGET-30-PAUGWT-01A-01D	01
PAUGZD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUGZD	TARGET-30-PAUGZD-01A-01D	01
PAUHBZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUHBZ	TARGET-30-PAUHBZ-01A-01D	01
PAUHFW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUHFW	TARGET-30-PAUHFW-01A-01D	01
PAUHHW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUHHW	TARGET-30-PAUHHW-01A-01D	01
PAUHIK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUHIK	TARGET-30-PAUHIK-01A-01D	01
PAUHSJ_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PAUHSJ	BS_8C5QG3GE	01
PAUHSJ_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PAUHSJ	TARGET-30-PAUHSJ-01A-01D	01
PAUHXD_01_Solid Tissue_Primary Tumor	22.9	NA	NA	NBL, MYCN amplified	PAUHXD	BS_NV9ZB445	01
PAUHXD_01_Solid Tissue_Primary Tumor	22.9	NA	NA	NBL, MYCN amplified	PAUHXD	BS_VV8GRGZ6	01
PAUHYY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUHYY	TARGET-30-PAUHYY-01A-01D	01
PAUICI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUICI	TARGET-30-PAUICI-01A-01D	01
PAUIDD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUIDD	BS_ZQEDB5RA	01
PAUIFL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUIFL	TARGET-30-PAUIFL-01A-01D	01
PAUIHH_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PAUIHH	BS_55AHFCX4	01
PAUIHH_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PAUIHH	TARGET-30-PAUIHH-01A-01D	01
PAUIJR_01_Solid Tissue_Primary Tumor	13.05	3	gain	NBL, MYCN non-amplified	PAUIJR	BS_00PH2T1P	01
PAUIJR_01_Solid Tissue_Primary Tumor	13.05	3	gain	NBL, MYCN non-amplified	PAUIJR	BS_P10Y42BX	01
PAUILS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUILS	BS_Y35YEDFF	01
PAUIRD_01_Solid Tissue_Primary Tumor	27.44	NA	NA	NBL, MYCN amplified	PAUIRD	BS_02X4QTNE	01
PAUIRD_01_Solid Tissue_Primary Tumor	27.44	NA	NA	NBL, MYCN amplified	PAUIRD	BS_20HSXMYQ	01
PAUITU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUITU	TARGET-30-PAUITU-01A-01D	01
PAUIWS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUIWS	BS_QWC51APP	01
PAUIWS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUIWS	TARGET-30-PAUIWS-01A-01D	01
PAUJEJ_01_Solid Tissue_Primary Tumor	111.17	5	amplification	NBL, MYCN amplified	PAUJEJ	BS_4J8JK335	01
PAUJEJ_01_Solid Tissue_Primary Tumor	111.17	5	amplification	NBL, MYCN amplified	PAUJEJ	BS_H4TFY19Z	01
PAUJLH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUJLH	TARGET-30-PAUJLH-01A-01D	01
PAUJPC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUJPC	TARGET-30-PAUJPC-01A-01D	01
PAUJRW_01_Solid Tissue_Primary Tumor	352.32	NA	gain	NBL, MYCN amplified	PAUJRW	BS_FJP95JXF	01
PAUJRW_01_Solid Tissue_Primary Tumor	352.32	NA	gain	NBL, MYCN amplified	PAUJRW	BS_ZFJS669M	01
PAUJRW_01_Solid Tissue_Primary Tumor	352.32	NA	gain	NBL, MYCN amplified	PAUJRW	TARGET-30-PAUJRW-01A-01D	01
PAUJTY_01_Solid Tissue_Primary Tumor	14.62	NA	NA	NBL, MYCN non-amplified	PAUJTY	BS_5DXK26YF	01
PAUJTY_01_Solid Tissue_Primary Tumor	14.62	NA	NA	NBL, MYCN non-amplified	PAUJTY	BS_X3F8NMS4	01
PAUJTY_01_Solid Tissue_Primary Tumor	14.62	NA	NA	NBL, MYCN non-amplified	PAUJTY	TARGET-30-PAUJTY-01A-01D	01
PAUJVX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUJVX	TARGET-30-PAUJVX-01A-01D	01
PAUKAP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUKAP	TARGET-30-PAUKAP-01A-01D	01
PAUKAW_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUKAW	TARGET-30-PAUKAW-01A-01D	01
PAUKIJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUKIJ	TARGET-30-PAUKIJ-01A-01D	01
PAUKLK_01_Solid Tissue_Primary Tumor	296.15	NA	amplification	NBL, MYCN amplified	PAUKLK	BS_2R0QBATZ	01
PAUKLK_01_Solid Tissue_Primary Tumor	296.15	NA	amplification	NBL, MYCN amplified	PAUKLK	BS_94JMQ7MX	01
PAUKLK_01_Solid Tissue_Primary Tumor	296.15	NA	amplification	NBL, MYCN amplified	PAUKLK	TARGET-30-PAUKLK-01A-01D	01
PAUKNU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUKNU	TARGET-30-PAUKNU-01A-01D	01
PAUKRF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUKRF	TARGET-30-PAUKRF-01A-01D	01
PAUKVC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUKVC	TARGET-30-PAUKVC-01A-01D	01
PAUKYI_01_Solid Tissue_Primary Tumor	1.68	NA	NA	NBL, MYCN non-amplified	PAUKYI	BS_63ACHY8K	01
PAUKYI_01_Solid Tissue_Primary Tumor	1.68	NA	NA	NBL, MYCN non-amplified	PAUKYI	BS_NV00B2Y5	01
PAULBY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAULBY	BS_B95NMCYN	01
PAULDT_01_Solid Tissue_Primary Tumor	27.11	3	neutral	NBL, MYCN non-amplified	PAULDT	BS_5ACNB1BG	01
PAULDT_01_Solid Tissue_Primary Tumor	27.11	3	neutral	NBL, MYCN non-amplified	PAULDT	BS_CN3256VE	01
PAULMT_01_Solid Tissue_Primary Tumor	13.26	NA	NA	NBL, MYCN non-amplified	PAULMT	BS_K59AGJKW	01
PAULMT_01_Solid Tissue_Primary Tumor	13.26	NA	NA	NBL, MYCN non-amplified	PAULMT	BS_YV3MJ2BD	01
PAULMT_01_Solid Tissue_Primary Tumor	13.26	NA	NA	NBL, MYCN non-amplified	PAULMT	TARGET-30-PAULMT-01A-01D	01
PAULNF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAULNF	TARGET-30-PAULNF-01A-01D	01
PAULVH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAULVH	TARGET-30-PAULVH-01A-01D	01
PAULZB_01_Solid Tissue_Primary Tumor	23.37	3	gain	NBL, MYCN non-amplified	PAULZB	BS_BTRGQHM4	01
PAULZB_01_Solid Tissue_Primary Tumor	23.37	3	gain	NBL, MYCN non-amplified	PAULZB	BS_HHNQ3N2V	01
PAUMBB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUMBB	TARGET-30-PAUMBB-01A-01D	01
PAUMFN_01_Solid Tissue_Primary Tumor	33.64	3	gain	NBL, MYCN non-amplified	PAUMFN	BS_RFEDCJTP	01
PAUMFN_01_Solid Tissue_Primary Tumor	33.64	3	gain	NBL, MYCN non-amplified	PAUMFN	BS_WKVJJF3F	01
PAUMJN_01_Solid Tissue_Primary Tumor	66.35	59	amplification	NBL, MYCN amplified	PAUMJN	BS_CCV91DR0	01
PAUMJN_01_Solid Tissue_Primary Tumor	66.35	59	amplification	NBL, MYCN amplified	PAUMJN	BS_P0BHM8S1	01
PAUMMZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUMMZ	TARGET-30-PAUMMZ-01A-01D	01
PAUMUC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUMUC	TARGET-30-PAUMUC-01A-01D	01
PAUMXC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUMXC	TARGET-30-PAUMXC-01A-01D	01
PAUNBM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUNBM	BS_SFQWVZ4N	01
PAUNST_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PAUNST	BS_GZG7GH62	01
PAUNST_01_Solid Tissue_Primary Tumor	NA	NA	gain	NBL, MYCN non-amplified	PAUNST	TARGET-30-PAUNST-01A-01D	01
PAUNTY_01_Solid Tissue_Primary Tumor	312.62	NA	NA	NBL, MYCN amplified	PAUNTY	BS_9BZBCZHK	01
PAUNTY_01_Solid Tissue_Primary Tumor	312.62	NA	NA	NBL, MYCN amplified	PAUNTY	BS_VNKT3ZZS	01
PAUNTY_01_Solid Tissue_Primary Tumor	312.62	NA	NA	NBL, MYCN amplified	PAUNTY	TARGET-30-PAUNTY-01A-01D	01
PAUNWR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUNWR	TARGET-30-PAUNWR-01A-01D	01
PAUNZM_01_Solid Tissue_Primary Tumor	26.7	3	gain	NBL, MYCN amplified	PAUNZM	BS_E9YW2KHS	01
PAUNZM_01_Solid Tissue_Primary Tumor	26.7	3	gain	NBL, MYCN amplified	PAUNZM	BS_VR7XMQZ3	01
PAUPDY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUPDY	TARGET-30-PAUPDY-01A-01D	01
PAUPGV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUPGV	TARGET-30-PAUPGV-01A-01D	01
PAUPIC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUPIC	TARGET-30-PAUPIC-01A-01D	01
PAUPKS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUPKS	BS_TBSPYEEW	01
PAUPMU_01_Solid Tissue_Primary Tumor	3.07	NA	NA	NBL, MYCN amplified	PAUPMU	BS_5QFRPR61	01
PAUPMU_01_Solid Tissue_Primary Tumor	3.07	NA	NA	NBL, MYCN amplified	PAUPMU	BS_FC37XAZK	01
PAUPNE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUPNE	BS_B5MDTA3Q	01
PAUPNR_01_Solid Tissue_Primary Tumor	21.78	NA	NA	NBL, MYCN amplified	PAUPNR	BS_2ABKFT99	01
PAUPNR_01_Solid Tissue_Primary Tumor	21.78	NA	NA	NBL, MYCN amplified	PAUPNR	BS_QCDCAX7G	01
PAUPRN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUPRN	TARGET-30-PAUPRN-01A-01D	01
PAUPSP_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAUPSP	BS_J5C6FMYZ	01
PAUPWN_01_Solid Tissue_Primary Tumor	28.78	3	gain	NBL, MYCN non-amplified	PAUPWN	BS_5BB8J64W	01
PAUPWN_01_Solid Tissue_Primary Tumor	28.78	3	gain	NBL, MYCN non-amplified	PAUPWN	BS_T7MWWC0A	01
PAUPWX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUPWX	TARGET-30-PAUPWX-01A-01D	01
PAURCG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAURCG	TARGET-30-PAURCG-01A-01D	01
PAURCX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAURCX	BS_E2EXBFN7	01
PAURFH_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAURFH	BS_X242DJMF	01
PAURGD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAURGD	TARGET-30-PAURGD-01A-01D	01
PAURJG_01_Solid Tissue_Primary Tumor	25.32	NA	NA	NBL, MYCN amplified	PAURJG	BS_KF4AR0FG	01
PAURJG_01_Solid Tissue_Primary Tumor	25.32	NA	NA	NBL, MYCN amplified	PAURJG	BS_MMBWD5VD	01
PAURPL_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAURPL	TARGET-30-PAURPL-01A-01D	01
PAURUR_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAURUR	TARGET-30-PAURUR-01A-01D	01
PAURYJ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAURYJ	TARGET-30-PAURYJ-01A-01D	01
PAURZH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAURZH	TARGET-30-PAURZH-01A-01D	01
PAUSJB_01_Solid Tissue_Primary Tumor	8.68	NA	NA	NBL, MYCN amplified	PAUSJB	BS_BJCTR4C8	01
PAUSJB_01_Solid Tissue_Primary Tumor	8.68	NA	NA	NBL, MYCN amplified	PAUSJB	BS_GB1XPW06	01
PAUSJB_01_Solid Tissue_Primary Tumor	8.68	NA	NA	NBL, MYCN amplified	PAUSJB	TARGET-30-PAUSJB-01A-01D	01
PAUSUV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUSUV	BS_08127AYS	01
PAUSXH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUSXH	TARGET-30-PAUSXH-01A-01D	01
PAUTFB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUTFB	BS_42Y9E1Q8	01
PAUTFT_01_Solid Tissue_Primary Tumor	86.79	30	amplification	NBL, MYCN amplified	PAUTFT	BS_896YFFGE	01
PAUTFT_01_Solid Tissue_Primary Tumor	86.79	30	amplification	NBL, MYCN amplified	PAUTFT	BS_ZED6T1CT	01
PAUTKJ_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUTKJ	TARGET-30-PAUTKJ-09A-01D	09
PAUTKP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUTKP	TARGET-30-PAUTKP-01A-01D	01
PAUTLP_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PAUTLP	BS_MA4DE9P2	01
PAUTLP_01_Solid Tissue_Primary Tumor	NA	NA	amplification	NBL, MYCN amplified	PAUTLP	TARGET-30-PAUTLP-01A-01D	01
PAUTRA_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAUTRA	BS_DHC9SHF6	01
PAUTVX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUTVX	TARGET-30-PAUTVX-01A-01D	01
PAUUGT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUUGT	TARGET-30-PAUUGT-01A-01D	01
PAUUHD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUUHD	TARGET-30-PAUUHD-01A-01D	01
PAUUHH_01_Solid Tissue_Primary Tumor	NA	72	amplification	NBL, MYCN amplified	PAUUHH	BS_56CA6BFQ	01
PAUUHY_01_Solid Tissue_Primary Tumor	NA	145	amplification	NBL, MYCN amplified	PAUUHY	BS_2FPVHEQS	01
PAUUTW_01_Solid Tissue_Primary Tumor	25.81	NA	NA	NBL, MYCN amplified	PAUUTW	BS_H9BW7Y9C	01
PAUUWG_01_Solid Tissue_Primary Tumor	0.83	NA	NA	NBL, MYCN non-amplified	PAUUWG	BS_5CR48ZM7	01
PAUUWG_01_Solid Tissue_Primary Tumor	0.83	NA	NA	NBL, MYCN non-amplified	PAUUWG	BS_TGDZ491N	01
PAUUZU_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUUZU	TARGET-30-PAUUZU-01A-01D	01
PAUVML_01_Solid Tissue_Primary Tumor	3.96	NA	NA	NBL, MYCN amplified	PAUVML	BS_591ZWG14	01
PAUVML_01_Solid Tissue_Primary Tumor	3.96	NA	NA	NBL, MYCN amplified	PAUVML	BS_VE90VKZY	01
PAUVPT_01_Solid Tissue_Primary Tumor	9.42	NA	NA	NBL, MYCN amplified	PAUVPT	BS_M7D3Q30Z	01
PAUVPT_01_Solid Tissue_Primary Tumor	9.42	NA	NA	NBL, MYCN amplified	PAUVPT	BS_XME1VS17	01
PAUVTG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUVTG	BS_P4C0QJ9K	01
PAUVVE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUVVE	TARGET-30-PAUVVE-01A-01D	01
PAUWBU_01_Solid Tissue_Primary Tumor	24.9	3	gain	NBL, MYCN non-amplified	PAUWBU	BS_2RFA5NWH	01
PAUWBU_01_Solid Tissue_Primary Tumor	24.9	3	gain	NBL, MYCN non-amplified	PAUWBU	BS_JTP91S1A	01
PAUWDK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUWDK	TARGET-30-PAUWDK-01A-01D	01
PAUWED_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUWED	TARGET-30-PAUWED-01A-01D	01
PAUWEV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUWEV	TARGET-30-PAUWEV-01A-01D	01
PAUWFE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUWFE	TARGET-30-PAUWFE-01A-01D	01
PAUWHB_01_Solid Tissue_Primary Tumor	11.54	NA	NA	NBL, MYCN non-amplified	PAUWHB	BS_NC4PWRVP	01
PAUWHB_01_Solid Tissue_Primary Tumor	11.54	NA	NA	NBL, MYCN non-amplified	PAUWHB	BS_ZPXVVM8K	01
PAUWTC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUWTC	BS_65F8T6N7	01
PAUWXY_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUWXY	TARGET-30-PAUWXY-01A-01D	01
PAUWYM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUWYM	TARGET-30-PAUWYM-01A-01D	01
PAUXFZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUXFZ	TARGET-30-PAUXFZ-01A-01D	01
PAUXGR_01_Solid Tissue_Primary Tumor	6.93	NA	NA	NBL, MYCN amplified	PAUXGR	BS_8MJNDM75	01
PAUXGR_01_Solid Tissue_Primary Tumor	6.93	NA	NA	NBL, MYCN amplified	PAUXGR	BS_MBNSCVMH	01
PAUXIW_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUXIW	TARGET-30-PAUXIW-09A-01D	09
PAUXPT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUXPT	BS_DAX3YVG0	01
PAUXSV_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAUXSV	BS_WZXHZN97	01
PAUXSZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUXSZ	TARGET-30-PAUXSZ-01A-01D	01
PAUXUP_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUXUP	TARGET-30-PAUXUP-01A-01D	01
PAUYDE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUYDE	TARGET-30-PAUYDE-01A-01D	01
PAUYFR_01_Solid Tissue_Primary Tumor	11.97	NA	NA	NBL, MYCN non-amplified	PAUYFR	BS_5Y98E084	01
PAUYFR_01_Solid Tissue_Primary Tumor	11.97	NA	NA	NBL, MYCN non-amplified	PAUYFR	BS_BVAVPKKN	01
PAUYJS_01_Solid Tissue_Primary Tumor	32.85	4	gain	NBL, MYCN non-amplified	PAUYJS	BS_48YZKWC2	01
PAUYJS_01_Solid Tissue_Primary Tumor	32.85	4	gain	NBL, MYCN non-amplified	PAUYJS	BS_CWPHVM94	01
PAUYKM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUYKM	BS_BBK329W5	01
PAUYXX_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUYXX	TARGET-30-PAUYXX-01A-01D	01
PAUZAE_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUZAE	TARGET-30-PAUZAE-01A-01D	01
PAUZMG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUZMG	TARGET-30-PAUZMG-01A-01D	01
PAUZRC_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUZRC	TARGET-30-PAUZRC-01A-01D	01
PAUZSB_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUZSB	TARGET-30-PAUZSB-01A-01D	01
PAUZTF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUZTF	TARGET-30-PAUZTF-01A-01D	01
PAUZZI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAUZZI	TARGET-30-PAUZZI-01A-01D	01
PAVABN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVABN	TARGET-30-PAVABN-01A-01D	01
PAVAEE_01_Solid Tissue_Primary Tumor	21.04	3	loss	NBL, MYCN non-amplified	PAVAEE	BS_323GG6M7	01
PAVAEE_01_Solid Tissue_Primary Tumor	21.04	3	loss	NBL, MYCN non-amplified	PAVAEE	BS_RR3T675W	01
PAVAGS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVAGS	TARGET-30-PAVAGS-01A-01D	01
PAVAHC_01_Solid Tissue_Primary Tumor	NA	3	gain	NBL, MYCN non-amplified	PAVAHC	BS_CQC29CK5	01
PAVALS_01_Solid Tissue_Primary Tumor	30.63	NA	NA	NBL, MYCN amplified	PAVALS	BS_H0MVFRCE	01
PAVALS_01_Solid Tissue_Primary Tumor	30.63	NA	NA	NBL, MYCN amplified	PAVALS	BS_NZDEF29S	01
PAVALS_01_Solid Tissue_Primary Tumor	30.63	NA	NA	NBL, MYCN amplified	PAVALS	TARGET-30-PAVALS-01A-01D	01
PAVAYF_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVAYF	TARGET-30-PAVAYF-01A-01D	01
PAVBAI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVBAI	BS_THY6PFYF	01
PAVBLT_01_Solid Tissue_Primary Tumor	15.15	3	gain	NBL, MYCN non-amplified	PAVBLT	BS_2NPW3A08	01
PAVBLT_01_Solid Tissue_Primary Tumor	15.15	3	gain	NBL, MYCN non-amplified	PAVBLT	BS_PRF6XPXV	01
PAVBLZ_01_Solid Tissue_Primary Tumor	26.37	NA	NA	NBL, MYCN amplified	PAVBLZ	BS_8EG9GQZS	01
PAVBLZ_01_Solid Tissue_Primary Tumor	26.37	NA	NA	NBL, MYCN amplified	PAVBLZ	BS_PNF2SHN9	01
PAVCGD_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVCGD	TARGET-30-PAVCGD-01A-01D	01
PAVCHH_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVCHH	TARGET-30-PAVCHH-01A-01D	01
PAVCJZ_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVCJZ	TARGET-30-PAVCJZ-01A-01D	01
PAVCKK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVCKK	TARGET-30-PAVCKK-01A-01D	01
PAVCLI_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVCLI	TARGET-30-PAVCLI-01A-01D	01
PAVCLX_01_Solid Tissue_Primary Tumor	45.57	3	loss	NBL, MYCN non-amplified	PAVCLX	BS_MEN59ZX5	01
PAVCLX_01_Solid Tissue_Primary Tumor	45.57	3	loss	NBL, MYCN non-amplified	PAVCLX	BS_NX91DYXQ	01
PAVCPT_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVCPT	BS_Q4PTDFKS	01
PAVDAS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVDAS	BS_GZ39V8AK	01
PAVDBS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVDBS	TARGET-30-PAVDBS-01A-01D	01
PAVDFW_01_Solid Tissue_Primary Tumor	0.51	NA	NA	NBL, MYCN non-amplified	PAVDFW	BS_B2BWSTJV	01
PAVDFW_01_Solid Tissue_Primary Tumor	0.51	NA	NA	NBL, MYCN non-amplified	PAVDFW	BS_Y3KBY0FY	01
PAVDGG_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVDGG	TARGET-30-PAVDGG-01A-01D	01
PAVDNK_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVDNK	TARGET-30-PAVDNK-01A-01D	01
PAVDPE_09_Bone Marrow_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVDPE	TARGET-30-PAVDPE-09A-01D	09
PAVDYS_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVDYS	TARGET-30-PAVDYS-01A-01D	01
PAVEKN_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVEKN	TARGET-30-PAVEKN-01A-01D	01
PAVETV_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVETV	TARGET-30-PAVETV-01A-01D	01
PAVEZM_01_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PAVEZM	TARGET-30-PAVEZM-01A-01D	01
PAVFAP_01_Solid Tissue_Primary Tumor	24.21	3	loss	NBL, MYCN non-amplified	PAVFAP	BS_0TER803R	01
PAVFAP_01_Solid Tissue_Primary Tumor	24.21	3	loss	NBL, MYCN non-amplified	PAVFAP	BS_ZGKT8MMX	01
PAVFNX_01_Solid Tissue_Primary Tumor	28.13	NA	NA	NBL, MYCN amplified	PAVFNX	BS_FJAQ3KAX	01
PAVFNX_01_Solid Tissue_Primary Tumor	28.13	NA	NA	NBL, MYCN amplified	PAVFNX	BS_J6FPW4H0	01
PAVFZW_09_Bone Marrow_Primary Tumor	NA	3	gain	NBL, To be classified	PAVFZW	BS_6K2SSJ77	09
PAVGYW_01_Solid Tissue_Primary Tumor	32.44	3	gain	NBL, MYCN non-amplified	PAVGYW	BS_82Q78622	01
PAVGYW_01_Solid Tissue_Primary Tumor	32.44	3	gain	NBL, MYCN non-amplified	PAVGYW	BS_JV1GTZ1Q	01
PAVHEU_01_Solid Tissue_Primary Tumor	6.12	NA	NA	NBL, MYCN amplified	PAVHEU	BS_KV05J5BX	01
PAVHEU_01_Solid Tissue_Primary Tumor	6.12	NA	NA	NBL, MYCN amplified	PAVHEU	BS_X8H38ZNB	01
PAVHGP_01_Solid Tissue_Primary Tumor	22.71	NA	NA	NBL, MYCN amplified	PAVHGP	BS_6DXDS5EE	01
PAVHGP_01_Solid Tissue_Primary Tumor	22.71	NA	NA	NBL, MYCN amplified	PAVHGP	BS_MW0JYGG1	01
PAVHWG_01_Solid Tissue_Primary Tumor	17.78	NA	NA	NBL, MYCN amplified	PAVHWG	BS_0T5A16N2	01
PAVHWG_01_Solid Tissue_Primary Tumor	17.78	NA	NA	NBL, MYCN amplified	PAVHWG	BS_KHW6ASK4	01
PAVIAZ_01_Solid Tissue_Primary Tumor	1.41	NA	NA	NBL, MYCN non-amplified	PAVIAZ	BS_4GHFYCWZ	01
PAVIAZ_01_Solid Tissue_Primary Tumor	1.41	NA	NA	NBL, MYCN non-amplified	PAVIAZ	BS_QM9CBE54	01
PAVINE_01_Solid Tissue_Primary Tumor	19.52	3	gain	NBL, MYCN non-amplified	PAVINE	BS_7BJQNVK8	01
PAVINE_01_Solid Tissue_Primary Tumor	19.52	3	gain	NBL, MYCN non-amplified	PAVINE	BS_EMBK3HHP	01
PAVINT_01_Solid Tissue_Primary Tumor	8.91	3	loss	NBL, MYCN non-amplified	PAVINT	BS_GNETMRJF	01
PAVINT_01_Solid Tissue_Primary Tumor	8.91	3	loss	NBL, MYCN non-amplified	PAVINT	BS_KG9X0NFD	01
PAVIZV_01_Solid Tissue_Primary Tumor	10.07	3	gain	NBL, MYCN non-amplified	PAVIZV	BS_3KPKZVGX	01
PAVIZV_01_Solid Tissue_Primary Tumor	10.07	3	gain	NBL, MYCN non-amplified	PAVIZV	BS_ZKQXXTG9	01
PAVJEG_01_Solid Tissue_Primary Tumor	5.13	NA	NA	NBL, MYCN amplified	PAVJEG	BS_70H191SN	01
PAVJEG_01_Solid Tissue_Primary Tumor	5.13	NA	NA	NBL, MYCN amplified	PAVJEG	BS_S8Q6R8MX	01
PAVJEV_01_Solid Tissue_Primary Tumor	14.22	NA	NA	NBL, MYCN non-amplified	PAVJEV	BS_HBMHZEGZ	01
PAVJEV_01_Solid Tissue_Primary Tumor	14.22	NA	NA	NBL, MYCN non-amplified	PAVJEV	BS_WBTZK7A2	01
PAVJMA_01_Solid Tissue_Primary Tumor	NA	1	loss	NBL, MYCN non-amplified	PAVJMA	BS_59BAHXTQ	01
PAVJTD_01_Solid Tissue_Primary Tumor	NA	4	gain	NBL, MYCN non-amplified	PAVJTD	BS_TKRH7YW7	01
PAVKRF_01_Solid Tissue_Primary Tumor	12.8	NA	NA	NBL, MYCN non-amplified	PAVKRF	BS_95PV1RRY	01
PAVKRF_01_Solid Tissue_Primary Tumor	12.8	NA	NA	NBL, MYCN non-amplified	PAVKRF	BS_SZ3EJPGV	01
PAVKZC_01_Solid Tissue_Primary Tumor	1.65	NA	NA	NBL, MYCN non-amplified	PAVKZC	BS_5Y7PNW71	01
PAVKZC_01_Solid Tissue_Primary Tumor	1.65	NA	NA	NBL, MYCN non-amplified	PAVKZC	BS_QWX24M4X	01
PAVLFB_01_Solid Tissue_Primary Tumor	48.11	NA	NA	NBL, MYCN amplified	PAVLFB	BS_P5VHEN5Q	01
PAVLFB_01_Solid Tissue_Primary Tumor	48.11	NA	NA	NBL, MYCN amplified	PAVLFB	BS_R232Y3SW	01
PAVMHB_01_Solid Tissue_Primary Tumor	1.03	NA	NA	NBL, MYCN non-amplified	PAVMHB	BS_YG0W2BBN	01
PAVNLK_01_Solid Tissue_Primary Tumor	27.75	NA	NA	NBL, MYCN amplified	PAVNLK	BS_135GYQQD	01
PAVNLK_01_Solid Tissue_Primary Tumor	27.75	NA	NA	NBL, MYCN amplified	PAVNLK	BS_87J6X9KJ	01
PPTC_P0061_CHLA-79_Patient Derived Xenograft_Progressive	62.14	NA	NA	NBL, MYCN amplified	PPTC_P0061	PPTC_VID4Q7JK	CHLA-79
PPTC_P0062_COG-N-415_Derived Cell Line_Progressive_NA_NA	812.6	NA	NA	NBL, MYCN amplified	PPTC_P0062	MARIS_EYOIVTPU	COG-N-415
PPTC_P0062_COG-N-415x_Patient Derived Xenograft_Progressive	2349.81	NA	NA	NBL, MYCN amplified	PPTC_P0062	PPTC_ATC9QVCW	COG-N-415x
PPTC_P0063_COG-N-421x_Patient Derived Xenograft_Relapse	865.82	NA	NA	NBL, MYCN amplified	PPTC_P0063	PPTC_LOUMEHPY	COG-N-421x
PPTC_P0064_COG-N-424x_Patient Derived Xenograft_Primary Tumor	1095.29	NA	NA	NBL, MYCN non-amplified	PPTC_P0064	PPTC_WESCL9QP	COG-N-424x
PPTC_P0065_COG-N-426x-Felix-PDX_Patient Derived Xenograft_Relapse	65.22	NA	NA	NBL, MYCN amplified	PPTC_P0065	PPTC_AZ37GWMQ	COG-N-426x-Felix-PDX
PPTC_P0065_Felix-COG-N-426_Derived Cell Line_Relapse_NA_NA	6.03	NA	NA	NBL, MYCN non-amplified	PPTC_P0065	MARIS_GSB8EQG2	Felix-COG-N-426
PPTC_P0066_COG-N-440_Derived Cell Line_Relapse_NA_NA	486.74	NA	NA	NBL, MYCN amplified	PPTC_P0066	MARIS_Y912NFAI	COG-N-440
PPTC_P0066_COG-N-440x_Patient Derived Xenograft_Relapse	1245.53	NA	NA	NBL, MYCN non-amplified	PPTC_P0066	PPTC_Z83IPQ2P	COG-N-440x
PPTC_P0067_COG-N-452x_Patient Derived Xenograft_Relapse	1063.69	NA	NA	NBL, MYCN non-amplified	PPTC_P0067	PPTC_OKKFERDA	COG-N-452x
PPTC_P0067_COG-N-453_Derived Cell Line_Relapse_NA_NA	285.88	NA	NA	NBL, MYCN amplified	PPTC_P0067	MARIS_U6GGLN7Q	COG-N-453
PPTC_P0067_COG-N-453x_Patient Derived Xenograft_Relapse	707	NA	NA	NBL, MYCN amplified	PPTC_P0067	PPTC_HSR1JTCY	COG-N-453x
PPTC_P0068_COG-N-471nb_Derived Cell Line_Relapse_NA_NA	340.04	NA	NA	NBL, MYCN amplified	PPTC_P0068	MARIS_LIHSF6XQ	COG-N-471nb
PPTC_P0068_COG-N-471x_Patient Derived Xenograft_Relapse	1119.62	NA	NA	NBL, MYCN non-amplified	PPTC_P0068	PPTC_NEVTLBQX	COG-N-471x
PPTC_P0069_COG-N-480x_Patient Derived Xenograft_Primary Tumor	2223.08	NA	NA	NBL, MYCN amplified	PPTC_P0069	PPTC_AMXOJX4R	COG-N-480x
PPTC_P0070_COG-N-496_Derived Cell Line_Primary Tumor_NA_NA	177.64	NA	NA	NBL, MYCN amplified	PPTC_P0070	MARIS_U1TN5LPF	COG-N-496
PPTC_P0070_COG-N-496x_Patient Derived Xenograft_Primary Tumor	653.37	NA	NA	NBL, MYCN amplified	PPTC_P0070	PPTC_PROQBSZV	COG-N-496x
PPTC_P0071_COG-N-519_Derived Cell Line_Relapse_NA_NA	1250.52	NA	NA	NBL, MYCN amplified	PPTC_P0071	MARIS_GCZQZERV	COG-N-519
PPTC_P0071_COG-N-519x_Patient Derived Xenograft_Relapse	2502.45	NA	NA	NBL, MYCN amplified	PPTC_P0071	PPTC_UKKD06QF	COG-N-519x
PPTC_P0072_COG-N-549_Derived Cell Line_Progressive_NA_NA	16.13	NA	NA	NBL, MYCN non-amplified	PPTC_P0072	MARIS_CHISQWZY	COG-N-549
PPTC_P0072_COG-N-549x_Patient Derived Xenograft_Progressive	47.69	NA	NA	NBL, MYCN amplified	PPTC_P0072	PPTC_LQ6Y7A1M	COG-N-549x
PPTC_P0073_COG-N-557nb_Derived Cell Line_Primary Tumor_NA_NA	271.98	NA	NA	NBL, MYCN amplified	PPTC_P0073	MARIS_ABSRSWVF	COG-N-557nb
PPTC_P0073_COG-N-557x_Patient Derived Xenograft_Primary Tumor	2177.22	NA	NA	NBL, MYCN amplified	PPTC_P0073	PPTC_54DHIOQ8	COG-N-557x
PPTC_P0074_COG-N-560x_Patient Derived Xenograft_Primary Tumor	1305.88	NA	NA	NBL, MYCN non-amplified	PPTC_P0074	PPTC_8IVKZKFF	COG-N-560x
PPTC_P0075_COG-N-561_Derived Cell Line_Relapse_NA_NA	431.61	NA	NA	NBL, MYCN amplified	PPTC_P0075	MARIS_ZJXYU1BK	COG-N-561
PPTC_P0075_COG-N-561x_Patient Derived Xenograft_Relapse	1797.29	NA	NA	NBL, MYCN amplified	PPTC_P0075	PPTC_SL7X6FA8	COG-N-561x
PPTC_P0076_COG-N-564x_Patient Derived Xenograft_Relapse	723.45	NA	NA	NBL, MYCN amplified	PPTC_P0076	PPTC_PA8ZOTZO	COG-N-564x
PPTC_P0077_COG-N-589x_Patient Derived Xenograft_Primary Tumor	41.95	NA	NA	NBL, MYCN amplified	PPTC_P0077	PPTC_QNLYDL7E	COG-N-589x
PPTC_P0078_COG-N-590x_Patient Derived Xenograft_Primary Tumor	314.31	NA	NA	NBL, MYCN amplified	PPTC_P0078	PPTC_TPFVVATE	COG-N-590x
PPTC_P0079_COG-N-603x_Patient Derived Xenograft_Primary Tumor	425.85	NA	NA	NBL, MYCN amplified	PPTC_P0079	PPTC_ZVWIYKN9	COG-N-603x
PPTC_P0079_COG-N-623x_Patient Derived Xenograft_Progressive	717.56	NA	NA	NBL, MYCN amplified	PPTC_P0079	PPTC_9LVWBU8B	COG-N-623x
PPTC_P0080_COG-N-619x_Patient Derived Xenograft_Progressive	13.7	NA	NA	NBL, MYCN non-amplified	PPTC_P0080	PPTC_XI4JM8IG	COG-N-619x
PPTC_P0081_COG-N-620x_Patient Derived Xenograft_Progressive	51.23	NA	NA	NBL, MYCN amplified	PPTC_P0081	PPTC_OPN43SQN	COG-N-620x
PPTC_P0082_COG-N-624x_Patient Derived Xenograft_Progressive	23.32	NA	NA	NBL, MYCN amplified	PPTC_P0082	PPTC_HDGGBVIL	COG-N-624x
PPTC_P0083_COG-N-625x_Patient Derived Xenograft_Progressive	48.55	NA	NA	NBL, MYCN amplified	PPTC_P0083	PPTC_AVD76PB4	COG-N-625x
PPTC_P0165_NB-1382_Patient Derived Xenograft_Progressive	1241.53	NA	NA	NBL, MYCN non-amplified	PPTC_P0165	PPTC_IW87M9YQ	NB-1382
PPTC_P0166_NB-1643_Derived Cell Line_Primary Tumor_NA_NA	630.08	NA	NA	NBL, MYCN amplified	PPTC_P0166	MARIS_FHJWCMO7	NB-1643
PPTC_P0166_NB-1643_Patient Derived Xenograft_Primary Tumor	1610.93	NA	NA	NBL, MYCN amplified	PPTC_P0166	PPTC_5YRNDC30	NB-1643
PPTC_P0167_NB-1691_Derived Cell Line_Progressive_NA_NA	152.33	NA	NA	NBL, MYCN amplified	PPTC_P0167	MARIS_UCRJOLAA	NB-1691
PPTC_P0167_NB-1691_Patient Derived Xenograft_Progressive	734.7	NA	NA	NBL, MYCN amplified	PPTC_P0167	PPTC_ZFRSXHVQ	NB-1691
PPTC_P0168_NB-1771_Patient Derived Xenograft_Primary Tumor	2285.16	NA	NA	NBL, MYCN amplified	PPTC_P0168	PPTC_AWZ9HDXM	NB-1771
PPTC_P0169_NB-EBc1_Derived Cell Line_Progressive_NA_NA	15.08	NA	NA	NBL, MYCN non-amplified	PPTC_P0169	MARIS_JGAXN9EJ	NB-EBc1
PPTC_P0169_NB-EBc1_Patient Derived Xenograft_Progressive	65.36	NA	NA	NBL, MYCN amplified	PPTC_P0169	PPTC_0OCOQKP9	NB-EBc1
PPTC_P0170_NB-Fly-623m_Patient Derived Xenograft_Relapse	61.14	NA	NA	NBL, MYCN amplified	PPTC_P0170	PPTC_WB6OSRXV	NB-Fly-623m
PPTC_P0171_NB-SD_Derived Cell Line_Progressive_NA_NA	650.92	NA	NA	NBL, MYCN amplified	PPTC_P0171	MARIS_9JXQHHNY	NB-SD
PPTC_P0171_NB-SD_Patient Derived Xenograft_Progressive	1168.36	NA	NA	NBL, MYCN non-amplified	PPTC_P0171	PPTC_KB5T2UVM	NB-SD
PPTC_P0181_NCH-NB-1_Patient Derived Xenograft_Primary Tumor	38.85	NA	NA	NBL, MYCN amplified	PPTC_P0181	PPTC_WS87CENR	NCH-NB-1
PT_0DR71Q13_7316-3517_Solid Tissue_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_0DR71Q13	BS_NZ133AHZ	7316-3517
PT_0Q496N0Q_ET_DVMP5JR3_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_0Q496N0Q	BS_JHEHJN1M	ET_DVMP5JR3
PT_203SE2J7_ET_2SFY7T52_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_203SE2J7	BS_PTTZ15MN	ET_2SFY7T52
PT_203SE2J7_ET_9KHW93V8_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_203SE2J7	BS_AK1A6MWG	ET_9KHW93V8
PT_203SE2J7_ET_F2D4F1MQ_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_203SE2J7	BS_WE9Z7PE2	ET_F2D4F1MQ
PT_23G70TEN_ET_6JDFDV10_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_23G70TEN	BS_YP080MN8	ET_6JDFDV10
PT_40VEXGGS_ET_3KTJ1ST0_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_40VEXGGS	BS_G0C2BKGC	ET_3KTJ1ST0
PT_5SX0GRW1_7316-1927_Solid Tissue_Deceased	11.88	4	gain	NBL, MYCN non-amplified	PT_5SX0GRW1	BS_1RT76ANT	7316-1927
PT_5SX0GRW1_7316-1927_Solid Tissue_Deceased	11.88	4	gain	NBL, MYCN non-amplified	PT_5SX0GRW1	BS_KP0YNTAK	7316-1927
PT_5SX0GRW1_7316-1927_Solid Tissue_Deceased	11.88	4	gain	NBL, MYCN non-amplified	PT_5SX0GRW1	BS_Z9WJ6WW1	7316-1927
PT_5ZPPR06P_7316-4214_Not Available_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_5ZPPR06P	BS_V1Q5A9B1	7316-4214
PT_5ZPPR06P_7316-4214_Solid Tissue_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_5ZPPR06P	BS_76YE7XNX	7316-4214
PT_5ZPPR06P_7316-4214_Solid Tissue_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_5ZPPR06P	BS_Z2QKNA0W	7316-4214
PT_5ZPPR06P_7316-6301_Solid Tissue_Progressive	NA	NA	NA	NBL, To be classified	PT_5ZPPR06P	BS_EBW10QNH	7316-6301
PT_5ZPPR06P_ET_1QEB44PQ_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_5ZPPR06P	BS_B9XBBA8D	ET_1QEB44PQ
PT_75K756RD_ET_B2BM718W_Not Available_Recurrence	NA	NA	NA	NBL, To be classified	PT_75K756RD	BS_8EKCJ7EF	ET_B2BM718W
PT_75K756RD_ET_DCF188S7_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_75K756RD	BS_0C4V1TW4	ET_DCF188S7
PT_8KF6YSTW_ET_5K8PDRFC_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_8KF6YSTW	BS_ZZA88AMB	ET_5K8PDRFC
PT_936J0BZ5_ET_9ZA5FKKS_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_936J0BZ5	BS_HEDCVFKC	ET_9ZA5FKKS
PT_9F58PWB3_7316-3960_Solid Tissue_Progressive	179.59	26	amplification	NBL, MYCN amplified	PT_9F58PWB3	BS_1D9VXFXY	7316-3960
PT_9F58PWB3_7316-3960_Solid Tissue_Progressive	179.59	26	amplification	NBL, MYCN amplified	PT_9F58PWB3	BS_YC4RWPH3	7316-3960
PT_9F58PWB3_7316-3960_Solid Tissue_Progressive	179.59	26	amplification	NBL, MYCN amplified	PT_9F58PWB3	BS_ZJGXGR1V	7316-3960
PT_BCBMG74N_ET_EJ3H8NNB_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_BCBMG74N	BS_H9YYADDT	ET_EJ3H8NNB
PT_BCBMG74N_ET_EJ3H8NNB_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_BCBMG74N	BS_RECF1S4Q	ET_EJ3H8NNB
PT_CQ3AXEKK_ET_2AZE66GF_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_CQ3AXEKK	BS_0Q47HY02	ET_2AZE66GF
PT_CQ9MX63F_ET_2ZJ7FWEY_Solid Tissue_Recurrence	NA	NA	NA	NBL, To be classified	PT_CQ9MX63F	BS_0X4NPYD3	ET_2ZJ7FWEY
PT_CQ9MX63F_ET_2ZJ7FWEY_Solid Tissue_Recurrence	NA	NA	NA	NBL, To be classified	PT_CQ9MX63F	BS_VV8Q40Y7	ET_2ZJ7FWEY
PT_CQN8M3RF_ET_44GZCX5A_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_CQN8M3RF	BS_EY0C9N6Z	ET_44GZCX5A
PT_D19XT3GV_ET_6JGS3HVH_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_D19XT3GV	BS_RWZRY9CF	ET_6JGS3HVH
PT_D37GET2Y_ET_7ENC4CDH_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_D37GET2Y	BS_CDVX7X1N	ET_7ENC4CDH
PT_D37GET2Y_ET_7GVE363R_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_D37GET2Y	BS_2VFDK3VF	ET_7GVE363R
PT_DF18YV38_ET_1CFP6054_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_DF18YV38	BS_TSNBH5A6	ET_1CFP6054
PT_DFCZAG9T_7316-224_Solid Tissue_Initial CNS Tumor	93.25	100	amplification	NBL, MYCN amplified	PT_DFCZAG9T	BS_4NPEMNAD	7316-224
PT_DFCZAG9T_7316-224_Solid Tissue_Initial CNS Tumor	93.25	100	amplification	NBL, MYCN amplified	PT_DFCZAG9T	BS_DY88N5ZT	7316-224
PT_DFCZAG9T_7316-224_Solid Tissue_Initial CNS Tumor	93.25	100	amplification	NBL, MYCN amplified	PT_DFCZAG9T	BS_H1DTKG7W	7316-224
PT_DHZ5KCNN_7316-7737_Solid Tissue_Recurrence	NA	NA	NA	NBL, To be classified	PT_DHZ5KCNN	BS_SNDPSMTW	7316-7737
PT_DHZ5KCNN_7316-7737_Solid Tissue_Recurrence	NA	NA	NA	NBL, To be classified	PT_DHZ5KCNN	BS_SR0TJ11R	7316-7737
PT_EB0D3BXG_7316-3311_Solid Tissue_Progressive	7.83	NA	NA	NBL, MYCN amplified	PT_EB0D3BXG	BS_F0GNWEJJ	7316-3311
PT_EB0D3BXG_7316-3311_Solid Tissue_Progressive	7.83	NA	NA	NBL, MYCN amplified	PT_EB0D3BXG	BS_VNWKNRY4	7316-3311
PT_EB0D3BXG_7316-3311_Solid Tissue_Progressive	7.83	NA	NA	NBL, MYCN amplified	PT_EB0D3BXG	BS_W808K35Z	7316-3311
PT_EQCQNN1B_7316-9256_Solid Tissue_Progressive	NA	NA	NA	NBL, To be classified	PT_EQCQNN1B	BS_79QMX6KP	7316-9256
PT_EQCQNN1B_7316-9256_Solid Tissue_Progressive	NA	NA	NA	NBL, To be classified	PT_EQCQNN1B	BS_C8MH6YDY	7316-9256
PT_ETJK03VA_ET_A2JE8M6H_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_ETJK03VA	BS_FR7HPS1H	ET_A2JE8M6H
PT_FXHEP8CH_ET_98V244ZC_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_FXHEP8CH	BS_NNS5GZ7J	ET_98V244ZC
PT_FZHGKJ0H_7316-4033_Solid Tissue_Initial CNS Tumor	0.02	NA	NA	NBL, MYCN non-amplified	PT_FZHGKJ0H	BS_0H08N9RR	7316-4033
PT_FZHGKJ0H_7316-4033_Solid Tissue_Initial CNS Tumor	0.02	NA	NA	NBL, MYCN non-amplified	PT_FZHGKJ0H	BS_JBGZ7HHZ	7316-4033
PT_FZHGKJ0H_7316-4033_Solid Tissue_Initial CNS Tumor	0.02	NA	NA	NBL, MYCN non-amplified	PT_FZHGKJ0H	BS_NHMPQ8Q1	7316-4033
PT_FZHGKJ0H_7316-4034_Solid Tissue_Initial CNS Tumor	0.18	NA	NA	NBL, MYCN non-amplified	PT_FZHGKJ0H	BS_060608PC	7316-4034
PT_FZHGKJ0H_7316-4034_Solid Tissue_Initial CNS Tumor	0.18	NA	NA	NBL, MYCN non-amplified	PT_FZHGKJ0H	BS_2SHWPB5P	7316-4034
PT_FZHGKJ0H_7316-4034_Solid Tissue_Initial CNS Tumor	0.18	NA	NA	NBL, MYCN non-amplified	PT_FZHGKJ0H	BS_5J5VH3X0	7316-4034
PT_FZHGKJ0H_7316-4258_Solid Tissue_Progressive	NA	NA	NA	NBL, To be classified	PT_FZHGKJ0H	BS_RA4GZM25	7316-4258
PT_GRZE094W_ET_AFWA6XC1_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_GRZE094W	BS_29E2B8BX	ET_AFWA6XC1
PT_GRZE094W_ET_EWVBBFT6_Not Available_Unknown	NA	NA	NA	NBL, To be classified	PT_GRZE094W	BS_3J9DF2XX	ET_EWVBBFT6
PT_HGWCJDHV_ET_FFDK4P5W_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_HGWCJDHV	BS_WAH4KKQ5	ET_FFDK4P5W
PT_HVCRDJ95_ET_AWW0E9A6_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_HVCRDJ95	BS_R91DDK9A	ET_AWW0E9A6
PT_J01MB51G_ET_DJ152PHW_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_J01MB51G	BS_9P9DNAHS	ET_DJ152PHW
PT_JPBMNESN_ET_C228BTEJ_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_JPBMNESN	BS_JS7G87QP	ET_C228BTEJ
PT_JPFR0046_ET_4Y4A3Y0P_Not Available_Recurrence	NA	NA	NA	NBL, To be classified	PT_JPFR0046	BS_WD253JB2	ET_4Y4A3Y0P
PT_JPFR0046_ET_AX052MKD_Not Available_Recurrence	NA	NA	NA	NBL, To be classified	PT_JPFR0046	BS_T88CNJ8A	ET_AX052MKD
PT_JQA14J4Z_ET_39DZBCF4_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_JQA14J4Z	BS_9NME41F4	ET_39DZBCF4
PT_K0YFKQ6V_7316-7085_Not Available_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_K0YFKQ6V	BS_A05MJ45Y	7316-7085
PT_K0YFKQ6V_7316-7085_Not Available_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_K0YFKQ6V	BS_YBXM34XV	7316-7085
PT_K0YFKQ6V_7316-7085_Solid Tissue_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_K0YFKQ6V	BS_TJ9KW884	7316-7085
PT_K0YFKQ6V_ET_A4K76DSF_Not Available_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_K0YFKQ6V	BS_9Z1VTWJV	ET_A4K76DSF
PT_M7B5AK7P_ET_C7H15JCF_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_M7B5AK7P	BS_BZXFZKPE	ET_C7H15JCF
PT_MRTHX2AQ_7316-23_Solid Tissue_Recurrence	3.35	NA	NA	NBL, MYCN amplified	PT_MRTHX2AQ	BS_5X9HJHRE	7316-23
PT_MRTHX2AQ_7316-23_Solid Tissue_Recurrence	3.35	NA	NA	NBL, MYCN amplified	PT_MRTHX2AQ	BS_TD1ZEQ7R	7316-23
PT_P1290MMP_7316-125_Solid Tissue_Progressive	0.19	NA	NA	NBL, MYCN non-amplified	PT_P1290MMP	BS_G1Y281HX	7316-125
PT_P1290MMP_7316-125_Solid Tissue_Progressive	0.19	NA	NA	NBL, MYCN non-amplified	PT_P1290MMP	BS_ZFCXH22E	7316-125
PT_P6PKT77Y_7316-7741_Solid Tissue_Second Malignancy	NA	NA	NA	NBL, To be classified	PT_P6PKT77Y	BS_ANFZNMQ4	7316-7741
PT_P6PKT77Y_7316-7741_Solid Tissue_Second Malignancy	NA	NA	NA	NBL, To be classified	PT_P6PKT77Y	BS_RF93Q7R6	7316-7741
PT_PE8M2298_ET_9W56H8D9_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_PE8M2298	BS_7DQNG6EM	ET_9W56H8D9
PT_QHJSYTWJ_7316-8120_Not Available_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_QHJSYTWJ	BS_NQ41MEBX	7316-8120
PT_QHJSYTWJ_7316-8120_Not Available_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_QHJSYTWJ	BS_XBQDMMB3	7316-8120
PT_QHJSYTWJ_7316-8120_Solid Tissue_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_QHJSYTWJ	BS_0H9QQRK0	7316-8120
PT_QHJSYTWJ_7316-8120_Solid Tissue_Initial CNS Tumor	NA	NA	NA	NBL, To be classified	PT_QHJSYTWJ	BS_NT49M4RG	7316-8120
PT_QNHGY3KQ_7316-28_Solid Tissue_Recurrence	NA	NA	NA	NBL, To be classified	PT_QNHGY3KQ	BS_24TKY0T9	7316-28
PT_RBCEW1B3_ET_4Z0Y8YHR_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_RBCEW1B3	BS_8Y7V5264	ET_4Z0Y8YHR
PT_RBCEW1B3_ET_5GJA7Q72_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_RBCEW1B3	BS_JKR644RJ	ET_5GJA7Q72
PT_RSVB8R50_ET_6Z42DYPP_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_RSVB8R50	BS_V13B2K9T	ET_6Z42DYPP
PT_RXT6KRR6_7316-3147_Solid Tissue_Recurrence	4.68	3	gain	NBL, MYCN amplified	PT_RXT6KRR6	BS_2KYCDB13	7316-3147
PT_RXT6KRR6_7316-3147_Solid Tissue_Recurrence	4.68	3	gain	NBL, MYCN amplified	PT_RXT6KRR6	BS_CK7CPM73	7316-3147
PT_RXT6KRR6_7316-3147_Solid Tissue_Recurrence	4.68	3	gain	NBL, MYCN amplified	PT_RXT6KRR6	BS_NFRXNAFE	7316-3147
PT_RXT6KRR6_7316-3168_Solid Tissue_Recurrence	8.48	NA	NA	NBL, MYCN amplified	PT_RXT6KRR6	BS_68BZ8N6P	7316-3168
PT_RXT6KRR6_7316-3168_Solid Tissue_Recurrence	8.48	NA	NA	NBL, MYCN amplified	PT_RXT6KRR6	BS_NGAWSN7T	7316-3168
PT_TC6A6TX7_ET_4SC6AA4T_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_TC6A6TX7	BS_8P02DSEP	ET_4SC6AA4T
PT_TMY5EVG3_ET_0QD356EC_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_TMY5EVG3	BS_327GE38E	ET_0QD356EC
PT_TSZV8DK6_ET_FJ2TDG7J_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_TSZV8DK6	BS_YTYSPH4Q	ET_FJ2TDG7J
PT_V5PCYAFJ_ET_FD9T78QE_Not Available_Recurrence	NA	NA	NA	NBL, To be classified	PT_V5PCYAFJ	BS_2HM4AE24	ET_FD9T78QE
PT_V5PCYAFJ_ET_FD9T78QE_Not Available_Recurrence	NA	NA	NA	NBL, To be classified	PT_V5PCYAFJ	BS_XV40PE3Q	ET_FD9T78QE
PT_W7FK539G_7316-76_Solid Tissue_Progressive	425.63	4	gain	NBL, MYCN amplified	PT_W7FK539G	BS_25VZM81R	7316-76
PT_W7FK539G_7316-76_Solid Tissue_Progressive	425.63	4	gain	NBL, MYCN amplified	PT_W7FK539G	BS_X36SF91S	7316-76
PT_W7FK539G_7316-76_Solid Tissue_Progressive	425.63	4	gain	NBL, MYCN amplified	PT_W7FK539G	BS_XBQZYS8G	7316-76
PT_WBXV5ZTN_ET_74PMXWSS_Solid Tissue_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_WBXV5ZTN	BS_HP3E8Q9A	ET_74PMXWSS
PT_XCA58RC8_ET_CZRV043G_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_XCA58RC8	BS_JFFXWZNX	ET_CZRV043G
PT_XN1P30ZC_ET_9KNRBT5Q_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_XN1P30ZC	BS_EPXNCYBP	ET_9KNRBT5Q
PT_XN1P30ZC_ET_AAGX4CBE_Not Available_Recurrence	NA	NA	NA	NBL, To be classified	PT_XN1P30ZC	BS_0F11M2BJ	ET_AAGX4CBE
PT_Y44DNH44_ET_0N820T72_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_Y44DNH44	BS_G91RJ5XW	ET_0N820T72
PT_Y44DNH44_ET_E5CPBMPG_Not Available_Progressive	NA	NA	NA	NBL, To be classified	PT_Y44DNH44	BS_7KTGJPVN	ET_E5CPBMPG
PT_Y5YHX20Q_ET_06Q9BSNT_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_Y5YHX20Q	BS_V8AE965P	ET_06Q9BSNT
PT_YNYR9X1H_ET_9RW90T87_Not Available_Primary Tumor	NA	NA	NA	NBL, To be classified	PT_YNYR9X1H	BS_JH6Z7W0J	ET_9RW90T87
